
<html lang="en"     class="pb-page"  data-request-id="75f7003f-4651-47e3-8c67-58f8722e36c3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b01328"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo" /></meta><meta name="dc.Creator" content="Yahui  Ding" /></meta><meta name="dc.Creator" content="Qingqing  Xue" /></meta><meta name="dc.Creator" content="Shuo  Liu" /></meta><meta name="dc.Creator" content="Kai  Hu" /></meta><meta name="dc.Creator" content="Da  Wang" /></meta><meta name="dc.Creator" content="Tianpeng  Wang" /></meta><meta name="dc.Creator" content="Ye  Li" /></meta><meta name="dc.Creator" content="Hongyu  Guo" /></meta><meta name="dc.Creator" content="Xin  Hao" /></meta><meta name="dc.Creator" content="Weizhi  Ge" /></meta><meta name="dc.Creator" content="Yan  Zhang" /></meta><meta name="dc.Creator" content="Ang  Li" /></meta><meta name="dc.Creator" content="Jing  Li" /></meta><meta name="dc.Creator" content="Yue  Chen" /></meta><meta name="dc.Creator" content="Quan  Zhang" /></meta><meta name="dc.Description" content="Herein we detail the discovery of a series of parthenolide dimers as activators of PKM2 and evaluation of their anti-GBM activities. The most promising compound 5 showed high potency to activate PK..." /></meta><meta name="Description" content="Herein we detail the discovery of a series of parthenolide dimers as activators of PKM2 and evaluation of their anti-GBM activities. The most promising compound 5 showed high potency to activate PK..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 24, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01328" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01328" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01328" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01328" /></link>
        
    
    

<title>Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01328" /></meta><meta property="og:title" content="Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0016.jpeg" /></meta><meta property="og:description" content="Herein we detail the discovery of a series of parthenolide dimers as activators of PKM2 and evaluation of their anti-GBM activities. The most promising compound 5 showed high potency to activate PKM2 with an AC50 value of 15 nM, inhibited proliferation and metastasis, and induced apoptosis of GBM cells. Compound 5 could promote tetramer formation of PKM2 and reduce nucleus translocation of PKM2 in GBM cells without influence on the expression of total PKM2, thereby inhibiting the STAT3 signal pathway in vitro and in vivo. PKM2 knockdown assay demonstrated that the anti-GBM effect of 5 mainly depended on the expression of PKM2 in vitro and in vivo. Compound 16, a prodrug of 5, markedly suppressed U118 tumor xenograft growth and reduced the weight of tumor. On the basis of these investigations, we propose that 16 might be considered as a promising lead compound for discovery of anti-GBM drugs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01328"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01328">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01328&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01328&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01328&amp;href=/doi/10.1021/acs.jmedchem.9b01328" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1597-1611</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01351" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01423" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yahui Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yahui Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yahui++Ding">Yahui Ding</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingqing Xue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingqing Xue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingqing++Xue">Qingqing Xue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuo Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuo Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuo++Liu">Shuo Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kai Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kai Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Medicine, Nankai University, 94 Weijin Road, Tianjin 3000710, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kai++Hu">Kai Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Da Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Da Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Da++Wang">Da Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tianpeng Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tianpeng Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tianpeng++Wang">Tianpeng Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ye Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ye Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ye++Li">Ye Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongyu Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongyu Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongyu++Guo">Hongyu Guo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Hao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Hao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Hao">Xin Hao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Weizhi Ge</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weizhi Ge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weizhi++Ge">Weizhi Ge</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yan Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Zhang">Yan Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ang++Li">Ang Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jing Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#dab0b3b4bdb6b3b4b19ab4bbb4b1bbb3f4bfbeaff4b9b4"><span class="__cf_email__" data-cfemail="761c1f18111a1f181d361817181d171f58131203581518">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Li">Jing Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4289-4829" title="Orcid link">http://orcid.org/0000-0002-4289-4829</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yue Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yue Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#542d2131373c313a143a353a3f353d7a3130217a373a"><span class="__cf_email__" data-cfemail="ec9599898f848982ac828d82878d85c2898899c28f82">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yue++Chen">Yue Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1317-7097" title="Orcid link">http://orcid.org/0000-0002-1317-7097</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Quan Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Quan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#c5bfada4aba2b4b0a4ab85aba4abaea4aceba0a1b0eba6ab"><span class="__cf_email__" data-cfemail="c3b9aba2ada4b2b6a2ad83ada2ada8a2aaeda6a7b6eda0ad">[email protected]</span></a> or <a href="/cdn-cgi/l/email-protection#601a08010e071115010e565152205156534e030f0d"><span class="__cf_email__" data-cfemail="a6dccec7c8c1d7d3c7c8909794e697909588c5c9cb">[email protected]</span></a>. Tel/fax: +86-022-85358387.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Quan++Zhang">Quan Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5280-0956" title="Orcid link">http://orcid.org/0000-0001-5280-0956</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01328&amp;href=/doi/10.1021%2Facs.jmedchem.9b01328" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1597–1611</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 24, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 September 2019</li><li><span class="item_label"><b>Published</b> online</span>24 January 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 February 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01328" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01328</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1597%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYahui%2BDing%252C%2BQingqing%2BXue%252C%2BShuo%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D4%26contentID%3Dacs.jmedchem.9b01328%26title%3DIdentification%2Bof%2BParthenolide%2BDimers%2Bas%2BActivators%2Bof%2BPyruvate%2BKinase%2BM2%2Bin%2BXenografts%2Bof%2BGlioblastoma%2BMultiforme%2Bin%2BVivo%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1611%26publicationDate%3DFebruary%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01328"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1346</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01328" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yahui&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Qingqing&quot;,&quot;last_name&quot;:&quot;Xue&quot;},{&quot;first_name&quot;:&quot;Shuo&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Kai&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Da&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tianpeng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Ye&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Hongyu&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Hao&quot;},{&quot;first_name&quot;:&quot;Weizhi&quot;,&quot;last_name&quot;:&quot;Ge&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yue&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Quan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;1597-1611&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01328&quot;},&quot;abstract&quot;:&quot;Herein we detail the discovery of a series of parthenolide dimers as activators of PKM2 and evaluation of their anti-GBM activities. The most promising compound 5 showed high potency to activate PKM2 with an AC50 value of 15 nM, inhibited proliferation and metastasis, and induced apoptosis of GBM cells. Compound 5 could promote tetramer formation of PKM2 and reduce nucleus translocation of PKM2 in GBM cells without influence on the expression of total PKM2, thereby inhibiting the STAT3 signal pathway in vitro and in vivo. PKM2 knockdown assay demonstrated that the anti-GBM effect of 5 mainly depended on the expression of PKM2 in vitro and in vivo. Compound 16, a prodrug of 5, markedly suppressed U118 tumor xenograft growth and reduced the weight of tumor. On the basis of these investigations, we propose that 16 might be considered as a promising lead compound for discovery of anti-GBM drugs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01328&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01328" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01328&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01328" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01328&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01328" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01328&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01328&amp;href=/doi/10.1021/acs.jmedchem.9b01328" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01328" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01328" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (15 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01328%26sid%3Dliteratum%253Aachs%26pmid%3D31977207%26genre%3Darticle%26aulast%3DDing%26date%3D2020%26atitle%3DIdentification%2Bof%2BParthenolide%2BDimers%2Bas%2BActivators%2Bof%2BPyruvate%2BKinase%2BM2%2Bin%2BXenografts%2Bof%2BGlioblastoma%2BMultiforme%2Bin%2BVivo%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D4%26spage%3D1597%26epage%3D1611%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291149" title="Apoptosis">Apoptosis</a>,</li><li><a href="/action/doSearch?ConceptID=292425" title="Oligomers">Oligomers</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/jmcmar.2020.63.issue-4/20200227/jmcmar.2020.63.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein we detail the discovery of a series of parthenolide dimers as activators of PKM2 and evaluation of their anti-GBM activities. The most promising compound <b>5</b> showed high potency to activate PKM2 with an AC<sub>50</sub> value of 15 nM, inhibited proliferation and metastasis, and induced apoptosis of GBM cells. Compound <b>5</b> could promote tetramer formation of PKM2 and reduce nucleus translocation of PKM2 in GBM cells without influence on the expression of total PKM2, thereby inhibiting the STAT3 signal pathway in vitro and in vivo. PKM2 knockdown assay demonstrated that the anti-GBM effect of <b>5</b> mainly depended on the expression of PKM2 in vitro and in vivo. Compound <b>16</b>, a prodrug of <b>5</b>, markedly suppressed U118 tumor xenograft growth and reduced the weight of tumor. On the basis of these investigations, we propose that <b>16</b> might be considered as a promising lead compound for discovery of anti-GBM drugs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73603" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73603" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glioblastoma multiforme (GBM) is an aggressive, fast-growing brain tumor and is the most common and most malignant type of primary brain tumor.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> The average survival of patients with GBM is less than 12–15 months after diagnosis.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> The widely accepted therapy for GBM is surgical resection, followed by radiotherapy and chemotherapy using alkylating agents.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Currently, temozolomide (approved 2005) and carmustine (approved 1996) are the only chemotherapeutics that are FDA approved for the treatment of newly diagnosed GBM.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, the prognosis of patients remains poor, and the median survival rate is far from satisfactory.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Therefore, discovery of therapeutic agents with unique modes of actions is urgently needed to overcome current challenges in GBM treatment.</div><div class="NLM_p">Targeting cancer metabolism is an emerging avenue in the development of new tumor treatment.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a> Many cancer cells show up-regulated glucose uptake and lactate production, even under the condition of sufficient oxygen. The way to access energy is known as aerobic glycolysis or the Warburg effect.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Pyruvate kinase catalyzes the final rate-limiting step of glycolysis, converting the phosphate from phosphoenolpyruvate (PEP) to ADP to produce pyruvate and ATP.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Pyruvate kinase M2 (PKM2), an isoform of pyruvate kinase, has emerged as a critical regulator in cancer cell metabolism.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21">(17−21)</a> PKM2 is predominantly expressed in tumor cells,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> including glioma,<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> with elevated anabolic demands. PKM2 has a dynamic equilibrium between a dimeric state and a tetrameric state with low and high levels of pyruvate kinase activity, respectively. Thus, PKM2 acts as a key metabolic regulator for cancer cells in maintaining a balance of energy (tetramer) and biomolecule precursor requirements (dimer).<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> Dimeric PKM2 mainly exists in nucleus of cancer cells, where it plays a key role in tumor cell proliferation, invasion, and metastasis.<a onclick="showRef(event, 'ref20 ref28'); return false;" href="javascript:void(0);" class="ref ref20 ref28">(20,28)</a> Activation of PKM2 can induce tetramerization of PKM2 and lead to a decrease in glycolytic intermediates that can be utilized as biosynthetic precursors and prevent nucleus translocation of dimeric PKM2. Therefore, activating PKM2 is supposed to be an effective strategy for treatment of cancer.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">Recently, we screened an in-house collection of natural products for potential PKM2 activator, parthenolide (<b>1</b>, PTL, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was identified as a moderate activator of PKM2. In view of its structure that is different from those of reported PKM2 activator, we were interested to synthesize its derivatives for discovery of more potent PKM2 activator. Thus, with compound <b>1</b> as the starting point, we designed and synthesized a series of parthenolide dimers and investigated their potency to activate PKM2, their mechanism, and their anti-GBM activity in vitro and in vivo.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of PTL and TEPP-46.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40571" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40571" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">PTL, a naturally occurring germacrane sesquiterpene lactone derived from feverfew (<i>Tanacetum parthenium</i>) in a yield of only 0.14–0.74%,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> showed extensive biological activities.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34">(31−34)</a> Recently, we identified that PTL could be readily isolated from root bark of <i>Magnolia delavayi</i> without chromatography in a yield of approximately 5% (kilogram scale).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> PKM2 has a dimer or tetramer state; accordingly, we speculated that PTL dimers would promote their binding to PKM2 and show higher activating activity. Previously, Crooks et al. demonstrated that dimers of melampomagnolide B showed elevated anticancer activity.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Structure–activity relationship studies of PTL have indicated that derivatives modified on the 14-methyl group always maintained anticancer activity.<a onclick="showRef(event, 'ref32 ref37'); return false;" href="javascript:void(0);" class="ref ref32 ref37">(32,37)</a> Accordingly, as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, we designed and synthesized a series of PTL dimers with different linkers. Oxidation of PTL with SeO<sub>2</sub>/<i>t</i>-BuOOH yielded melampomagnolide B (MMB, <b>2</b>).<a onclick="showRef(event, 'ref32 ref37'); return false;" href="javascript:void(0);" class="ref ref32 ref37">(32,37)</a> Treatment of <b>2</b> with Dess–Martin periodinane in the presence of NaHCO<sub>3</sub> followed by further oxidation of aldehyde <b>3</b> with NaClO<sub>2</sub> produced acid <b>4</b>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Coupling of acid <b>4</b> with different lengths of polyethylene glycols afforded dimers <b>5</b>–<b>15</b>. Compound <b>5</b> showed high anti-GBM activity in vitro, which prompted us to evaluate its anti-GBM activity in vivo. However, compound <b>5</b> showed low water solubility. We designed compound <b>16</b> as its prodrug.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39−41)</a> Reaction of compound <b>5</b> with dimethylamine, followed by acidification with fumaric acid, provided compound <b>16</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>5</b>–<b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SeO<sub>2</sub>, <i>t</i>-BuOOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 4 d, 75%; (b) Dess–Martin periodinane, NaHCO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 90%; (c) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, 2-methyl-2-butene, <i>t</i>-BuOH, H<sub>2</sub>O, 0 °C, 1 h, 90%; (d) DMAP, DIC, CH<sub>2</sub>Cl<sub>2</sub>, 6.6–62.4%; (e) dimethylamine, THF, 1 h; fumaric acid, methanol, 71.2%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Parthenoide Dimers Activated the Pyruvate Kinase Activity of PKM2</h3><div class="NLM_p">To identify the potent activator targeting PKM2, a percent activation assay was performed as a preliminary screening. In this assay, the activity of the rPKM2 was compared in the absence or presence of synthesized dimers <b>5</b>–<b>15</b>, and PKM2 activator TEPP-46 was used as a positive control. PTL was also included for comparison. Eleven compounds showed >2-fold activation compared to PKM2 enzyme alone at a concentration of 10 μM (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Compounds <b>5</b>, <b>6</b>, and <b>10</b> were selected to further analyze their effects on PKM2 activity. We measured the pyruvate kinase activity of rPKM2 proteins in the presence of <b>5</b>, <b>6</b>, and <b>10</b> at a series of different concentrations. The results demonstrated that <b>5</b>, <b>6</b>, and <b>10</b> effectively promoted the pyruvate kinase activity of rPKM2 with a half-maximum activating concentration (AC<sub>50</sub>) value at 15 nM, 52 nM, and 65 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The most potent compound <b>5</b> was better than TEPP-46 (AC<sub>50</sub> = 92 nM).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Parthenolide dimers activated the pyruvate kinase activity of PKM2. (A) The relative enzyme activity of PKM2 after treatment with compounds at a concentration of 10 μM. (B–D) Recombinant PKM2 proteins were incubated with compound <b>5</b>, compound <b>6</b>, and compound <b>10</b> for 50 min at room temperature with different concentrations, and then the pyruvate kinase activity was monitored and the value of AC<sub>50</sub> calculated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Compound <b>5</b> Inhibited Proliferation and Metastasis and Induced Apoptosis of GBM Cells</h3><div class="NLM_p">PKM2 acts as a protein kinase and regulates the expression of cell proliferation, apoptosis, and metastasis-related genes. As potential PKM2 activators, parthenolide dimers <b>5</b>–<b>15</b> probably affect cell proliferation. To investigate the antiproliferation activity of these compounds, MTT assay was performed with PTL<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and TEPP-46 for comparison and with ADR as a positive control. The antiproliferation of <b>5</b>–<b>15</b> against six brain tumor cell types, U87, U118, SF126, SHG44, U251, and C6, and a normal immortal line of fibroblast-like cells, 3T3, was evaluated. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> ant <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compound <b>5</b> showed the most potent cytotoxicity against U87, U118, SF126, SHG44, U251, and C6 glioma cell lines with IC<sub>50</sub> values of 3.03 ± 0.54 μM, 1.80 ± 0.28 μM, 7.49 ± 0.64 μM, 5.24 ± 3.49 μM, 7.14 ± 0.08 μM, and 1.66 ± 0.01 μM, respectively, which are more potent than that of the parent compound PTL, respectively. Compound <b>5</b> showed low toxicity against the normal immortal line of fibroblast-like 3T3 cells compared with its highly potent anti-GBM activity. Moreover, we further evaluated other kinds of cancer cell lines including cervical carcinoma (HeLa), liver cancer (HepG2), breast cancer (SUM159), and lung cancer (A549) compared with glioma (U118). As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, compound <b>5</b> showed IC<sub>50</sub> values for U118, HeLa, HepG2, SUM159, and A549 at 1.8 ± 0.28 μM, 5.05 ± 1.17 μM, 10.2 ± 0.83 μM, 2.82 ± 0.39 μM, and 11.9 ± 0.23 μM, respectively (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), which indicated that glioblastoma multiforme cells were more sensitive to compound <b>5</b> than other cancer cells. Taking account that compound <b>5</b> showed the most potent anti-GBM activity and did not significantly affect the viability of normal cells, compound <b>5</b> was selected for further investigation of its anti-GBM activity and mechanism of action.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Parthenolide dimers inhibited the proliferation of different GBM cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. IC<sub>50</sub> values of compound <b>5</b> against five kinds of cancer cells including glioma (U118), cervical carcinoma (HeLa), liver cancer (HepG2), breast cancer (SUM159), and lung cancer (A549).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Antiproliferation Activity of Parthenolide Dimers <b>5</b>–<b>15</b> against Different Brain Tumor Cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">U87</th><th class="colsep0 rowsep0" align="center">U118</th><th class="colsep0 rowsep0" align="center">SF126</th><th class="colsep0 rowsep0" align="center">SHG44</th><th class="colsep0 rowsep0" align="center">U251</th><th class="colsep0 rowsep0" align="center">C6</th><th class="colsep0 rowsep0" align="center">3T3<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTL (<b>1</b>)</td><td class="colsep0 rowsep0" align="left">4.38 ± 1.17</td><td class="colsep0 rowsep0" align="left">5.94 ± 0.23</td><td class="colsep0 rowsep0" align="left">17.10 ± 2.40</td><td class="colsep0 rowsep0" align="left">9.52 ± 2.17</td><td class="colsep0 rowsep0" align="left">12.55 ± 2.05</td><td class="colsep0 rowsep0" align="left">5.45 ± 0.22</td><td class="colsep0 rowsep0" align="left">7.14 ± 2.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEPP-46<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">86.3 ± 2.12</td><td class="colsep0 rowsep0" align="left">85.0 ± 2.37</td><td class="colsep0 rowsep0" align="left">88.98 ± 1.48</td><td class="colsep0 rowsep0" align="left">49.0 ± 1.90</td><td class="colsep0 rowsep0" align="left">65.43 ± 5.13</td><td class="colsep0 rowsep0" align="left">81.8 ± 8.80</td><td class="colsep0 rowsep0" align="left">56.58 ± 2.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ADR<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.15 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.090 ± 0.00</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.16</td><td class="colsep0 rowsep0" align="left">1.84 ± 0.06</td><td class="colsep0 rowsep0" align="left">48 ± 0.14</td><td class="colsep0 rowsep0" align="left">0.06 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.34 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">3.03 ± 0.54</td><td class="colsep0 rowsep0" align="left">1.80 ± 0.28</td><td class="colsep0 rowsep0" align="left">7.49 ± 0.45</td><td class="colsep0 rowsep0" align="left">5.24 ± 2.46</td><td class="colsep0 rowsep0" align="left">7.14 ± 0.06</td><td class="colsep0 rowsep0" align="left">1.66 ± 0.01</td><td class="colsep0 rowsep0" align="left">7.93 ± 3.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">3.09 ± 1.09</td><td class="colsep0 rowsep0" align="left">2.87 ± 0.09</td><td class="colsep0 rowsep0" align="left">10.18 ± 0.44</td><td class="colsep0 rowsep0" align="left">10.45 ± 0.55</td><td class="colsep0 rowsep0" align="left">9.59 ± 0.87</td><td class="colsep0 rowsep0" align="left">1.59 ± 0.56</td><td class="colsep0 rowsep0" align="left">7.86 ± 2.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">9.13 ± 1.58</td><td class="colsep0 rowsep0" align="left">7.97 ± 0.53</td><td class="colsep0 rowsep0" align="left">20.11 ± 1.46</td><td class="colsep0 rowsep0" align="left">16.27 ± 4.88</td><td class="colsep0 rowsep0" align="left">16.64 ± 1.11</td><td class="colsep0 rowsep0" align="left">4.26 ± 0.59</td><td class="colsep0 rowsep0" align="left">16.09 ± 3.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">10.59 ± 1.20</td><td class="colsep0 rowsep0" align="left">7.50 ± 0.85</td><td class="colsep0 rowsep0" align="left">21.01 ± 1.43</td><td class="colsep0 rowsep0" align="left">18.47 ± 6.59</td><td class="colsep0 rowsep0" align="left">14.08 ± 1.41</td><td class="colsep0 rowsep0" align="left">4.82 ± 0.02</td><td class="colsep0 rowsep0" align="left">18.83 ± 3.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">15.07 ± 4.90</td><td class="colsep0 rowsep0" align="left">10.58 ± 1.08</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">12.92 ± 3.75</td><td class="colsep0 rowsep0" align="left">11.75 ± 3.11</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">25.67 ± 0.13</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">4.98 ± 0.45</td><td class="colsep0 rowsep0" align="left">22.03 ± 7.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">18.67 ± 6.27</td><td class="colsep0 rowsep0" align="left">23.07 ± 2.83</td><td class="colsep0 rowsep0" align="left">24.48 ± 5.28</td><td class="colsep0 rowsep0" align="left">23.33 ± 6.68</td><td class="colsep0 rowsep0" align="left">14.25 ± 0.45</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">16.17 ± 5.13</td><td class="colsep0 rowsep0" align="left">17.39 ± 3.89</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">50.05 ± 10.0</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All values are the means of three independent experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">TEPP-46, a prominent PKM2 activator.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">ADR, adriamycin, was used as a positive control.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">3T3 cells, a normal immortal line of fibroblast-like cells.</p></div></div></div><div class="NLM_p">To further investigate the potential anti-GBM effect of <b>5</b>, colony formation assay, cell apoptosis assay, and transwell assay were performed. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, compoud <b>5</b> significantly inhibited the colony formation of U87 and U118 cells and induced apoptosis of U87 and U118 cells in a dose-dependent manner. Moreover, the number of migration and invasion cells was strongly reduced after treatment with <b>5</b> for 24 h (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>5</b> inhibited colony formation and induced apoptosis of different GBM cells. (A) The colony formation of U118 and U87 cells after treatment with compound <b>5</b> for 7 days. (B, C) The colony number of U118 and U87 cells after treatment with compound <b>5</b> was calculated. (D) Representative pictures of cell apoptosis with or without treatment with <b>5</b> for 48 h. (E, F) The percentage of cell apoptosis with or without treatment with <b>5</b> for 48 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>5</b> inhibited invasion and migration of different GBM cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Parthenolide Dimer <b>5</b> Could Directly Bind to PKM2</h3><div class="NLM_p">To reveal whether <b>5</b> could directly bind to PKM2, the molecular docking assay and the thermal stability experiments were performed. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, the molecular docking assay proposed that <b>5</b> would directly bind to PKM2. The thermal stability experiments further illustrated that <b>5</b> increased the thermal stability of PKM2 by an increase in melting temperature at 42 °C, 49 °C, and 56 °C, which demonstrated that <b>5</b> could directly bind to PKM2. To further explore the possibility of compound <b>5</b> covalently binding to PKM2, we performed LC-MS/MS analysis of PKM2 after treatment with <b>5</b>. As shown in <a class="ref internalNav" href="#notes1" aria-label="Figures S1 and S2">Figures S1 and S2</a>, we speculated that compound <b>5</b> might directly bind to PKM2 through the sulfhydryl group of C424.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>5</b> could directly bind to PKM2. (A, B) Molecular docking studies of dimeric PKM2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T5A">1T5A</a>) with parthenolide dimer <b>5</b>. (C) Compound <b>5</b> stabilized PKM2 at 42 °C, 49 °C, and 56 °C by thermal stability assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Compound <b>5</b> Promoted Tetramer PKM2 and Reduced Nucleus Translocation of Dimer PKM2 in GBM Cells</h3><div class="NLM_p">To explain the mechanism of <b>5</b> in the activation of PKM2, we first analyzed the protein expression after treatment with <b>5</b>. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, after treatment with <b>5</b> at different concentrations, the protein expressions of total PKM2 were not evidently changed in U87 and U118 cells. The translocation of PKM2 from the cytoplasm to the nucleus played important roles for tumor proliferation. The tetramer form of PKM2 in the cytoplasm, which is the glycolytically active form (acts as pyruvate kinase), suppressed tumorigenesis. The dimer of PKM2 regulates gene transcription by acting as a protein kinase in the cancer cell nucleus and correlates with cancer cell proliferation. To determine whether <b>5</b> affected the nucleus translocation, PKM2 in the nucleus was analyzed. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C, PKM2 in the nucleus was significantly decreased in U87 and U118 cells after treatment with <b>5</b> for 48 h. Tetrameric PKM2 is the active form of PKM2. To evaluate whether <b>5</b> promoted the tetramer formation of intracellular PKM2, a chemical cross-linking assay was performed. From the results of <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>E, compound <b>5</b> enhanced the tetrameric PKM2 in U87 and U118 cells which was similar to the effect of TEPP-46 (a prominent PKM2 activator<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>). In addition, after the incubation of <b>5</b> and PKM2 protein, the size distributions of the particles were analyzed with a particle size analyzer (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>F). The results showed that <b>5</b> and TEPP-46 increased the particle size, which indicated the increased formation of tetrameric PKM2. It is worth to note that compound <b>5</b> was more effective than TEPP-46 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>F).</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>5</b> promoted formation of tetrameric PKM2 and reduced nuclear translocation. (A) The protein expression of PKM2 after treatment with <b>5</b> for 48 h. (B, C) The protein levels of PKM2 in the nucleus and cytoplasm in U118 and U87 cells after treatment with <b>5</b> for 48 h. (D, E) The tetrameric formation of PKM2 was analyzed in U118 and U87 cells after being treated with <b>5</b> (0.5 μM and 1 μM), or TEPP-46 (10 μM) for 48 h using the chemical cross-linking assay. (F) The changes in PKM2 particle size were detected after treatment with <b>5</b> or TEPP-46.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Parthenolide Dimer 5 Inhibited the STAT3 Signal Pathway</h3><div class="NLM_p">PTL is a well characterized IKKβ and p65 inhibitor. At concentrations of 0.2 μM and 0.5 μM, compound <b>5</b> could significantly activate PKM2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) but did not evidently affect the level of IKKβ and p65 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). We further analyzed the IKKβ phosphorylation and nuclear translocation of p65 after treatment with compound <b>5</b> at concentrations of 0.2 μM and 0.5 μM with PTL as positive control. <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>C demonstrated that the dimer <b>5</b> did not significantly affect the IKKβ phosphorylation and nuclear translocation of p65 at concentrations of 0.2 μM and 0.5 μM where dimer <b>5</b> significantly activated PKM2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). These results indicated that dimer <b>5</b> did not affect the NF kB pathway at a concentration where dimer <b>5</b> significantly activated PKM2.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>5</b> inhibited the STAT3 pathway. (A) The protein expression of P65 and IKKβ after treatment with compound <b>5</b> for 48 h. (B) The protein expression of p-IKKβ was analyzed after the treatment with compound <b>5</b> in U118 cells for 48 h. (C) The nuclear translocation of P65 was analyzed after the treatment with compound <b>5</b> in U118 cells for 48 h. (D) The protein expression of STAT3, p-STAT3, Bcl-xl, Bax, Bcl-2, E-cadherin, and vimentin was analyzed after the treatment with compound <b>5</b> for 48 h in U118 and U87 cells. (E) The protein level of STAT3 and PKD4 after being treated with compound <b>5</b> and PTL for 48 h at concentrations of 2 μM in U118 cells, and 5 μM in U87 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family of transcription factors and is activated in several cancers. STAT3 tyrosine phosphorylation has been associated with cancer cell proliferation, apoptosis, and metastasis. It was reported that nuclear PKM2 regulated constitutive activation of STAT3 in colorectal carcinoma cells.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> To determine whether <b>5</b> could inhibit STAT3 pathway by reducing nuclear translocation of PKM2 in GBM cells, the protein expression was detected. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>D, the STAT3 expression and phosphorylation were clearly inhibited after treatment with <b>5</b> in U118 and U87 cells for 24 h. As an important transcription factor in cancer cells, STAT3 regulated the expression of the metastasis inhibition protein E-cadherin, the metastasis-inducing protein vimentin, the pro-apoptotic protein Bax, and the antiapoptotic proteins Bcl-2 and Bcl-xl. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>D, E-cadherin was strongly increased, while vimentin was significantly decreased in U87 and U118 cells after treatment with <b>5</b> for 24 h. In addition, the pro-apoptotic protein Bax was clearly increased, while the antiapoptotic proteins Bcl-2 and Bcl-xl were significantly decreased. These results suggested that compound <b>5</b> inhibited GBM cell proliferation, induced cell apoptosis, and inhibited metastasis by inhibiting the STAT3 signal pathway.</div><div class="NLM_p last">It was reported that PTL could inhibit the STAT3 signaling pathway<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> and activate pyruvate dehydrogenase kinase 4 (PDK4).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> We evaluated and compared the effects of PTL and compound <b>5</b> on STAT3 and PDK4. The results in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>E demonstrated that compound <b>5</b> could inhibit STAT3 and activate PDK4, and compound <b>5</b> showed more potent effects than PTL.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Anticancer Activity of <b>5</b> Was Dependent on the Expression of PKM2</h3><div class="NLM_p">To verify the influence of PKM2 on the effect of <b>5</b>, we stably knocked down the expression of PKM2 in U87 and U118 GBM cells by lentiviral (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). Then shPKM2 and shNC cells were treated with <b>5</b> at different concentrations for 24 h, and the cell viability was assayed. The results showed that the shPKM2 U118 and shPKM2 U87 cells are less sensitive to the inhibitory effect of <b>5</b> compared to shNC cells (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C), which indicated that the antiproliferation effect of <b>5</b> on GBM cells was mainly dependent on the expression PKM2. To further identify the significance of PKM2 for anti-GBM activity of <b>5</b>, the cell apoptosis assay was performed. The results shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>D–F demonstrated that the <b>5</b>-mediated apoptosis in shPKM2 U118 and shPKM2 U87 cells was clearly reduced compared to the corresponding shNC cells, respectively. Furthermore, the migration and invasion results indicated that the <b>5</b>-mediated metastasis in the shPKM2 U118 and shPKM2 U87 cells was strongly reduced compared to the corresponding shNC cells, respectively (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). All these results demonstrated that the anti-GBM effects of <b>5</b> inhibiting proliferation and metastasis and inducing apoptosis mainly depended on the expression of PKM2.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Induction of apoptosis of U87 and U118 by <b>5</b> was dependent on the expression of PKM2. (A) The protein level of PKM2 in U87 and U118 cells after stably expressing shNC or shPKM2 plasmid. (B, C) The antiproliferative effect of <b>5</b> on U118 and U87 cells with stably knocked down PKM2. (D) The representative pictures of cell apoptosis after treatment with <b>5</b> in U87 and U118 cells with stably knocked down PKM2. (E, F) The percentage of cell apoptosis after treatment with compound <b>5</b> in U87 and U118 cells with stably knocked down PKM2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Inhibition of invasion and migration of U87 and U118 cells by <b>5</b> was dependent on the expression of PKM2. (A) The representative pictures and number of invasion cells after treatment with <b>5</b> in stably knocked down PKM2 cells. (B) The representative pictures and number of migration cells after treatment with <b>5</b> in stably knocked down PKM2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Compound <b>16</b>, a Prodrug of Parthenolide Dimer <b>5</b>, Inhibited U118 Tumor Xenograft Growth in Vivo</h3><div class="NLM_p">Because <b>5</b> showed significant anti-GBM activity in vitro, we decided to determine the anti-GBM effect of <b>5</b> in vivo. However, compound <b>5</b> demonstrated low water solubility, so compound <b>5</b> was transformed to its prodrug <b>16</b> following our previously reported strategy.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Using a mouse xenograft tumor model, we investigated the anti-GBM activity of <b>16</b> in vivo. U118 cells (5 × 10<sup>6</sup>) were injected into the subcutaneous right forelimb armpit. After the tumors had grown to an average size of about 100 mm<sup>3</sup>, either vehicle or <b>16</b> (50 mg/kg) was administered ip for 3 weeks (twice a week). The results indicated that <b>16</b> markedly suppressed tumor growth and reduced the weight of tumor. The body weight in the <b>16</b>-treated group had no significant difference compared to vehicle group (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Compound <b>16</b> inhibited GBM growth in vivo. (A) Images of the xenograft tumors derived from U118 cells. Compound <b>16</b> was administered twice a week intraperitoneally. siPKM2 was administered twice a week by intratumoral injection. (B) Tumor growth rate of control-, compound <b>16</b>-, siPKM2-, and compound <b>16</b>+siPKM2-treated mice. (C) The body weight change of control-, compound <b>16</b>-, siPKM2-, and compound <b>16</b>+siPKM2-treated mice. (D) Tumor weight of control-, compound <b>16</b>-, siPKM2-, and compound <b>16</b>+siPKM2-treated mice. (E) The protein level of Bax, Bcl-2, E-cadherin, STAT3, and vimentin in tumor tissue lysate obtained from vehicle control group and compound <b>16</b>-treated group. (F–I) The gene expression of E-cadherin, N-cadherin, Bcl-2, and STAT3 in tumor tissue derived from vehicle control group and compound <b>16</b>-treated group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Western blot of the tumor tissue indicated that E-cadherin and Bax were significantly increased, while STAT3, vimentin, and Bcl-2 were decreased after administration of <b>16</b>, which were in accordance with the results in vitro. Moreover, the gene expression also showed that E-cadherin was markedly up-regulated, while Bcl-2 and STAT3 were significantly down-regulated after administration of <b>16</b>.</div><div class="NLM_p">To verify that the effect of <b>16</b> mainly depended on expression of PKM2 in vivo, we set a siPKM2 administration group with 0.3 pM siRNA was injected by intratumoral injection twice a week. The <b>16</b>-mediated tumor growth inhibition was strongly reduced after the knockdown of PKM2, which indicated that PKM2 expression was important for the anti-GBM activity of <b>16</b>. The xenograft tumors were then harvested for immunohistochemical (IHC) staining. The IHC staining implied that <b>16</b> administration treatment markedly up-regulated the expression levels of E-cadherin and Bax and down-regulated the expression level of vimentin, P-STAT3, and Bcl-2, while these changes disappeared in the <b>16</b>-treated group with knockdown of PKM2 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</div><figure id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. IHC analysis of the protein level of PKM2, Bax, Bcl-2, E-cadherin, vimentin, and p-STAT3 in control group, compound <b>16</b>-treated group, siPKM2 group, and compound <b>16</b>/siPKM2 group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Compound <b>16</b> Had the Potential To Penetrate the BBB</h3><div class="NLM_p">The potency to penetrate the blood–brain barrier (BBB) is important for anti-GBM drugs. Therefore, we evaluated the potency of compound <b>16</b> for penetrating the BBB. Impedance analysis is commonly used to evaluate the integrity of the blood–brain barrier by detecting alterations in the transendothelial electric resistance measurements assay (TEER).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, exposure of Madin–Darby canine kidney (MDCK II) cells to compound <b>16</b> transiently lowered the barrier integrity within 3 h. Temozolomide (TMZ), a clinically used drug for treatment of glioma, continuously lowered barrier integrity within 7 h. It is important to note that the TEER values of MDCK II cells were recovered within 7 h in the compound <b>16</b> treatment group. This result suggested that compound <b>16</b> transiently lowered the barrier integrity and had the potential to penetrate the BBB.</div><figure id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. TEER values were measured for 7 h after treatment with TMZ or compound <b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86585" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86585" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Targeting cancer-specific metabolism is an attractive strategy for cancer therapy. PKM2 is significantly up-regulated in many tumor cells, including GBM. PKM2 plays important roles in metabolism (tetrameric PKM2) and signals in cancer cells (dimeric PKM2). It was reported that genetic replacement of PKM2 with PKM1 greatly suppressed aerobic glycolysis and tumor growth of lung cancer in vitro and in vivo.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Therefore, PKM2 has been considered as an ideal therapeutic target for GBM treatment. PKM2 inhibitors showed anticancer activity because they could ablate the glycolytic phenotype that tumors are reliant upon.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> However, PKM2 knockdown in U87 and U118 GBM cells did not affect the proliferation of cancer cells in vitro (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a class="ref internalNav" href="#notes1" aria-label="Figure S3">Figure S3</a>) and the growth of xenograft tumors in vivo (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Similarly, knockdown of PKM2 did not suppress the growth of xenograft colon tumors, breast tumors, and liver tumors.<a onclick="showRef(event, 'ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54">(52−54)</a> These results suggested that inhibition of PKM2 is not sufficient to significantly reduce cellular proliferation of tumor cells. PKM2 exists in equilibrium between the dimeric form with low-glycolytic activity and the tetrameric form with high-glycolytic activity. Nucleic PKM2 exists as a dimer, which is essential for cancer proliferation and metastasis.<a onclick="showRef(event, 'ref20 ref28'); return false;" href="javascript:void(0);" class="ref ref20 ref28">(20,28)</a> PKM2 activators reduce PKM2 translocation into the nucleus and thereby suppress tumorigenesis of nucleic PKM2. Thus, PKM2 activators provide a novel antitumor therapeutic strategy.</div><div class="NLM_p last">We identified a series of parthenolide dimers as activators of PKM2 and evaluated their anti-GBM activities. The most promising dimer <b>5</b> exhibited significant potency to activate PKM2 with an AC<sub>50</sub> value of 15 nM (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which is more potent than that of the positive control TEPP-46 (AC<sub>50</sub> = 92 nM).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Compound <b>5</b> greatly inhibited proliferation and metastasis and induced apoptosis of U87 and U118 GBM cells (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>–<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). The mechanism study revealed that dimer <b>5</b> did not affect the expression of PKM2 but promoted tetramer formation of PKM2 and prevented PKM2 from moving into the nucleus in U87 and U118 GBM cells (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), thereby inhibiting the STAT3 signal pathway in vitro (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) and in vivo (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> and <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Further study indicated that the anti-GBM activity of dimer <b>5</b> was dependent on the expression of PKM2 in U87 and U118 cells in vitro (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) and in vivo (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> and <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Compound <b>16</b>, a prodrug of parthenolide dimer <b>5</b>, markedly suppressed the growth of xenograft U118 GBM tumors and reduced the weight of GBM tumors, and the <b>16</b>-treated group showed no apparent toxicity (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Moreover, compound <b>16</b> had the potential to penetrate the BBB (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). On the basis of these investigations, we propose that <b>16</b> might be considered as a promising lead compound for the ultimate development of an anti-GBM drug.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38300" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38300" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Chemistry</h3><div class="NLM_p last">Unless otherwise mentioned, all reactions were carried out under a nitrogen atmosphere with dry solvents under anhydrous conditions. The solvents used were purified and dried according to common procedures. Reactions were monitored by thin-layer chromatography carried out on 0.25 mm Tsingdao silica gel plates (60F-254). Visualization was achieved using UV light, phosphomolybdic acid in ethanol, or potassium permanganate in water, each followed by heating. Tsingdao silica gel (60, particle size 0.040–0.063 mm) was used for flash column chromatography. Reagents were purchased at the highest commercial quality and used without further purification, unless otherwise stated. NMR spectra were recorded with a 400 MHz (<sup>1</sup>H: 400 MHz, <sup>13</sup>C: 100 MHz) spectrometer and referenced to the solvent peak for CDCl<sub>3</sub> and CD<sub>3</sub>OD. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants, and integration. The purity of the final compounds was determined to be ≥95% by means of analytical high pressure liquid chromatography (HPLC) on a Shimadzu LD-20A system with an ODS-C18 column (4.6 × 150 mm, 5 μm) eluted at 1 mL/min with Milli-Q water and CH<sub>3</sub>CN.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure for Synthesis of Compounds <b>5</b>–<b>15</b></h3><div class="NLM_p">To a solution of compound <b>4</b> (200 mg, 0.72 mmol) in dry DCM (1.5 mL) were added polyethylene glycol (0.24 mmol), DMAP(45 mg, 0.36 mmol), and DIC (0.065 mL). The solution was stirred at room temperature for 8 h, quenched with saturated aqueous NaCl, and extracted with DCM (3 × 10 mL). The combined organic layers were washed with saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give an oily crude product, which was purified on a silica gel column to yield parthenolide dimers.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Oxybis(ethane-2,1-diyl)</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>5</b>), white amorphous solid, 10.6% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.83 (t, <i>J</i> = 8.4 Hz, 2H), 6.20 (d, <i>J</i> = 3.4 Hz, 2H), 5.55 (d, <i>J</i> = 3.1 Hz, 2H), 4.38–4.19 (m, 4H), 3.80 (t, <i>J</i> = 9.4 Hz, 2H), 3.76–3.64 (m, 4H), 2.84–2.72 (m, 4H), 2.68–2.56 (m, 4H), 2.52–2.31 (m, 6H), 2.30–2.20 (m, 2H), 1.67–1.57 (m, 2H), 1.55 (s, 6H), 1.21–1.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 166.8, 141.7, 138.6, 133.1, 120.3, 81.6, 69.0, 63.4, 62.8, 59.5, 42.2, 36.0, 25.8, 24.5, 23.7, 17.9. HRMS (ESI) calcd for C<sub>34</sub>H<sub>46</sub>NO<sub>11</sub> [M + NH<sub>4</sub>]<sup>+</sup> 644.3065, found 644.3067.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (Ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl)</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>6</b>), white amorphous solid, 23.9% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.93–6.66 (m, 2H), 6.18 (d, <i>J</i> = 3.4 Hz, 2H), 5.56 (d, <i>J</i> = 3.0 Hz, 2H), 4.40–4.17 (m, 4H), 3.87–3.72 (m, 2H), 3.72–3.65 (m, 4H), 3.61–3.53 (m, 4H), 2.78 (t, <i>J</i> = 7.8 Hz, 4H), 2.68–2.54 (m, 4H), 2.41 (m, 6H), 2.27–2.17 (m, 2H), 1.65–1.56 (m, 2H), 1.53 (s, 6H), 1.20–1.12 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 166.9, 141.5, 138.6, 133.1, 120.3, 81.6, 70.3, 69.0, 63.5, 62.7, 59.5, 42.1, 35.9, 25.8, 24.4, 23.6, 17.9. HRMS (ESI) calcd for C<sub>36</sub>H<sub>50</sub>NO<sub>12</sub> [M + NH<sub>4</sub>]<sup>+</sup> 688.3328, found 688.3328.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> ((Oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl)</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>7</b>), white amorphous solid, 20.6% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.91 (t, <i>J</i> = 8.6 Hz, 2H), 6.22 (d, <i>J</i> = 3.4 Hz, 2H), 5.59 (d, <i>J</i> = 3.0 Hz, 2H), 4.45–4.20 (m, 4H), 3.80 (t, <i>J</i> = 9.4 Hz, 2H), 3.75–3.67 (m, 4H), 3.61 (s, 8H), 2.85–2.74 (m, 4H), 2.68–2.57 (m, 4H), 2.51–2.32 (m, 6H), 2.28–2.21 (m, 2H), 1.68–1.58 (m, 2H), 1.55 (s, 6H), 1.22–1.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 167.0, 141.5, 138.5, 133.2, 120.5, 81.7, 70.5, 70.4, 69.1, 63.7, 62.8, 59.6, 42.2, 36.0, 25.9, 24.5, 23.7, 18.0. HRMS (ESI) calcd for C<sub>38</sub>H<sub>54</sub>NO<sub>13</sub> [M + NH<sub>4</sub>]<sup>+</sup> 732.3590, found 732.3591.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 3,6,9,12-Tetraoxatetradecane-1,14-diyl</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>8</b>), white amorphous solid, 52.6% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.80 (t, <i>J</i> = 8.6 Hz, 2H), 6.15 (d, <i>J</i> = 3.2 Hz, 2H), 5.55 (d, <i>J</i> = 2.8 Hz, 2H), 4.35–4.14 (m, 4H), 3.76 (t, <i>J</i> = 9.4 Hz, 2H), 3.71–3.63 (m, 4H), 3.57 (s, 12H), 2.80–2.71 (m, 4H), 2.64–2.52 (m, 4H), 2.38 (m, 6H), 2.19 (m, 2H), 1.62–1.53 (m, 2H), 1.50 (s, 6H), 1.13 (d, <i>J</i> = 12.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.3, 166.9, 141.3, 138.4, 133.0, 120.3, 81.5, 70.3, 70.2, 68.9(2C), 63.5, 62.6, 59.4, 42.0, 35.8, 25.7, 24.2, 23.5, 17.7. HRMS (ESI) calcd for C<sub>40</sub>H<sub>58</sub>NO<sub>14</sub> [M + NH<sub>4</sub>]<sup>+</sup> 776.3852, found 776.3853.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3,6,9,12,15-Pentaoxaheptadecane-1,17-diyl</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>9</b>), white amorphous solid, 7.2% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.82 (t, <i>J</i> = 8.2 Hz, 2H), 6.19 (d, <i>J</i> = 3.5 Hz, 2H), 5.57 (d, <i>J</i> = 3.1 Hz, 2H), 4.39–4.29 (m, 2H), 4.28–4.19 (m, 2H), 3.78 (t, <i>J</i> = 9.4 Hz, 2H), 3.72–3.67 (m, 4H), 3.60 (s, 16H), 2.84–2.71 (m, 4H), 2.66–2.56 (m, 4H), 2.49–2.32 (m, 6H), 2.26–2.17 (m, 2H), 1.62–1.55 (m, 2H), 1.53 (s, 6H), 1.21–1.12 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 167.1, 141.5, 138.6, 133.3, 120.5, 81.7, 70.5, 70.5, 69.1, 63.7, 62.9, 59.6, 42.2, 36.0, 26.0, 24.5, 23.7, 18.0; HRMS (ESI) calcd for C<sub>42</sub>H<sub>62</sub>NO<sub>15</sub> [M + NH<sub>4</sub>]<sup>+</sup> 820.4119, found 820.4115.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 3,6,9,12,15,18,21-Heptaoxatricosane-1,23-diyl</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>10</b>), white amorphous solid, 36.4% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.85 (s, 2H), 6.21 (d, <i>J</i> = 3.5 Hz, 2H), 5.61 (d, <i>J</i> = 3.1 Hz, 2H), 4.35 (dd, <i>J</i> = 5.7, 4.2 Hz, 2H), 4.27 (dd, <i>J</i> = 10.7, 6.7 Hz, 2H), 3.82 (t, <i>J</i> = 9.4 Hz, 2H), 3.75–3.70 (m, 4H), 3.64 (d, <i>J</i> = 1.6 Hz, 24H), 2.81 (d, <i>J</i> = 9.5 Hz, 4H), 2.64 (dd, <i>J</i> = 9.0, 5.8 Hz, 4H), 2.51–2.36 (m, 6H), 2.24 (dd, <i>J</i> = 9.3, 7.6 Hz, 2H), 1.68–1.59 (m, 2H), 1.56 (s, 6H), 1.20 (d, <i>J</i> = 2.5 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 167.0, 141.5, 138.6, 133.2, 120.4, 81.7, 70.5, 70.5, 70.4, 69.0, 63.7, 62.8, 59.6, 42.2, 36.0, 25.9, 24.4, 23.6, 17.9; HRMS (ESI) calcd for C<sub>46</sub>H<sub>66</sub>NaO<sub>17</sub> [M + Na]<sup>+</sup> 913.4198, found 913.4198.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 3,6,9,12,15,18,21,24,27-Nonaoxanonacosane-1,29-diyl</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>11</b>), white amorphous solid, 62.4% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.84 (t, <i>J</i> = 8.5 Hz, 2H), 6.21 (s, 2H), 5.59 (s, 2H), 4.35 (d, <i>J</i> = 11.8 Hz, 2H), 4.25 (d, <i>J</i> = 11.8 Hz, 2H), 3.80 (t, <i>J</i> = 9.1 Hz, 2H), 3.71 (s, 4H), 3.63 (s, 36H), 2.80 (d, <i>J</i> = 8.8 Hz, 4H), 2.61 (d, <i>J</i> = 9.7 Hz, 4H), 2.51–2.32 (m, 6H), 2.24 (d, <i>J</i> = 12.7 Hz, 2H), 1.61 (d, <i>J</i> = 13.5 Hz, 2H), 1.54 (s, 6H), 1.18 (d, <i>J</i> = 12.5 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.5, 167.2, 141.6, 138.7, 133.4, 120.6, 81.8, 70.7, 70.6, 69.2, 63.9, 63.0, 59.6, 42.4, 36.2, 26.1, 24.6, 23.8, 18.1. HRMS (ESI) calcd for C<sub>50</sub>H<sub>78</sub>NO<sub>19</sub> [M + NH<sub>4</sub>]<sup>+</sup> 996.5166, found 996.5171.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 3,6,9,12,15,18,21,24,27,30,33-Undecaoxapentatriacontane-1,35-diyl</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>12</b>), white amorphous solid, 9.6% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.85 (d, <i>J</i> = 7.4 Hz, 2H), 6.20 (s, 2H), 5.58 (s, 2H), 4.33 (s, 2H), 4.26 (s, 2H), 3.80 (d, <i>J</i> = 8.9 Hz, 2H), 3.70 (s, 4H), 3.62 (s, 40H), 2.79 (d, <i>J</i> = 8.9 Hz, 4H), 2.61 (d, <i>J</i> = 11.8 Hz, 4H), 2.51–2.16 (m, 6H), 2.22 (s, 2H), 1.59 (s, 2H), 1.54 (s, 6H), 1.16 (s, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 167.1, 141.5, 138.6, 133.3, 120.5, 81.7, 70.5, 70.5, 69.1, 63.8, 62.9, 59.6, 42.3, 36.0, 26.0, 24.5, 23.7, 18.0; HRMS (ESI) calcd for C<sub>54</sub>H<sub>82</sub>NaO<sub>21</sub> [M + Na]<sup>+</sup> 1089.5246, found 1089.5249.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-Heptadecaoxatripentacontane-1,53-diyl</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>13</b>), white amorphous solid, 6.6% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.83 (t, <i>J</i> = 8.8 Hz, 2H), 6.19 (d, <i>J</i> = 3.4 Hz, 2H), 5.58 (d, <i>J</i> = 3.0 Hz, 2H), 4.38–4.30 (m, 2H), 4.27–4.20 (m, 2H), 3.79 (s, 2H), 3.72–3.68 (m, 4H), 3.62 (s, 64H), 2.80 (t, <i>J</i> = 10.4 Hz, 4H), 2.65–2.56 (m, 4H), 2.44–2.36 (m, 6H), 2.26–2.18 (m, 2H), 1.68–1.63 (m, 2H), 1.53 (s, 6H), 1.23–1.11 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 167.1, 141.5, 138.5, 133.2, 120.5, 81.7, 70.5, 70.5, 69.1, 63.7, 62.8, 59.6, 42.2, 36.0, 25.9, 24.5, 23.7, 18.0; HRMS (ESI) calcd for C<sub>66</sub>H<sub>106</sub>NaO<sub>27</sub> [M + Na]<sup>+</sup> 1353.6819, found1353.6818.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-Nonadecaoxanonapentacontane-1,59-diyl</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>14</b>), white amorphous solid, 8.5% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.80 (t, <i>J</i> = 8.5 Hz, 2H), 6.16 (s, 2H), 5.55 (s, 2H), 4.35–4.28 (m, 2H), 4.24–4.18 (m, 2H), 3.76 (s, 2H), 3.73–3.65 (m, 6H), 3.59 (s, 70H), 2.76 (d, <i>J</i> = 9.5 Hz, 4H), 2.67–2.52 (m, 4H), 2.44–2.32 (m, 6H), 2.24–2.18 (m, 2H), 1.62–1.53 (m, 2H), 1.51 (s, 6H), 1.18 (d, <i>J</i> = 17.4 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 167.0, 141.5, 138.5, 133.2, 120.5, 81.7, 70.5, 70.5, 69.1, 63.7, 62.8, 59.6, 42.2, 36.0, 25.9, 24.5, 23.7, 18.0; HRMS (ESI) calcd for C<sub>70</sub>H<sub>114</sub>NaO<sub>29</sub> [M + Na]<sup>+</sup> 1441.7343, found 1441.7342.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69-Tricosaoxahenheptacontane-1,71-diyl</h4><div class="NLM_p last">(1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-Bis(1a-methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5-carboxylate) (<b>15</b>), white amorphous solid, 7.3% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.86 (t, <i>J</i> = 8.6 Hz, 2H), 6.23 (d, <i>J</i> = 3.3 Hz, 2H), 5.60 (d, <i>J</i> = 3.0 Hz, 2H), 4.41–4.33 (m, 2H), 4.31–4.23 (m, 2H), 3.84–3.79 (m, 2H), 3.73 (dd, <i>J</i> = 7.6, 4.2 Hz, 4H), 3.65 (s, 88H), 2.81 (d, <i>J</i> = 9.5 Hz, 4H), 2.68–2.58 (m, 4H), 2.50–2.38 (m, 6H), 2.32–2.20 (m, 2H), 1.66–1.60 (m, 2H), 1.56 (s, 6H), 1.22–1.14 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 167.1, 141.5, 138.5, 133.3, 120.6, 81.7, 70.5, 70.5, 69.1, 63.8, 62.9, 59.6, 42.2, 36.0, 26.0, 24.5, 23.7, 18.0; HRMS (ESI) calcd for C<sub>78</sub>H<sub>130</sub>O<sub>33</sub> [M + Na]<sup>+</sup> 1617.8392, found 1617.8389.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Synthesis of Compound <b>16</b></h3><div class="NLM_p">Compound <b>5</b> (380 mg, 0.6 mmol) was dissolved in dimethylamine (6 mL, 12.0 mmol, 2 N in THF) at 0 °C. The mixture was stirred 1 h at 0 °C. The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (DCM: MeOH = 20:1) to afford a white solid (314 mg). To a solution of the white solid in methanol (4.5 mL) was added fumaric acid (104 mg, 0.9 mmol). The mixture was stirred for 6.5 h and concentrated under vacuum to afford compound <b>16</b> (400 mg, yield 71.2% for two steps).</div><div class="NLM_p last">1,1′-((1a<i>R</i>,1a′<i>R</i>,4<i>E</i>,4′<i>E</i>,7a<i>S</i>,7a′<i>S</i>,8<i>R</i>,8′<i>R</i>,10a<i>S</i>,10b<i>S</i>,10a′<i>S</i>,10b′<i>S</i>)-(((Oxybis(ethane-2,1-diyl))bis(oxy))bis(carbonyl))bis(1a-methyl-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2′,3′:9,10]cyclodeca[1,2-<i>b</i>]furan-5,8-diyl))bis(<i>N</i>,<i>N</i>-dimethylmethanaminium) (<i>E</i>)-3-carboxyacrylate (<b>16</b>), white amorphous solid, <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.81–6.73 (m, 2H), 6.60 (s, 4H), 4.31–4.21 (m, 2H), 4.21–4.12 (m, 2H), 4.04 (t, <i>J</i> = 9.6 Hz, 2H), 3.81–3.62 (m, 4H), 3.30 (dd, <i>J</i> = 13.2, 8.9 Hz, 2H), 3.10–2.95 (m, 4H), 2.81 (s, 12H), 2.67 (d, <i>J</i> = 9.5 Hz, 2H), 2.52–2.35 (m, 8H), 2.30–2.08 (m, 4H), 2.03–1.88 (m, 2H), 1.71–1.60 (m, 2H), 1.48 (s, 6H), 1.06 (t, <i>J</i> = 12.9 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ 177.9, 171.4, 168.6, 143.5, 136.3, 134.4, 84.0, 70.2, 64.8, 64.0, 61.3, 56.8, 44.4, 43.7, 43.1, 37.1, 26.9, 25.3, 24.7, 17.9. HRMS (MALDI) calcd for C<sub>38</sub>H<sub>57</sub>N<sub>2</sub>O<sub>11</sub><sup>+</sup> [M + H]<sup>+</sup> 717.3957, found 717.3960.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Materials</h3><div class="NLM_p last">Cell culture medium (DMEM) and fetal bovine serum were purchased from Gibco (NY). MTT Pyruvate kinase assay kit and DMSO were purchased from Sigma Chemical Company (St. Louis, MO). Cell lysis buffer and the nuclear protein extraction kit were purchased from Beyotime Institute of Biotechnology (Beijing, China). Annexin V-FITC and PI apoptosis detection kit was purchased from BD Biosciences (San Jose, CA). Rabbit polyclonal antihuman Bax, Bcl-2, Bcl-xl, STAT3, p- STAT3, E-cadherin, vimentin, and β-actin antibodies were purchased from Cell Signaling Technology (Beverly, MA). The secondary antibodies used were horseradish peroxidase-conjugated goat antirabbit or antimouse IgG were purchased from Solarbio (Beijing, China). ECL-Plus Kit was purchased from Solarbio (Beijing, China). Bar b/c nude mice (5–6 weeks) were purchased from the Chinese Academy of Medical Sciences.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Cell Culture</h3><div class="NLM_p last">U118, U87, U251, SHG44, SF126, C6, 3T3, HeLa, HepG2, SUM159, and A549 cells were cultured in standard DMEM-based media, supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin. All cells were cultured in a humidified incubator at 37 °C/5% CO<sub>2</sub> unless otherwise stated.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Preparation of Recombinant Proteins</h3><div class="NLM_p last">The human cDNA for PKM2, were cloned into pET28a with a N-terminal 6 × -His tag and purified from <i>E. coli</i> BL21 using Ni-Agarose beads (Qiagen). Briefly, BL21 grown to an OD 600 nm of 0.7 were induced with 0.1 mM IPTG at 18 °C for 20 h. Cells were collected and lysed by freeze/thaw cycles and sonication. Lysate was passed over a Ni-NTA agarose column, and rPKM2 (recombinant PKM2) was eluted with 250 mM imidazole in 1 mL fractions. Fractions with a high concentration of rPKM2 were determined using SDS-PAGE and Coomassie brilliant blue staining according to standard protocol.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> In Vitro Assay for rPKM2 Activity</h3><div class="NLM_p last">rPKM2 activity was measured with a pyruvate kinase assay kit (Sigma, MAK72-1KT). One microgram of rPKM2 was first incubated with compound for 30 min at room temperature and then transferred to a 96-well plate. According to the kit instruction, 50 μL of mix was added to the plate and immediately assayed in a microplate reader. Fluorescence change was detected at excitation wavelength of 535 nm and emission wavelength of 587 nm. Concentration at half-maximal activation (AC<sub>50</sub>) values were determined using Prism GraphPad Software.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Protein Cross-Linking Experiment</h3><div class="NLM_p last">Cells attached to culture dishes were quickly washed twice with ice-cold PBS and then lysed with NP40 supplemented with protease inhibitors on ice for 30 min. After centrifugation at 4 °C/12 000 rpm, the supernatant was collected and protein concentration determined with the BCA assay kit. The same amount of cellular supernatant was incubated with different concentrations of <b>5</b> for 30 min and then added to 5 mM DSS for 30 min at room temperature. Subsequently, samples were separated by SDS-PAGE and further transferred to PVDF membrane (Bio-Rad) using standard Western blotting procedures. Anti-PKM2 (Cell Signaling, 4053, dilution 1:1000) was used to indicate the band of PKM2.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Dynamic Laser Light Scattering (LLS) To Analyze the Changes of PKM2 Particle Size</h3><div class="NLM_p last">The recombinant PKM2 (1.0 mg/mL) and compound solutions were clarified by 20 nm (Whatman, Anotop 10) and 0.45 mm hydrophilic PTFE (Millipore) filters, respectively, and then PKM2 was incubated with compounds (10 μM) for 30 min at room temperature. Each solution mixture was measured by dynamic LLS (ALV/DLS/SLS-5022F). The theory and other details of LLS instrumentation can be found elsewhere.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Cell Apoptosis Assay</h3><div class="NLM_p last">U87 and U118 cells were seeded into a 24-well plate. After 12 h, compound <b>5</b> was added and incubated for 48 h. Then the cells were collected, washed with PBS buffer, and then resuspended with 1× binding buffer according to the manufacturer’s suggestions. After that, the cells were stained with Annxin-V and PI for 15 min at room temperature. Then 200 μL of 1× binding buffer was added and analyzed with flow cytometry.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> MTT Assay</h3><div class="NLM_p last">U118, U87, U251, SHG44, SF126, C6, 3T3, HeLa, HepG2, SUM159, and A549 cells were seeded into 96-well plates with 5000 cells/well. After 12 h, compounds with different concentrations were added and incubated for 72 h. Then 20 μL of MTT solution (5 mg/mL) was added into each well and incubated for another 4 h. The supernatant was discarded, and the precipitate was dissolved in DMSO and measured with a Microplate Reader at OD570 nm.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Transwell Assay</h3><div class="NLM_p last">U87 and U118 cells were treated with compound <b>5</b> at 2 μM for 48 h, and then the living cells were collected and resuspended with DMEM without FBS. For transwell assays, 1 × 10<sup>5</sup> cells were plated in the upper chamber with the noncoated (migration assay) or matrigel-coated (invasion assay) transwell inserts containing 8 μm filters (BD Falcon). In both assays, the cambers were putted into the 24-well plate containing DMEM with 20% FBS as a chemoattractant in the lower chamber. After 24 h fixing and staining with crystal Viol, the cells in the upper camber that did not migrate or invade through the pores were removed by a cotton swab. The number of cells on the lower surface of the membrane were counted and analyzed with Graphad Prism5.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Western Blot Assay</h3><div class="NLM_p last">U87 and U118 cells were treated with compound <b>5</b> at 2 μM for 48 h, and then the cells were collected and split with RIPA. An amount of 50 μg of total protein was separated with 12% SDS-PAGE, transferred to nitrocellulose membranes, blocked with 5% skimmed milk for 1 h at room temperature, and incubated with primary antibodies at 4 °C overnight (dilution for 1:1000). After the membrane were washed five times with PBST, they were incubated with HRP-conjugated secondary antibodies (dilution for 1:5000) for 2 h at room temperature. Then the membranes were visualized by chemiluminescence.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Nuclear Translocation Assay</h3><div class="NLM_p last">The nuclear protein and cytoplasm protein were collected respectively according to the protocol of Nuclear and Cytoplasmic Extraction Kit. Then the protein was analyzed by Western blot assay.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Animal Assay</h3><div class="NLM_p last">Animal assay was performed according to national and international guidelines, and all animal studies were performed at the Chinese Academy of Medical Sciences and approved by the Nankai University Ethical Committee. Bar b/c nude mice (5–6 weeks) were purchased from the Chinese Academy of Medical Sciences. Tumor cells (1 × 10<sup>7</sup>) in 100 μL of PBS were injected in the subcutaneous right forelimb armpit. The drugs were administered every 3 days with 50 mg/kg by abdominal administration. Tumor sizes were measured every 3 days in two dimensions using a caliper, and the tumor volume was calculated. After 20 days, the mice were sacrificed and the tumor tissue were fixed with 10% formalin and then embedded in paraffin, sectioned, and analyzed by immunohistochemistry.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Immunohistochemistry</h3><div class="NLM_p last">Paraffin blocks were sectioned by a rotary microtome to a thickness of 4 μm. Sections were deparaffinized in xylene and rehydrated through a graded ethanol series before antigen retrieval. Sections were blocked using 2% and 5% sheep serum, incubated in primary antibodies including PKM2, Bax, Bcl-2, E-cadherin, vimentin, and p-STAT3 for 24 h at 4 °C and then rinsed with TBS. Sections were then incubated with secondary antibodies. For immunohistochemical analysis, sections were incubated with HRP solution and developed with DAB chromogen before counterstaining with hematoxylin. Slides were dehydrated and coverslipped with neutral balsam.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Knockdown of PKM2</h3><div class="NLM_p last">The recombinant lentivirus particles containing shPKM2 or NC and 5 μg/mL Polybrene were added to U87 or U118 cells for 24 h. For generating stable cell lines, infected cells were selected with 2 μg/mL puromycin (Sigma) for 7 days. Then the protein level of PKM2 was analyzed by Western blot.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Transendothelial Electric Resistance Measurements (TEER) aAssay</h3><div class="NLM_p last">For TEER measurement, filters with microporous polycarbonate membranes (0.4 μm pore size, 0.33 cm<sup>2</sup> growth area, Transwell TM no. 3041 Costar) were coated for 24 h at 37 °C with a 27 μg/mL rat tail collagen solution. Madin–Darby canine kidney (MDCK II) cells were seeded in a density of 50 000 cells/filter. For all measurements, the cellZscope  module was preheated to 37 °C for at least 1 h beforehand. A 1.2 mL amount of basolateral medium was taken from each well of the filter plates and added to the lower chamber within the measuring module. In the following step, the filter inserts were placed into the wells of the measuring chamber. Then 50 μL of the cell suspension in each filter was replaced by the respective sample of the same volume according to the planned sequence of experiments. The measurement was subsequently carried out at 37 °C in a 5% CO<sub>2</sub> atmosphere with saturated humidity. The TEER in each well of the cellZscope  module were measured sequentially with an approximate rate of 1 well/min.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Statistical Analysis</h3><div class="NLM_p last">Each experiment was performed in triplicate, and all results were repeated three times. All animal experiments were performed using randomly assigned mice. Student’s <i>t</i> test was performed with GraphPad Prism 5 software to analysis the significance between two groups. <i>P</i>-value <0.05 was considered to be statistically significant. Values of <i>P</i> < 0.05, <i>P</i> < 0.01, and <i>P</i> < 0.001 are denoted by *, **, and ***, respectively.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01328" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84648" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84648" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01328?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01328</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Figures S1–S3, HPLC assessment of purity for compounds <b>5</b> and <b>16</b>, NMR spectra (<sup>1</sup>H NMR, <sup>13</sup>C NMR) of compounds <b>5</b>–<b>16</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01328/suppl_file/jm9b01328_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01328/suppl_file/jm9b01328_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01328/suppl_file/jm9b01328_si_001.pdf">jm9b01328_si_001.pdf (1.49 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01328/suppl_file/jm9b01328_si_002.csv">jm9b01328_si_002.csv (2.39 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01328" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18361" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18361" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4289-4829" title="Orcid link">http://orcid.org/0000-0002-4289-4829</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b7ddded9d0dbded9dcf7d9d6d9dcd6de99d2d3c299d4d9"><span class="__cf_email__" data-cfemail="02686b6c656e6b6c69426c636c69636b2c6766772c616c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yue Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1317-7097" title="Orcid link">http://orcid.org/0000-0002-1317-7097</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6f161a0a0c070a012f010e01040e06410a0b1a410c01"><span class="__cf_email__" data-cfemail="5c2529393f3439321c323d32373d3572393829723f32">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Quan Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5280-0956" title="Orcid link">http://orcid.org/0000-0001-5280-0956</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#215b49404f465054404f614f404f4a40480f4445540f424f015b49404f465054404f171013611017120f424e4c"><span class="__cf_email__" data-cfemail="6a10020b040d1b1f0b042a040b04010b03440f0e1f440904">[email protected]</span> <span class="__cf_email__" data-cfemail="39435158575e484c58570f080b79080f0a175a5654">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yahui Ding</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingqing Xue</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuo Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kai Hu</span> - <span class="hlFld-Affiliation affiliation">College
of Medicine, Nankai University, 94 Weijin Road, Tianjin 3000710, People’s
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Da Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianpeng Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ye Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongyu Guo</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Hao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weizhi Ge</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ang Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People’s Republic of China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16488" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16488" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the support of the National Natural Science Foundation of China (no. 81872764 and no. 81573308 to Q.Z.; no. 81573282 to Y.C.), The National Science Fund for Distinguished Young Scholars (no. 81625021) to Y.C., Guangdong Joint Fund of the National Natural Science Foundation of China (no. U1801288), Natural Science Foundation of Tianjin (no. 17JCQNJC13400) to Q.Z., the Fundamental Research Funds for the Central Universities to Y. D. (Nankai University, no. 63191407), and the Fundamental Research Funds for the Central Universities to Q.Z. (Nankai University, no. 63191519).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glioblastoma multiforme</p></td></tr><tr><td class="NLM_term">PKM2</td><td class="NLM_def"><p class="first last">pyruvate kinase M2</p></td></tr><tr><td class="NLM_term">PEP</td><td class="NLM_def"><p class="first last">phosphoenolpyruvate</p></td></tr><tr><td class="NLM_term">PTL</td><td class="NLM_def"><p class="first last">parthenolide</p></td></tr><tr><td class="NLM_term">MMB</td><td class="NLM_def"><p class="first last">melampomagnolide B</p></td></tr><tr><td class="NLM_term">AC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximum activating concentration</p></td></tr><tr><td class="NLM_term">ADR</td><td class="NLM_def"><p class="first last">adriamycin</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 54 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reifenberger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figarella-Branger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenee, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohgaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestler, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleihues, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, D. W.</span></span> <span> </span><span class="NLM_article-title">The 2016 World Health Organization classification of tumors of the central nervous system: a summary</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1007/s00401-016-1545-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1007%2Fs00401-016-1545-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=27157931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC28bnsVektA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2016&pages=803-820&author=D.+N.+Louisauthor=A.+Perryauthor=G.+Reifenbergerauthor=A.+Von+Deimlingauthor=D.+Figarella-Brangerauthor=W.+K.+Caveneeauthor=H.+Ohgakiauthor=O.+D.+Wiestlerauthor=P.+Kleihuesauthor=D.+W.+Ellison&title=The+2016+World+Health+Organization+classification+of+tumors+of+the+central+nervous+system%3A+a+summary&doi=10.1007%2Fs00401-016-1545-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary</span></div><div class="casAuthors">Louis David N; Perry Arie; Reifenberger Guido; Reifenberger Guido; von Deimling Andreas; von Deimling Andreas; Figarella-Branger Dominique; Cavenee Webster K; Ohgaki Hiroko; Wiestler Otmar D; Kleihues Paul; Ellison David W</div><div class="citationInfo"><span class="NLM_cas:title">Acta neuropathologica</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">803-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor.  For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era.  As such, the 2016 CNS WHO presents major restructuring of the diffuse gliomas, medulloblastomas and other embryonal tumors, and incorporates new entities that are defined by both histology and molecular features, including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, WNT-activated and medulloblastoma, SHH-activated; and embryonal tumour with multilayered rosettes, C19MC-altered.  The 2016 edition has added newly recognized neoplasms, and has deleted some entities, variants and patterns that no longer have diagnostic and/or biological relevance.  Other notable changes include the addition of brain invasion as a criterion for atypical meningioma and the introduction of a soft tissue-type grading system for the now combined entity of solitary fibrous tumor / hemangiopericytoma-a departure from the manner by which other CNS tumors are graded.  Overall, it is hoped that the 2016 CNS WHO will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7YzqOXqWReQqdek-gHSrIfW6udTcc2eY6_PSG-BLHdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bnsVektA%253D%253D&md5=f9ac51999bf1b171477b20ea0085c9e8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs00401-016-1545-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-016-1545-1%26sid%3Dliteratum%253Aachs%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DPerry%26aufirst%3DA.%26aulast%3DReifenberger%26aufirst%3DG.%26aulast%3DVon%2BDeimling%26aufirst%3DA.%26aulast%3DFigarella-Branger%26aufirst%3DD.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26aulast%3DOhgaki%26aufirst%3DH.%26aulast%3DWiestler%26aufirst%3DO.%2BD.%26aulast%3DKleihues%26aufirst%3DP.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26atitle%3DThe%25202016%2520World%2520Health%2520Organization%2520classification%2520of%2520tumors%2520of%2520the%2520central%2520nervous%2520system%253A%2520a%2520summary%26jtitle%3DActa%2520Neuropathol.%26date%3D2016%26volume%3D131%26spage%3D803%26epage%3D820%26doi%3D10.1007%2Fs00401-016-1545-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturiale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galzio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danieli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, A. A.</span></span> <span> </span><span class="NLM_article-title">The effect of re-operation on survival in patients with recurrent glioblastoma</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1743</span>– <span class="NLM_lpage">1748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=25750337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC2MnhvVyktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1743-1748&author=E.+Franceschiauthor=M.+Bartolottiauthor=A.+Tosoniauthor=S.+Bartoliniauthor=C.+Sturialeauthor=A.+Fioravantiauthor=E.+Pozzatiauthor=R.+Galzioauthor=A.+Talacchiauthor=L.+Volpinauthor=L.+Morandiauthor=D.+Danieliauthor=M.+Ermaniauthor=A.+A.+Brandes&title=The+effect+of+re-operation+on+survival+in+patients+with+recurrent+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of re-operation on survival in patients with recurrent glioblastoma</span></div><div class="casAuthors">Franceschi Enrico; Bartolotti Marco; Tosoni Alicia; Bartolini Stefania; Brandes Alba A; Sturiale Carmelo; Fioravanti Antonio; Pozzati Eugenio; Galzio Renato; Talacchi Andrea; Volpin Lorenzo; Morandi Luca; Danieli Daniela; Ermani Mario</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1743-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Treatment options for glioblastoma (GBM) at recurrence have limited efficacy.  Re-surgery has been used for confirmation of recurrent disease and to provide relief of symptoms but the real impact on survival is unknown.  PATIENTS AND METHODS:  A retrospective analysis was performed for GBM patients followed between 01/2005 and 06/2010 at our Institution.  RESULTS:  Two hundred and thirty-two patients with recurrent GBM were evaluated.  One hundred and two patients (44%) were treated with re-surgery followed by chemotherapy and 130 patients (56%) with chemotherapy alone.  In multivariate analysis, no significant effect of re-surgery was found, with age (p=0.001), MGMT methylation (p=0.002) and PFS at 6 months (p=0.0001) being significant prognostic factors.  CONCLUSION:  Second surgery might have a limited impact in the clinical course of recurrent GBM patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOo1G9GMq1wEBuFdjgVNKSfW6udTcc2eY6_PSG-BLHdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnhvVyktA%253D%253D&md5=c658d55ebb01f3dc8c8503376cd7044f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFranceschi%26aufirst%3DE.%26aulast%3DBartolotti%26aufirst%3DM.%26aulast%3DTosoni%26aufirst%3DA.%26aulast%3DBartolini%26aufirst%3DS.%26aulast%3DSturiale%26aufirst%3DC.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DPozzati%26aufirst%3DE.%26aulast%3DGalzio%26aufirst%3DR.%26aulast%3DTalacchi%26aufirst%3DA.%26aulast%3DVolpin%26aufirst%3DL.%26aulast%3DMorandi%26aufirst%3DL.%26aulast%3DDanieli%26aufirst%3DD.%26aulast%3DErmani%26aufirst%3DM.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26atitle%3DThe%2520effect%2520of%2520re-operation%2520on%2520survival%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%26jtitle%3DAnticancer%2520Res.%26date%3D2015%26volume%3D35%26spage%3D1743%26epage%3D1748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrom, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittleman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondracek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolinsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroup, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruchko, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnholtz-Sloan, J. S.</span></span> <span> </span><span class="NLM_article-title">CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010</span>. <i>Neuro. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1093/neuonc/not151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1093%2Fneuonc%2Fnot151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=23284031" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1-56&author=Q.+T.+Ostromauthor=H.+Gittlemanauthor=P.+Farahauthor=A.+Ondracekauthor=Y.+Chenauthor=Y.+Wolinskyauthor=N.+E.+Stroupauthor=C.+Kruchkoauthor=J.+S.+Barnholtz-Sloan&title=CBTRUS+statistical+report%3A+primary+brain+and+central+nervous+system+tumors+diagnosed+in+the+United+States+in+2006%E2%80%932010&doi=10.1093%2Fneuonc%2Fnot151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnot151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnot151%26sid%3Dliteratum%253Aachs%26aulast%3DOstrom%26aufirst%3DQ.%2BT.%26aulast%3DGittleman%26aufirst%3DH.%26aulast%3DFarah%26aufirst%3DP.%26aulast%3DOndracek%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWolinsky%26aufirst%3DY.%26aulast%3DStroup%26aufirst%3DN.%2BE.%26aulast%3DKruchko%26aufirst%3DC.%26aulast%3DBarnholtz-Sloan%26aufirst%3DJ.%2BS.%26atitle%3DCBTRUS%2520statistical%2520report%253A%2520primary%2520brain%2520and%2520central%2520nervous%2520system%2520tumors%2520diagnosed%2520in%2520the%2520United%2520States%2520in%25202006%25E2%2580%25932010%26jtitle%3DNeuro.%2520Oncol.%26date%3D2013%26volume%3D15%26spage%3D1%26epage%3D56%26doi%3D10.1093%2Fneuonc%2Fnot151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abi-Said, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourney, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokaslan, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMonte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutcheon, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassenbusch, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawaya, R.</span></span> <span> </span><span class="NLM_article-title">A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival</span>. <i>J. Neurosurg.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.3171/jns.2001.95.2.0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.3171%2Fjns.2001.95.2.0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=11780887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FlsFGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2001&pages=190-198&author=M.+Lacroixauthor=D.+Abi-Saidauthor=D.+R.+Fourneyauthor=Z.+L.+Gokaslanauthor=W.+Shiauthor=F.+DeMonteauthor=F.+F.+Langauthor=I.+E.+McCutcheonauthor=S.+J.+Hassenbuschauthor=E.+Hollandauthor=K.+Hessauthor=C.+Michaelauthor=D.+Millerauthor=R.+Sawaya&title=A+multivariate+analysis+of+416+patients+with+glioblastoma+multiforme%3A+prognosis%2C+extent+of+resection%2C+and+survival&doi=10.3171%2Fjns.2001.95.2.0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival</span></div><div class="casAuthors">Lacroix M; Abi-Said D; Fourney D R; Gokaslan Z L; Shi W; DeMonte F; Lang F F; McCutcheon I E; Hassenbusch S J; Holland E; Hess K; Michael C; Miller D; Sawaya R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurosurgery</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">190-8</span>
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    </div><div class="casAbstract">OBJECT:  The extent of tumor resection that should be undertaken in patients with glioblastoma multiforme (GBM) remains controversial.  The purpose of this study was to identify significant independent predictors of survival in these patients and to determine whether the extent of resection was associated with increased survival time.  METHODS:  The authors retrospectively analyzed 416 consecutive patients with histologically proven GBM who underwent tumor resection at the authors' institution between June 1993 and June 1999.  Volumetric data and other tumor characteristics identified on magnetic resonance (MR) imaging were collected prospectively.  CONCLUSIONS:  Five independent predictors of survival were identified: age, Karnofsky Performance Scale (KPS) score, extent of resection, and the degree of necrosis and enhancement on preoperative MR imaging studies.  A significant survival advantage was associated with resection of 98% or more of the tumor volume (median survival 13 months, 95% confidence interval [CI] 11.4-14.6 months), compared with 8.8 months (95% CI 7.4-10.2 months; p < 0.0001) for resections of less than 98%.  Using an outcome scale ranging from 0 to 5 based on age, KPS score, and tumor necrosis on MR imaging, we observed significantly longer survival in patients with lower scores (1-3) who underwent aggressive resections, and a trend toward slightly longer survival was found in patients with higher scores (4-5).  Gross-total tumor resection is associated with longer survival in patients with GBM, especially when other predictive variables are favorable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxfgUiUw3arqqcneEtCi92fW6udTcc2ea0RsB_KcDtCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FlsFGitA%253D%253D&md5=4f82792eeb0f0f63c6aca3124c774088</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3171%2Fjns.2001.95.2.0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3171%252Fjns.2001.95.2.0190%26sid%3Dliteratum%253Aachs%26aulast%3DLacroix%26aufirst%3DM.%26aulast%3DAbi-Said%26aufirst%3DD.%26aulast%3DFourney%26aufirst%3DD.%2BR.%26aulast%3DGokaslan%26aufirst%3DZ.%2BL.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DDeMonte%26aufirst%3DF.%26aulast%3DLang%26aufirst%3DF.%2BF.%26aulast%3DMcCutcheon%26aufirst%3DI.%2BE.%26aulast%3DHassenbusch%26aufirst%3DS.%2BJ.%26aulast%3DHolland%26aufirst%3DE.%26aulast%3DHess%26aufirst%3DK.%26aulast%3DMichael%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSawaya%26aufirst%3DR.%26atitle%3DA%2520multivariate%2520analysis%2520of%2520416%2520patients%2520with%2520glioblastoma%2520multiforme%253A%2520prognosis%252C%2520extent%2520of%2520resection%252C%2520and%2520survival%26jtitle%3DJ.%2520Neurosurg.%26date%3D2001%26volume%3D95%26spage%3D190%26epage%3D198%26doi%3D10.3171%2Fjns.2001.95.2.0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang-Xuan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delattre, J.-Y.</span></span> <span> </span><span class="NLM_article-title">Primary brain tumours in adults</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(03)12328-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2FS0140-6736%2803%2912328-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=12559880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FltVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2003&pages=323-331&author=A.+Behinauthor=K.+Hoang-Xuanauthor=A.+F.+Carpentierauthor=J.-Y.+Delattre&title=Primary+brain+tumours+in+adults&doi=10.1016%2FS0140-6736%2803%2912328-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Primary brain tumours in adults</span></div><div class="casAuthors">Behin Anthony; Hoang-Xuan Khe; Carpentier Antoine F; Delattre Jean-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">9354</span>),
    <span class="NLM_cas:pages">323-31</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">The most frequent primary brain tumours in adults are gliomas and primary CNS lymphomas.  In gliomas, molecular genetic analysis plays an increasing part in classification and treatment planning, a feature well illustrated by the chemosensitive oligodendrogliomas.  Unfortunately, management of glioblastoma is still mainly palliative.  Incidence of primary CNS lymphoma has increased strikingly in the past 20 years; substantial progress has been achieved in patients who are immunocompetent with the addition of methotrexate-based chemotherapy to radiotherapy, but the potential neurotoxic effects of this combination in elderly patients is worrisome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8yCAPPun1X5Pq5LRczm8ffW6udTcc2ea0RsB_KcDtCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FltVCltQ%253D%253D&md5=38588e3ab15d4f4a8c1e3379c94f06e1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2803%2912328-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252803%252912328-8%26sid%3Dliteratum%253Aachs%26aulast%3DBehin%26aufirst%3DA.%26aulast%3DHoang-Xuan%26aufirst%3DK.%26aulast%3DCarpentier%26aufirst%3DA.%2BF.%26aulast%3DDelattre%26aufirst%3DJ.-Y.%26atitle%3DPrimary%2520brain%2520tumours%2520in%2520adults%26jtitle%3DLancet%26date%3D2003%26volume%3D361%26spage%3D323%26epage%3D331%26doi%3D10.1016%2FS0140-6736%2803%2912328-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nieder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosu, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andratschke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molls, M.</span></span> <span> </span><span class="NLM_article-title">Treatment of malignant gliomas: Radiotherapy, chemotherapy and integration of new targeted agents</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1586/14737175.4.4.691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1586%2F14737175.4.4.691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15853588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlSmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=691-703&author=C.+Niederauthor=A.+L.+Grosuauthor=M.+P.+Mehtaauthor=N.+Andratschkeauthor=M.+Molls&title=Treatment+of+malignant+gliomas%3A+Radiotherapy%2C+chemotherapy+and+integration+of+new+targeted+agents&doi=10.1586%2F14737175.4.4.691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of malignant gliomas: Radiotherapy, chemotherapy and integration of new targeted agents</span></div><div class="casAuthors">Nieder, Carsten; Grosu, Anca L.; Mehta, Minesh P.; Andratschke, Nicolaus; Molls, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">691-703</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Progress in the biol. and mol. characterization of gliomas and studies of factors assocd. with tumor growth and progression have led to translational research projects and the development of rational new approaches regarding prognostic models, better prediction of response to treatment and innovative therapeutic strategies.  This review summarizes the available data on established and emerging prognostic factors and prognostic scores, and discusses their limitations as well as their potential influence on future therapeutic efforts.  Recent developments in std. treatment options (i.e., surgery, radiotherapy and chemotherapy) are reviewed.  Exptl. data indicate that inhibition of several signaling pathways (e.g., epidermal growth factor, transforming growth factor-β and phosphatidylinositol 3 kinase) may represent a promising therapeutic strategy.  Some inhibitory agents (i.e., drugs, antibodies and antisense oligonucleotides) have now entered clin. trials, mainly for recurrent gliomas and a small no. are being tested in combination with radiotherapy.  Early results of such approaches are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp69CJ3jfTdorVg90H21EOLACvtfcHk0ljTXh8anSvfRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlSmsLo%253D&md5=65ceab2d3f9328b44398733d45c31c5d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1586%2F14737175.4.4.691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.4.4.691%26sid%3Dliteratum%253Aachs%26aulast%3DNieder%26aufirst%3DC.%26aulast%3DGrosu%26aufirst%3DA.%2BL.%26aulast%3DMehta%26aufirst%3DM.%2BP.%26aulast%3DAndratschke%26aufirst%3DN.%26aulast%3DMolls%26aufirst%3DM.%26atitle%3DTreatment%2520of%2520malignant%2520gliomas%253A%2520Radiotherapy%252C%2520chemotherapy%2520and%2520integration%2520of%2520new%2520targeted%2520agents%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2004%26volume%3D4%26spage%3D691%26epage%3D703%26doi%3D10.1586%2F14737175.4.4.691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stupp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Bent, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taphoorn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdahn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curschmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzer, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwin, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allgeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairncross, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirimanoff, R. O.</span></span> <span> </span><span class="NLM_article-title">Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa043330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1056%2FNEJMoa043330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15758009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Wksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=987-996&author=R.+Stuppauthor=W.+P.+Masonauthor=M.+J.+van+den%0ABentauthor=M.+Wellerauthor=B.+Fisherauthor=M.+J.+Taphoornauthor=K.+Belangerauthor=A.+A.+Brandesauthor=C.+Marosiauthor=U.+Bogdahnauthor=J.+Curschmannauthor=R.+C.+Janzerauthor=S.+K.+Ludwinauthor=T.+Gorliaauthor=A.+Allgeierauthor=D.+Lacombeauthor=J.+G.+Cairncrossauthor=E.+Eisenhauerauthor=R.+O.+Mirimanoff&title=Radiotherapy+plus+concomitant+and+adjuvant+Temozolomide+for+glioblastoma&doi=10.1056%2FNEJMoa043330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</span></div><div class="casAuthors">Stupp, Roger; Mason, Warren P.; van den Bent, Martin J.; Weller, Michael; Fisher, Barbara; Taphoorn, Martin J. B.; Belanger, Karl; Brandes, Alba A.; Marosi, Christine; Bogdahn, Ulrich; Curschmann, Jurgen; Janzer, Robert C.; Ludwin, Samuel K.; Gorlia, Thierry; Allgeier, Anouk; Lacombe, Denis; Cairncross, J. Gregory; Eisenhauer, Elizabeth; Mirimanoff, Rene O.; Forsyth, P.; Fulton, D.; Kirby, S.; Wong, R.; Fenton, D.; Fisher, B.; Cairncross, G.; Whitlock, P.; Belanger, K.; Burdette-Radoux, S.; Gertler, S.; Saunders, S.; Laing, K.; Siddiqui, J.; Martin, L. A.; Gulavita, S.; Perry, J.; Mason, W.; Thiessen, B.; Pai, H.; Alam, Z. Y.; Eisenstat, D.; Mingrone, W.; Hofer, S.; Pesce, G.; Curschmann, J.; Dietrich, P. Y.; Stupp, R.; Mirimanoff, R. O.; Thum, P.; Baumert, B.; Ryan, G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">987-996</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal.  The current std. of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy.  In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety.  METHODS Patients with newly diagnosed, histol. confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradn. in daily fractions of 2 Gy given 5 days per wk for 6 wk, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per wk from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).  The primary end point was overall survival.  RESULTS A total of 573 patients from 85 centers underwent randomization.  The median age was 56 years, and 84 % of patients had undergone debulking surgery.  At a median follow-up of 28 mo, the median survival was 14.6 mo with radiotherapy plus temozolomide and 12.1 mo with radiotherapy alone.  The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 % confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test).  The two-year survival rate was 26.5 % with radiotherapy plus temozolomide and 10.4 % with radiotherapy alone.  Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematol. toxic effects in 7 % of patients.  Conclusions The addn. of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clin. meaningful and statistically significant survival benefit with minimal addnl. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdNLD2mISWE7Vg90H21EOLACvtfcHk0lisMbhs3Zgnow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Wksbk%253D&md5=28546eb2e78f7346974d7d029c9fa916</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043330%26sid%3Dliteratum%253Aachs%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DW.%2BP.%26aulast%3Dvan%2Bden%2BBent%26aufirst%3DM.%2BJ.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DTaphoorn%26aufirst%3DM.%2BJ.%26aulast%3DBelanger%26aufirst%3DK.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26aulast%3DMarosi%26aufirst%3DC.%26aulast%3DBogdahn%26aufirst%3DU.%26aulast%3DCurschmann%26aufirst%3DJ.%26aulast%3DJanzer%26aufirst%3DR.%2BC.%26aulast%3DLudwin%26aufirst%3DS.%2BK.%26aulast%3DGorlia%26aufirst%3DT.%26aulast%3DAllgeier%26aufirst%3DA.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DCairncross%26aufirst%3DJ.%2BG.%26aulast%3DEisenhauer%26aufirst%3DE.%26aulast%3DMirimanoff%26aufirst%3DR.%2BO.%26atitle%3DRadiotherapy%2520plus%2520concomitant%2520and%2520adjuvant%2520Temozolomide%2520for%2520glioblastoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D987%26epage%3D996%26doi%3D10.1056%2FNEJMoa043330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Small molecule kinase inhibitors for the treatment of brain cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10030</span>– <span class="NLM_lpage">10066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10030-10066&author=T.+P.+Heffron&title=Small+molecule+kinase+inhibitors+for+the+treatment+of+brain+cancer&doi=10.1021%2Facs.jmedchem.6b00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</span></div><div class="casAuthors">Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10030-10066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In addn. to each of the factors that govern the identification of a successful oncol. drug candidate, drug discovery aimed at treating neurol. cancer must also consider the presence of the blood-brain barrier (BBB).  The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small mols. from freely reaching the brain, where neurooncol. malignancies reside.  Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable.  This Perspective discusses the unmet need for neurooncol. treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clin. inhibitors of kinases that are of interest for the treatment of brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqij86WIpk16LVg90H21EOLACvtfcHk0lisMbhs3Zgnow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E&md5=7e184f17a60658174cb44a9fbadc8dfd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DSmall%2520molecule%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520brain%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10030%26epage%3D10066%26doi%3D10.1021%2Facs.jmedchem.6b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darefsky, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, J. T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrow, R.</span></span> <span> </span><span class="NLM_article-title">Adult glioblastoma multiforme survival in the Temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2172</span>, <span class="refDoi"> DOI: 10.1002/cncr.26494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1002%2Fcncr.26494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21882183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC38zlsFagtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=2163-2172&author=A.+S.+Darefskyauthor=J.+T.+Kingauthor=R.+Dubrow&title=Adult+glioblastoma+multiforme+survival+in+the+Temozolomide+era%3A+a+population-based+analysis+of+Surveillance%2C+Epidemiology%2C+and+End+Results+registries&doi=10.1002%2Fcncr.26494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries</span></div><div class="casAuthors">Darefsky Amy S; King Joseph T Jr; Dubrow Robert</div><div class="citationInfo"><span class="NLM_cas:title">Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2163-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Survival after a glioblastoma multiforme (GBM) diagnosis remained static during the several decades before 1999.  We hypothesized that the progressive increase in temozolomide use for GBM treatment that began in 1999 in the United States would be paralleled by a corresponding improvement in survival.  METHODS:  We included 19,674 GBM cases, ages 20 years or greater, diagnosed 1993 to 2007 in the population-based Surveillance, Epidemiology, and End Results Program database.  We used proportional hazards models to calculate calendar period hazard ratios (HR) and 95% confidence intervals (CI), adjusted for demographic covariates.  We compared survival across periods using the Kaplan-Meier method.  RESULTS:  Starting with cases diagnosed in 1999 to 2001, we observed a progressive decrease in HRs compared with cases diagnosed in 1993 to 1995.  The multivariate-adjusted HR for 2005 to 2007 versus 1993 to 1995 was 0.69 (95% CI, 0.65-0.72).  Age-stratified analyses revealed that this progressive decrease occurred in all age groups except 80+ years.  Two-year survival increased from 7% among cases diagnosed in 1993 to 1995 and 1996 to 1998 to 9% among cases diagnosed in 1999 to 2001, 13% in 2002 to 2004, and 17% in 2005 to 2007.  The disparity in survival between young and old patients increased in the temozolomide era, with 2-year survival of 39% among cases diagnosed at ages 20 to 44 years and 1% among cases diagnosed at 80+ years in 2005 to 2007.  CONCLUSIONS:  We observed a modest, but meaningful, population-based survival improvement for GBM patients in the United States.  Widespread adoption of temozolomide represents the most likely explanation, although other treatment advances, such as increased extent of surgical resection, also may have played a role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8CSz82skSzjC850By6mxpfW6udTcc2eYNP9XegQToirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zlsFagtQ%253D%253D&md5=a555a44bcfbe7065dc9d09824ae72562</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fcncr.26494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.26494%26sid%3Dliteratum%253Aachs%26aulast%3DDarefsky%26aufirst%3DA.%2BS.%26aulast%3DKing%26aufirst%3DJ.%2BT.%26aulast%3DDubrow%26aufirst%3DR.%26atitle%3DAdult%2520glioblastoma%2520multiforme%2520survival%2520in%2520the%2520Temozolomide%2520era%253A%2520a%2520population-based%2520analysis%2520of%2520Surveillance%252C%2520Epidemiology%252C%2520and%2520End%2520Results%2520registries%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26spage%3D2163%26epage%3D2172%26doi%3D10.1002%2Fcncr.26494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Outschoorn, U. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peiris-Pages, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span> <span> </span><span class="NLM_article-title">Cancer metabolism: a therapeutic perspective</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2016.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnrclinonc.2016.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=27141887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsF2qu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=11-31&author=U.+E.+Martinez-Outschoornauthor=M.+Peiris-Pagesauthor=R.+G.+Pestellauthor=F.+Sotgiaauthor=M.+P.+Lisanti&title=Cancer+metabolism%3A+a+therapeutic+perspective&doi=10.1038%2Fnrclinonc.2016.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer metabolism: a therapeutic perspective</span></div><div class="casAuthors">Martinez-Outschoorn, Ubaldo E.; Peiris-Pages, Maria; Pestell, Richard G.; Sotgia, Federica; Lisanti, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-31</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Awareness that the metabolic phenotype of cells within tumors is heterogeneous - and distinct from that of their normal counterparts - is growing.  In general, tumor cells metabolize glucose, lactate, pyruvate, hydroxybutyrate, acetate, glutamine, and fatty acids at much higher rates than their nontumor equiv.; however, the metabolic ecol. of tumors is complex because they contain multiple metabolic compartments, which are linked by the transfer of these catabolites.  This metabolic variability and flexibility enables tumor cells to generate ATP as an energy source, while maintaining the redn.-oxidn. (redox) balance and committing resources to biosynthesis - processes that are essential for cell survival, growth, and proliferation.  Importantly, exptl. evidence indicates that metabolic coupling between cell populations with different, complementary metabolic profiles can induce cancer progression.  Thus, targeting the metabolic differences between tumor and normal cells holds promise as a novel anticancer strategy.  In this Review, we discuss how cancer cells reprogramme their metab. and that of other cells within the tumor microenvironment in order to survive and propagate, thus driving disease progression; in particular, we highlight potential metabolic vulnerabilities that might be targeted therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNuUI8-igjaLVg90H21EOLACvtfcHk0lh2yTXqfe2-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsF2qu7g%253D&md5=a4f92ba92569fca1d35e20ec7acb9394</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2016.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2016.60%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Outschoorn%26aufirst%3DU.%2BE.%26aulast%3DPeiris-Pages%26aufirst%3DM.%26aulast%3DPestell%26aufirst%3DR.%2BG.%26aulast%3DSotgia%26aufirst%3DF.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26atitle%3DCancer%2520metabolism%253A%2520a%2520therapeutic%2520perspective%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D11%26epage%3D31%26doi%3D10.1038%2Fnrclinonc.2016.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer metabolism: a therapeutic window opens</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1038/nrd3504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnrd3504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21878982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSltb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=671-684&author=M.+G.+Vander%0AHeiden&title=Targeting+cancer+metabolism%3A+a+therapeutic+window+opens&doi=10.1038%2Fnrd3504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer metabolism: a therapeutic window opens</span></div><div class="casAuthors">Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genetic events in cancer activate signalling pathways that alter cell metab.  Clin. evidence has linked cell metab. with cancer outcomes.  Together, these observations have raised interest in targeting metabolic enzymes for cancer therapy, but they have also raised concerns that these therapies would have unacceptable effects on normal cells.  However, some of the first cancer therapies that were developed target the specific metabolic needs of cancer cells and remain effective agents in the clinic today.  Research into how changes in cell metab. promote tumor growth has accelerated in recent years.  This has refocused efforts to target metabolic dependencies of cancer cells as a selective anticancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdwef_xmbtRrVg90H21EOLACvtfcHk0lh2yTXqfe2-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSltb3J&md5=5051a52f70ba7dd0cd99cf6ffce7f4c6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd3504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3504%26sid%3Dliteratum%253Aachs%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DTargeting%2520cancer%2520metabolism%253A%2520a%2520therapeutic%2520window%2520opens%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D671%26epage%3D684%26doi%3D10.1038%2Fnrd3504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNicola, G. M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in cancer metabolism: a technological perspective</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">31</span>, <span class="refDoi"> DOI: 10.1038/s12276-018-0027-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fs12276-018-0027-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=29657324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC1MjivV2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=31&author=Y.+P.+Kangauthor=N.+P.+Wardauthor=G.+M.+DeNicola&title=Recent+advances+in+cancer+metabolism%3A+a+technological+perspective&doi=10.1038%2Fs12276-018-0027-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in cancer metabolism: a technological perspective</span></div><div class="casAuthors">Kang Yun Pyo; Ward Nathan P; DeNicola Gina M</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & molecular medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer cells are highly dependent on metabolic pathways to sustain both their proliferation and adaption to harsh microenvironments.  Thus, understanding the metabolic reprogramming that occurs in tumors can provide critical insights for the development of therapies targeting metabolism.  In this review, we will discuss recent advancements in metabolomics and other multidisciplinary techniques that have led to the discovery of novel metabolic pathways and mechanisms in diverse cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfl2bVO8UffAwxfk_AGB-EfW6udTcc2eZh2hHQkLJnZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjivV2rtg%253D%253D&md5=f340410bf7acc31a200c4f012cff648c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs12276-018-0027-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-018-0027-z%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%2BP.%26aulast%3DWard%26aufirst%3DN.%2BP.%26aulast%3DDeNicola%26aufirst%3DG.%2BM.%26atitle%3DRecent%2520advances%2520in%2520cancer%2520metabolism%253A%2520a%2520technological%2520perspective%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2018%26volume%3D50%26spage%3D31%26doi%3D10.1038%2Fs12276-018-0027-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boros, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-N. P.</span></span> <span> </span><span class="NLM_article-title">Metabolic profifiling of cell growth and death in cancer: applications in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(02)02179-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2FS1359-6446%2802%2902179-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=11893545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVWhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=364-372&author=L.+G.+Borosauthor=M.+Cascanteauthor=W.-N.+P.+Lee&title=Metabolic+profifiling+of+cell+growth+and+death+in+cancer%3A+applications+in+drug+discovery&doi=10.1016%2FS1359-6446%2802%2902179-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic profiling of cell growth and death in cancer: applications in drug discovery</span></div><div class="casAuthors">Boros, Laszlo G.; Cascante, Marta; Lee, Wai-Nang Paul</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">364-372</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabolic profiling using stable-isotope tracer technol. enables the measurement of substrate redistribution within major metabolic pathways in living cells.  This technique has demonstrated that transformed human cells exhibit profound metabolic shifts and that some anti-cancer drugs produce their effects by forcing the reversion of these metabolic changes.  By revealing tumor-specific metabolic shifts in tumor cells, metabolic profiling enables drug developers to identify the metabolic steps that control cell proliferation, thus aiding the identification of new anti-cancer targets and screening of lead compds. for anti-proliferative metabolic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyu4s3EPCxtrVg90H21EOLACvtfcHk0ljhe0Lj3oksvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVWhsbg%253D&md5=24c1ccaddac0d9e5a0154d738535ad94</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2802%2902179-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252802%252902179-7%26sid%3Dliteratum%253Aachs%26aulast%3DBoros%26aufirst%3DL.%2BG.%26aulast%3DCascante%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DW.-N.%2BP.%26atitle%3DMetabolic%2520profifiling%2520of%2520cell%2520growth%2520and%2520death%2520in%2520cancer%253A%2520applications%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2002%26volume%3D7%26spage%3D364%26epage%3D372%26doi%3D10.1016%2FS1359-6446%2802%2902179-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warburg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negelein, E.</span></span> <span> </span><span class="NLM_article-title">The metabolism of tumors in the body</span>. <i>J. Gen. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1927</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1085/jgp.8.6.519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1085%2Fjgp.8.6.519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19872213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADyaB2sXitlyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1927&pages=519-530&author=O.+Warburgauthor=F.+Windauthor=E.+Negelein&title=The+metabolism+of+tumors+in+the+body&doi=10.1085%2Fjgp.8.6.519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of tumors in the body</span></div><div class="casAuthors">Warburg, O.; Wind, F.; Negelein, E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Physiology</span>
        (<span class="NLM_cas:date">1927</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519-30</span>CODEN:
                <span class="NLM_cas:coden">JGPLAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-1295</span>.
    </div><div class="casAbstract">See C. A. 20, 2364.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqArKTpFMYzGbVg90H21EOLACvtfcHk0ljhe0Lj3oksvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaB2sXitlyhuw%253D%253D&md5=4706b45fc56643446d1c1a45f491213b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1085%2Fjgp.8.6.519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1085%252Fjgp.8.6.519%26sid%3Dliteratum%253Aachs%26aulast%3DWarburg%26aufirst%3DO.%26aulast%3DWind%26aufirst%3DF.%26aulast%3DNegelein%26aufirst%3DE.%26atitle%3DThe%2520metabolism%2520of%2520tumors%2520in%2520the%2520body%26jtitle%3DJ.%2520Gen.%2520Physiol.%26date%3D1927%26volume%3D8%26spage%3D519%26epage%3D530%26doi%3D10.1085%2Fjgp.8.6.519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gatenby, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Why do cancers have high aerobic glycolysis?</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1038/nrc1478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnrc1478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15516961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFegt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=891-899&author=R.+A.+Gatenbyauthor=R.+J.+Gillies&title=Why+do+cancers+have+high+aerobic+glycolysis%3F&doi=10.1038%2Fnrc1478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Why do cancers have high aerobic glycolysis?</span></div><div class="casAuthors">Gatenby, Robert A.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  If carcinogenesis occurs by somatic evolution, then common components of the cancer phenotype result from active selection and must, therefore, confer a significant growth advantage.  A near-universal property of primary and metastatic cancers is upregulation of glycolysis, resulting in increased glucose consumption, which can be obsd. with clin. tumor imaging.  We propose that persistent metab. of glucose to lactate even in aerobic conditions is an adaptation to intermittent hypoxia in pre-malignant lesions.  However, upregulation of glycolysis leads to microenvironmental acidosis requiring evolution to phenotypes resistant to acid-induced cell toxicity.  Subsequent cell populations with upregulated glycolysis and acid resistance have a powerful growth advantage, which promotes unconstrained proliferation and invasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCkeoJiIxH7Vg90H21EOLACvtfcHk0ljhe0Lj3oksvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFegt7w%253D&md5=0584954722468b0bfaa5821fa17f2db5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc1478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1478%26sid%3Dliteratum%253Aachs%26aulast%3DGatenby%26aufirst%3DR.%2BA.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DWhy%2520do%2520cancers%2520have%2520high%2520aerobic%2520glycolysis%253F%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D891%26epage%3D899%26doi%3D10.1038%2Fnrc1478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valentini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speranza, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span> <span> </span><span class="NLM_article-title">The allosteric regulation of pyruvate kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">18145</span>– <span class="NLM_lpage">18152</span>, <span class="refDoi"> DOI: 10.1074/jbc.M001870200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1074%2Fjbc.M001870200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10751408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlymtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=18145-18152&author=G.+Valentiniauthor=L.+Chiarelliauthor=R.+Fortinauthor=M.+L.+Speranzaauthor=A.+Galizziauthor=A.+Mattevi&title=The+allosteric+regulation+of+pyruvate+kinase&doi=10.1074%2Fjbc.M001870200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The allosteric regulation of pyruvate kinase. A site-directed mutagenesis study</span></div><div class="casAuthors">Valentini, Giovanna; Chiarelli, Laurent; Fortin, Riccardo; Speranza, Maria L.; Galizzi, Alessandro; Mattevi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">18145-18152</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Pyruvate kinase (PK) is crit. for the regulation of the glycolytic pathway.  The regulatory properties of Escherichia coli were investigated by mutating six charged residues involved in interdomain salt bridges (Arg271, Arg292, Asp297, and Lys413) and in the binding of the allosteric activator (Lys382 and Arg431).  Arg271 and Lys413 are located at the interface between A and C domains within one subunit.  The R271L and K413Q mutant enzymes exhibit altered kinetic properties.  In K413Q, there is partial enzyme activation, whereas R271L is characterized by a bias toward the T-state in the allosteric equil.  In the T-state, Arg292 and Asp297 form an intersubunit salt bridge.  The mutants R292D and D297R are totally inactive.  The crystal structure of R292D reveals that the mutant enzyme retains the T-state quaternary structure.  However, the mutation induces a reorganization of the interface with the creation of a network of interactions similar to that obsd. in the crystal structures of R-state yeast and M1 PK proteins.  Furthermore, in the R292D structure, two loops that are part of the active site are disordered.  The K382Q and R431E mutations were designed to probe the binding site for fructose 1,6-bisphosphate, the allosteric activator.  R431E exhibits only slight changes in the regulatory properties.  Conversely, K382Q displays a highly altered responsiveness to the activator, suggesting that Lys382 is involved in both activator binding and allosteric transition mechanism.  Taken together, these results support the notion that domain interfaces are crit. for the allosteric transition.  They couple changes in the tertiary and quaternary structures to alterations in the geometry of the fructose 1,6-bisphosphate and substrate binding sites.  These site-directed mutagenesis data are discussed in the light of the mol. basis for the hereditary nonspherocytic hemolytic anemia, which is caused by mutations in human erythrocyte PK gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB0YeFSAkn2bVg90H21EOLACvtfcHk0ljhe0Lj3oksvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlymtL0%253D&md5=bb560dbaa21eba0e557e753b2261018b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M001870200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M001870200%26sid%3Dliteratum%253Aachs%26aulast%3DValentini%26aufirst%3DG.%26aulast%3DChiarelli%26aufirst%3DL.%26aulast%3DFortin%26aufirst%3DR.%26aulast%3DSperanza%26aufirst%3DM.%2BL.%26aulast%3DGalizzi%26aufirst%3DA.%26aulast%3DMattevi%26aufirst%3DA.%26atitle%3DThe%2520allosteric%2520regulation%2520of%2520pyruvate%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D18145%26epage%3D18152%26doi%3D10.1074%2Fjbc.M001870200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">The multifaceted regulation and functions of PKM2 in tumor progression</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1846</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.bbcan.2014.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bbcan.2014.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=25064846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1OrtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1846&publication_year=2014&pages=285-296&author=Z.+Liauthor=P.+Yangauthor=Z.+Li&title=The+multifaceted+regulation+and+functions+of+PKM2+in+tumor+progression&doi=10.1016%2Fj.bbcan.2014.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted regulation and functions of PKM2 in tumor progression</span></div><div class="casAuthors">Li, Zongwei; Yang, Peng; Li, Zhuoyu</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1846</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-296</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo metabolic rewiring from oxidative phosphorylation towards aerobic glycolysis to maintain the increased anabolic requirements for cell proliferation.  It is widely accepted that specific expression of the M2 type pyruvate kinase (PKM2) in tumor cells contributes to this aerobic glycolysis phenotype.  To date, researchers have uncovered myriad forms of functional regulation for PKM2, which confers a growth advantage on the tumor cells to enable them to adapt to various microenvironmental signals.  Here the richness of our understanding on the modulations and functions of PKM2 in tumor progression is reviewed, and some new insights into the paradoxical expression and functional differences of PKM2 in distinct cancer types are offered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKAFPW-94IkbVg90H21EOLACvtfcHk0ljopj1BoF-PTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1OrtbzF&md5=d7eddc5c0f4c977e385f234ba3e03545</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2014.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2014.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DThe%2520multifaceted%2520regulation%2520and%2520functions%2520of%2520PKM2%2520in%2520tumor%2520progression%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2014%26volume%3D1846%26spage%3D285%26epage%3D296%26doi%3D10.1016%2Fj.bbcan.2014.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Israelsen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase: function, regulation and role in cancer</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2015.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.semcdb.2015.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=26277545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGgtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=43-51&author=W.+J.+Israelsenauthor=M.+G.+Vander+Heiden&title=Pyruvate+kinase%3A+function%2C+regulation+and+role+in+cancer&doi=10.1016%2Fj.semcdb.2015.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase: Function, regulation and role in cancer</span></div><div class="casAuthors">Israelsen, William J.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cell & Developmental Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">SCDBFX</span>;
        ISSN:<span class="NLM_cas:issn">1084-9521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pyruvate kinase is an enzyme that catalyzes the conversion of phosphoenolpyruvate and ADP to pyruvate and ATP in glycolysis and plays a role in regulating cell metab.  There are four mammalian pyruvate kinase isoforms with unique tissue expression patterns and regulatory properties.  The M2 isoform of pyruvate kinase (PKM2) supports anabolic metab. and is expressed both in cancer and normal tissue.  The enzymic activity of PKM2 is allosterically regulated by both intracellular signaling pathways and metabolites; PKM2 thus integrates signaling and metabolic inputs to modulate glucose metab. according to the needs of the cell.  Recent advances have increased our understanding of metabolic regulation by pyruvate kinase, raised new questions, and suggested the possibility of non-canonical PKM2 functions to regulate gene expression and cell cycle progression via protein-protein interactions and protein kinase activity.  Here we review the structure, function, and regulation of pyruvate kinase and discuss how these properties enable regulation of PKM2 for cell proliferation and tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrylgQY9GHGw7Vg90H21EOLACvtfcHk0ljopj1BoF-PTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGgtbzP&md5=b8bbed5fa7653fc200d3a290268212d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2015.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2015.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DIsraelsen%26aufirst%3DW.%2BJ.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DPyruvate%2520kinase%253A%2520function%252C%2520regulation%2520and%2520role%2520in%2520cancer%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2015%26volume%3D43%26spage%3D43%26epage%3D51%26doi%3D10.1016%2Fj.semcdb.2015.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span> <span> </span><span class="NLM_article-title">PKM2 and cancer: the function of PKM2 beyond glycolysis</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1980</span>– <span class="NLM_lpage">1986</span>, <span class="refDoi"> DOI: 10.3892/ol.2016.4168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.3892%2Fol.2016.4168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=26998110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmt12gsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1980-1986&author=G.+Dongauthor=Q.+Maoauthor=W.+Xiaauthor=Y.+Xuauthor=J.+Wangauthor=L.+Xuauthor=F.+Jiang&title=PKM2+and+cancer%3A+the+function+of+PKM2+beyond+glycolysis&doi=10.3892%2Fol.2016.4168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PKM2 and cancer: The function of PKM2 beyond glycolysis (Review)</span></div><div class="casAuthors">Dong, Gaochao; Mao, Qixing; Xia, Wenjie; Xu, Youtao; Wang, Jie; Xu, Lin; Jiang, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1980-1986</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1082</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Metabolic reprogramming is a hallmark of cancer cells and is used by cancer cells for growth and survival.  Pyruvate kinase muscle isoenzyme M2 (PKM2) is a limiting glycolytic enzyme that catalyzes the final step in glycolysis, which is key in tumor metab. and growth.  The present review discusses the expression and regulation of PKM2, and reports the dominant role that PKM2 plays in glycolysis to achieve the nutrient demands of cancer cell proliferation.  In addn., the present study discusses the non-metabolic function of PKM2, and its role as a coactivator and protein kinase, which contributes to tumorigenesis.  Furthermore, conflicting studies concerning the role of PKM2 as a therapeutic target are reviewed.  The improved understanding of PKM2 may provide a noval approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6iyPmfctlibVg90H21EOLACvtfcHk0ljopj1BoF-PTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmt12gsL0%253D&md5=c82505c1572efe541656f773dc4374d0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3892%2Fol.2016.4168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2016.4168%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DF.%26atitle%3DPKM2%2520and%2520cancer%253A%2520the%2520function%2520of%2520PKM2%2520beyond%2520glycolysis%26jtitle%3DOncol.%2520Lett.%26date%3D2016%26volume%3D11%26spage%3D1980%26epage%3D1986%26doi%3D10.3892%2Fol.2016.4168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerszten, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>452</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nature06734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnature06734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=18337823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1Gnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=452&publication_year=2008&pages=230-233&author=H.+R.+Christofkauthor=M.+G.+Vander+Heidenauthor=M.+H.+Harrisauthor=A.+Ramanathanauthor=R.+E.+Gersztenauthor=R.+Weiauthor=M.+D.+Flemingauthor=S.+L.+Schreiberauthor=L.+C.+Cantley&title=The+M2+splice+isoform+of+pyruvate+kinase+is+important+for+cancer+metabolism+and+tumour+growth&doi=10.1038%2Fnature06734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth</span></div><div class="casAuthors">Christofk, Heather R.; Vander Heiden, Matthew G.; Harris, Marian H.; Ramanathan, Arvind; Gerszten, Robert E.; Wei, Ru; Fleming, Mark D.; Schreiber, Stuart L.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">452</span>
        (<span class="NLM_cas:issue">7184</span>),
    <span class="NLM_cas:pages">230-233</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many tumor cells have elevated rates of glucose uptake but reduced rates of oxidative phosphorylation.  This persistence of high lactate prodn. by tumors in the presence of oxygen, known as aerobic glycolysis, was first noted by Otto Warburg more than 75 yr ago.  How tumor cells establish this altered metabolic phenotype and whether it is essential for tumorigenesis is as yet unknown.  Here we show that a single switch in a splice isoform of the glycolytic enzyme pyruvate kinase is necessary for the shift in cellular metab. to aerobic glycolysis and that this promotes tumorigenesis.  Tumor cells have been shown to express exclusively the embryonic M2 isoform of pyruvate kinase.  Here we use short hairpin RNA to knockdown pyruvate kinase M2 expression in human cancer cell lines and replace it with pyruvate kinase M1.  Switching pyruvate kinase expression to the M1 (adult) isoform leads to reversal of the Warburg effect, as judged by reduced lactate prodn. and increased oxygen consumption, and this correlates with a reduced ability to form tumors in nude mouse xenografts.  These results demonstrate that M2 expression is necessary for aerobic glycolysis and that this metabolic phenotype provides a selective growth advantage for tumor cells in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvmgcXNsSjpbVg90H21EOLACvtfcHk0lhHXzhuwxFLww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1Gnu74%253D&md5=e7e6b7cc09477e1f9d270018d1c38be4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnature06734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06734%26sid%3Dliteratum%253Aachs%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DHarris%26aufirst%3DM.%2BH.%26aulast%3DRamanathan%26aufirst%3DA.%26aulast%3DGerszten%26aufirst%3DR.%2BE.%26aulast%3DWei%26aufirst%3DR.%26aulast%3DFleming%26aufirst%3DM.%2BD.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520M2%2520splice%2520isoform%2520of%2520pyruvate%2520kinase%2520is%2520important%2520for%2520cancer%2520metabolism%2520and%2520tumour%2520growth%26jtitle%3DNature%26date%3D2008%26volume%3D452%26spage%3D230%26epage%3D233%26doi%3D10.1038%2Fnature06734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">Understanding the Warburg effect: the metabolic requirements of cell proliferation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1126/science.1160809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1126%2Fscience.1160809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19460998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1029-1033&author=M.+G.+Vander%0AHeidenauthor=L.+C.+Cantleyauthor=C.+B.+Thompson&title=Understanding+the+Warburg+effect%3A+the+metabolic+requirements+of+cell+proliferation&doi=10.1126%2Fscience.1160809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation</span></div><div class="casAuthors">Vander Heiden, Matthew G.; Cantley, Lewis C.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5930</span>),
    <span class="NLM_cas:pages">1029-1033</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed "the Warburg effect".  Aerobic glycolysis is an inefficient way to generate ATP, however, and the advantage it confers to cancer cells has been unclear.  Here we propose that the metab. of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell.  Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-assocd. mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP prodn.  A better understanding of the mechanistic links between cellular metab. and growth control may ultimately lead to better treatments for human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGvLHGQ9TX77Vg90H21EOLACvtfcHk0lhHXzhuwxFLww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsbg%253D&md5=f927402a43cdca471c3f4874dcbeb943</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1160809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1160809%26sid%3Dliteratum%253Aachs%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DUnderstanding%2520the%2520Warburg%2520effect%253A%2520the%2520metabolic%2520requirements%2520of%2520cell%2520proliferation%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1029%26epage%3D1033%26doi%3D10.1126%2Fscience.1160809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span> <span> </span><span class="NLM_article-title">PKM2 contributes to cancer metabolism</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2014.01.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.canlet.2014.01.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=24508027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2015&pages=184-191&author=N.+Wongauthor=D.+Ojoauthor=J.+Yanauthor=D.+Tang&title=PKM2+contributes+to+cancer+metabolism&doi=10.1016%2Fj.canlet.2014.01.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">PKM2 contributes to cancer metabolism</span></div><div class="casAuthors">Wong, Nicholas; Ojo, Diane; Yan, Judy; Tang, Damu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2_Part_A</span>),
    <span class="NLM_cas:pages">184-191</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Reprogramming of cell metab. is essential for tumorigenesis, and is regulated by a complex network, in which PKM2 plays a crit. role.  PKM2 exists as an inactive monomer, less active dimer and active tetramer.  While dimeric PKM2 diverts glucose metab. towards anabolism through aerobic glycolysis, tetrameric PKM2 promotes the flux of glucose-derived carbons for ATP prodn. via oxidative phosphorylation.  Equil. of the PKM2 dimers and tetramers is crit. for tumorigenesis, and is controlled by multiple factors.  The PKM2 dimer also promotes aerobic glycolysis by modulating transcriptional regulation.  We will discuss the current understanding of PKM2 in regulating cancer metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxTIgwuY8YnLVg90H21EOLACvtfcHk0lhHXzhuwxFLww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVart7c%253D&md5=8562ddc23e089703d976d165b3a2bb3b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.01.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.01.031%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DN.%26aulast%3DOjo%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DD.%26atitle%3DPKM2%2520contributes%2520to%2520cancer%2520metabolism%26jtitle%3DCancer%2520Lett.%26date%3D2015%26volume%3D356%26spage%3D184%26epage%3D191%26doi%3D10.1016%2Fj.canlet.2014.01.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span> <span> </span><span class="NLM_article-title">Tissue-specifific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">8202</span>– <span class="NLM_lpage">8210</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.18632%2Foncotarget.1159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=24077665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FitFamsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=8202-8210&author=S.+Desaiauthor=M.+Dingauthor=B.+Wangauthor=Z.+Luauthor=Q.+Zhaoauthor=K.+Shawauthor=W.+K.+Yungauthor=J.+N.+Weinsteinauthor=M.+Tanauthor=J.+Yao&title=Tissue-specifific+isoform+switch+and+DNA+hypomethylation+of+the+pyruvate+kinase+PKM+gene+in+human+cancers&doi=10.18632%2Foncotarget.1159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers</span></div><div class="casAuthors">Desai Shruti; Tan Ming; Ding Minming; Wang Bin; Lu Zhimin; Yung W K Alfred; Yao Jun; Zhao Qi; Shaw Kenna; Weinstein John N</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8202-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The M2 isoform of pyruvate kinase (PKM2) plays an important role in aerobic glycolysis and is a mediator of the Warburg effect in tumors.  It was previously thought that tumor cells switch expression of PKM from normal tissue-expressed PKM1 to tumor-specific PKM2 via an alternative splicing mechanism.  This view was challenged by a recent report demonstrating that PKM2 is already the major PKM isoform expressed in many differentiated normal tissues.  Here, through analyses on sixteen tumor types using the cancer genome atlas RNA-Seq and exon array datasets, we confirmed that isoform switch from PKM1 to PKM2 occurred in glioblastomas but not in other tumor types examined.  Despite lacking of isoform switches, PKM2 expression was found to be increased in all cancer types examined, and correlated strongly to poor prognosis in head and neck cancers.  We further demonstrated that elevated PKM2 expression correlated well with the hypomethylation status of intron 1 of the PKM gene in multiple cancer types, suggesting epigenetic regulation by DNA methylation as a major mechanism in controlling PKM transcription in tumors.  Our study suggests that isoform switch of PKM1 to PKM2 in cancers is tissue-specific and targeting PKM2 activity in tumors remains a promising approach for clinical intervention of multiple cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWoKJoTs3QNtts4TFFB11gfW6udTcc2eaYeotY_63YTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FitFamsg%253D%253D&md5=fb78a92711d9c581c1e5d50d73037ef2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1159%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DShaw%26aufirst%3DK.%26aulast%3DYung%26aufirst%3DW.%2BK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DJ.%26atitle%3DTissue-specifific%2520isoform%2520switch%2520and%2520DNA%2520hypomethylation%2520of%2520the%2520pyruvate%2520kinase%2520PKM%2520gene%2520in%2520human%2520cancers%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D8202%26epage%3D8210%26doi%3D10.18632%2Foncotarget.1159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Veelen, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staal, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbiest, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlug, A. M.</span></span> <span> </span><span class="NLM_article-title">Alanine inhibition of pyruvate kinase in gliomas and meningiomas. A diagnostic tool in surgery for gliomas?</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(77)90308-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2FS0140-6736%2877%2990308-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=70592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADyaE2s3ltlOmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1977&pages=384-385&author=C.+W.+van%0AVeelenauthor=G.+E.+Staalauthor=H.+Verbiestauthor=A.+M.+Vlug&title=Alanine+inhibition+of+pyruvate+kinase+in+gliomas+and+meningiomas.+A+diagnostic+tool+in+surgery+for+gliomas%3F&doi=10.1016%2FS0140-6736%2877%2990308-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Alanine inhibition of pyruvate kinase in gliomas and meningiomas. A diagnostic tool in surgery for gliomas?</span></div><div class="casAuthors">van Veelen C W; Staal G E; Verbiest H; Vlug A M</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8034</span>),
    <span class="NLM_cas:pages">384-5</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">In gliomas a shift was found in the composition of enzymes, manifested by abnormal inhibition of pyruvate kinase by alanine.  This study demonstrates the appearance of the MII-type isoenzyme in various gliomas.  This MII type is also found in meningiomas but not in normal brain tissue.  The method of enzyme examination described may be valuable as a diagnostic aid in the surgery of gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS23fTQs9fVTn6CEoQgWY10fW6udTcc2ebfWt1I1U4r97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2s3ltlOmug%253D%253D&md5=2ac721a67cd7993e95395d6a8710a997</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2877%2990308-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252877%252990308-7%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVeelen%26aufirst%3DC.%2BW.%26aulast%3DStaal%26aufirst%3DG.%2BE.%26aulast%3DVerbiest%26aufirst%3DH.%26aulast%3DVlug%26aufirst%3DA.%2BM.%26atitle%3DAlanine%2520inhibition%2520of%2520pyruvate%2520kinase%2520in%2520gliomas%2520and%2520meningiomas.%2520A%2520diagnostic%2520tool%2520in%2520surgery%2520for%2520gliomas%253F%26jtitle%3DLancet%26date%3D1977%26volume%3D2%26spage%3D384%26epage%3D385%26doi%3D10.1016%2FS0140-6736%2877%2990308-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaneton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddocks, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chokkathukalam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankevics, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holding, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vousden, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, E.</span></span> <span> </span><span class="NLM_article-title">Serine is a natural ligand and allosteric activator of pyruvate kinase M2</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1038/nature11540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnature11540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=23064226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2012&pages=458-462&author=B.+Chanetonauthor=P.+Hillmannauthor=L.+Zhengauthor=A.+C.+Martinauthor=O.+D.+Maddocksauthor=A.+Chokkathukalamauthor=J.+E.+Coyleauthor=A.+Jankevicsauthor=F.+P.+Holdingauthor=K.+H.+Vousdenauthor=C.+Frezzaauthor=M.+O%E2%80%99Reillyauthor=E.+Gottlieb&title=Serine+is+a+natural+ligand+and+allosteric+activator+of+pyruvate+kinase+M2&doi=10.1038%2Fnature11540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Serine is a natural ligand and allosteric activator of pyruvate kinase M2</span></div><div class="casAuthors">Chaneton, Barbara; Hillmann, Petra; Zheng, Liang; Martin, Agnes C. L.; Maddocks, Oliver D. K.; Chokkathukalam, Achuthanunni; Coyle, Joseph E.; Jankevics, Andris; Holding, Finn P.; Vousden, Karen H.; Frezza, Christian; O'Reilly, Marc; Gottlieb, Eyal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">7424</span>),
    <span class="NLM_cas:pages">458-462</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells exhibit several unique metabolic phenotypes that are crit. for cell growth and proliferation.  Specifically, they overexpress the M2 isoform of the tightly regulated enzyme, pyruvate kinase (PKM2), which controls glycolytic flux, and are highly dependent on the de novo biosynthesis of serine and glycine.  Here, the authors describe a new rheostat-like mechanistic relation between PKM2 activity and serine biosynthesis.  The authors show that serine can bind to and activate human PKM2, and that PKM2 activity in cells is reduced in response to serine deprivation.  This redn. in PKM2 activity shifts cells to a fuel-efficient mode in which more pyruvate is diverted to the mitochondria and more glucose-derived carbon is channeled into serine biosynthesis to support cell proliferation.  By activating PKM2, serine supports aerobic glycolysis and lactate prodn., events that are crit. for cancer growth and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGong16lcMeQXbVg90H21EOLACvtfcHk0ljL5FC92OCSWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rsL7K&md5=4f4af944baaded05fa4bc93c4c2eb181</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature11540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11540%26sid%3Dliteratum%253Aachs%26aulast%3DChaneton%26aufirst%3DB.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DMartin%26aufirst%3DA.%2BC.%26aulast%3DMaddocks%26aufirst%3DO.%2BD.%26aulast%3DChokkathukalam%26aufirst%3DA.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DJankevics%26aufirst%3DA.%26aulast%3DHolding%26aufirst%3DF.%2BP.%26aulast%3DVousden%26aufirst%3DK.%2BH.%26aulast%3DFrezza%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DGottlieb%26aufirst%3DE.%26atitle%3DSerine%2520is%2520a%2520natural%2520ligand%2520and%2520allosteric%2520activator%2520of%2520pyruvate%2520kinase%2520M2%26jtitle%3DNature%26date%3D2012%26volume%3D491%26spage%3D458%26epage%3D462%26doi%3D10.1038%2Fnature11540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Israelsen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase: function, regulation and role in cancer</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2015.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.semcdb.2015.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=26277545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGgtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=43-51&author=W.+J.+Israelsenauthor=M.+G.+Vander+Heiden&title=Pyruvate+kinase%3A+function%2C+regulation+and+role+in+cancer&doi=10.1016%2Fj.semcdb.2015.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase: Function, regulation and role in cancer</span></div><div class="casAuthors">Israelsen, William J.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cell & Developmental Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">SCDBFX</span>;
        ISSN:<span class="NLM_cas:issn">1084-9521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pyruvate kinase is an enzyme that catalyzes the conversion of phosphoenolpyruvate and ADP to pyruvate and ATP in glycolysis and plays a role in regulating cell metab.  There are four mammalian pyruvate kinase isoforms with unique tissue expression patterns and regulatory properties.  The M2 isoform of pyruvate kinase (PKM2) supports anabolic metab. and is expressed both in cancer and normal tissue.  The enzymic activity of PKM2 is allosterically regulated by both intracellular signaling pathways and metabolites; PKM2 thus integrates signaling and metabolic inputs to modulate glucose metab. according to the needs of the cell.  Recent advances have increased our understanding of metabolic regulation by pyruvate kinase, raised new questions, and suggested the possibility of non-canonical PKM2 functions to regulate gene expression and cell cycle progression via protein-protein interactions and protein kinase activity.  Here we review the structure, function, and regulation of pyruvate kinase and discuss how these properties enable regulation of PKM2 for cell proliferation and tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrylgQY9GHGw7Vg90H21EOLACvtfcHk0ljL5FC92OCSWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGgtbzP&md5=b8bbed5fa7653fc200d3a290268212d7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2015.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2015.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DIsraelsen%26aufirst%3DW.%2BJ.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DPyruvate%2520kinase%253A%2520function%252C%2520regulation%2520and%2520role%2520in%2520cancer%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2015%26volume%3D43%26spage%3D43%26epage%3D51%26doi%3D10.1016%2Fj.semcdb.2015.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazurek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschek, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrodt, E.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase type M2 and its role in tumor growth and spreading</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2005.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.semcancer.2005.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15908230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVKntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=300-308&author=S.+Mazurekauthor=C.+B.+Boschekauthor=F.+Hugoauthor=E.+Eigenbrodt&title=Pyruvate+kinase+type+M2+and+its+role+in+tumor+growth+and+spreading&doi=10.1016%2Fj.semcancer.2005.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase type M2 and its role in tumor growth and spreading</span></div><div class="casAuthors">Mazurek, Sybille; Boschek, C. Bruce; Hugo, Ferdinand; Eigenbrodt, Erich</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">300-308</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proliferating cells and tumor cells in particular express the pyruvate kinase isoenzyme type M2 (M2-PK).  Within the tumor metabolome M2-PK regulates the proportions of glucose carbons that are channelled to synthetic processes (inactive dimeric form) or used for glycolytic energy prodn. (highly active tetrameric form, a component of the glycolytic enzyme complex).  In tumor cells, the dimeric form of M2-PK (Tumor M2-PK) is always predominant.  The dimerization is caused by direct interaction of M2-PK with certain oncoproteins.  The switch between the tetrameric and dimeric form of M2-PK allows tumor cells to survive in environments with varying oxygen und nutrient supply.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAGWFw-vXg7Vg90H21EOLACvtfcHk0lj9tkwQliacEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVKntbw%253D&md5=617c052dfc629ac074acc006f90947b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2005.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2005.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DMazurek%26aufirst%3DS.%26aulast%3DBoschek%26aufirst%3DC.%2BB.%26aulast%3DHugo%26aufirst%3DF.%26aulast%3DEigenbrodt%26aufirst%3DE.%26atitle%3DPyruvate%2520kinase%2520type%2520M2%2520and%2520its%2520role%2520in%2520tumor%2520growth%2520and%2520spreading%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2005%26volume%3D15%26spage%3D300%26epage%3D308%26doi%3D10.1016%2Fj.semcancer.2005.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y. H.</span></span> <span> </span><span class="NLM_article-title">PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.18632%2Foncotarget.2749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=25514599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC2MznvFKrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=846-861&author=W.+R.+Liuauthor=M.+X.+Tianauthor=L.+X.+Yangauthor=Y.+L.+Linauthor=L.+Jinauthor=Z.+B.+Dingauthor=Y.+H.+Shenauthor=Y.+F.+Pengauthor=D.+M.+Gaoauthor=J.+Zhouauthor=S.+J.+Qiuauthor=Z.+Daiauthor=R.+Heauthor=J.+Fanauthor=Y.+H.+Shi&title=PKM2+promotes+metastasis+by+recruiting+myeloid-derived+suppressor+cells+and+indicates+poor+prognosis+for+hepatocellular+carcinoma&doi=10.18632%2Foncotarget.2749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma</span></div><div class="casAuthors">Liu Wei-Ren; Tian Meng-Xin; Yang Liu-Xiao; Jin Lei; Ding Zhen-Bin; Shen Ying-Hao; Peng Yuan-Fei; Gao Dong-Mei; Zhou Jian; Qiu Shuang-Jian; Dai Zhi; Fan Jia; Shi Ying-Hong; Lin Yu-Li; He Rui; Zhou Jian; Fan Jia</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">846-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pyruvate kinase M2 (PKM2) is a member of the pyruvate kinase family.  Recent work has defined the "non-metabolic" functions of PKM2.  However, the role of PKM2 in HCC remains unclear.  To investigate the role of PKM2 in tumor growth, invasion and the prognosis of hepatocellular carcinoma (HCC), PKM2 expression was measured in HCC cell lines and tissues using qRT-PCR, western blot, and immunofluorescence assays.  In in vitro experiments, PKM2 was knocked down using a short hairpin RNA lentivirus vector, and tumor cell behavior and the downstream signaling pathways and chemokine were analyzed.  For the analysis of in vivo tumor growth, intratumoral and peritumoral lymphocyte infiltration were examined in nude mice.  The prognostic value of PKM2 was analyzed by immunohistochemistry in two cohorts including 721 HCC patients.  Together, our data obtained from cell lines, tumorigenicity studies, and primary HCC samples illustrate an oncogenic role for PKM2 in tumors.  Moreover, PKM2 may serve as a novel prognostic indicator for HCC patients after curative resection, targeted therapy aimed at PKM2 may represent an effective treatment approach for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWhnKWAUjbzEewzGPswiWOfW6udTcc2ebiN_7P8uiisrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MznvFKrug%253D%253D&md5=7388ac1f54d8183cb264888e169513e5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2749%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%2BR.%26aulast%3DTian%26aufirst%3DM.%2BX.%26aulast%3DYang%26aufirst%3DL.%2BX.%26aulast%3DLin%26aufirst%3DY.%2BL.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DZ.%2BB.%26aulast%3DShen%26aufirst%3DY.%2BH.%26aulast%3DPeng%26aufirst%3DY.%2BF.%26aulast%3DGao%26aufirst%3DD.%2BM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DS.%2BJ.%26aulast%3DDai%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%2BH.%26atitle%3DPKM2%2520promotes%2520metastasis%2520by%2520recruiting%2520myeloid-derived%2520suppressor%2520cells%2520and%2520indicates%2520poor%2520prognosis%2520for%2520hepatocellular%2520carcinoma%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D846%26epage%3D861%26doi%3D10.18632%2Foncotarget.2749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span> <span> </span><span class="NLM_article-title">Activators of PKM2 in cancer metabolism</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1167</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.70</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.4155%2Ffmc.14.70" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=25078136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1167-1178&author=S.+L.+Warnerauthor=K.+J.+Carpenterauthor=D.+J.+Bearss&title=Activators+of+PKM2+in+cancer+metabolism&doi=10.4155%2Ffmc.14.70"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Activators of PKM2 in cancer metabolism</span></div><div class="casAuthors">Warner, Steven L.; Carpenter, Kent J.; Bearss, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1167-1178</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Pyruvate kinase converts phosphoenolpyruvate to pyruvate, catalyzing the rate-limiting step of glycolysis.  The M1 isoenzyme of pyruvate kinase (PKM1) is found in adult tissues; whereas, PKM2 is a splicesome variant found in embryonic and cancer cells.  PKM2 expression in malignant cells is a result of the tumor microenvironment and is responsible for maintaining a glycolytic phenotype.  PKM2 has other nonmetabolic functions in malignant cells, including transcriptional coactivation and protein kinase activity.  PKM2 activators have antitumor properties by inducing tetramerization of two PKM2 dimers causing PKM2 to function like PKM1.  Restoring PKM2 to PKM1-like levels of activity causes reversal of the Warburg effect in cancer cells.  PKM2 activators have therapeutic potential in the treatment of cancer and other metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsWUMVHeRw87Vg90H21EOLACvtfcHk0lj9tkwQliacEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurnN&md5=276eca6bcf45a7d9ff677e27f6c7b6c0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.70%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DCarpenter%26aufirst%3DK.%2BJ.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26atitle%3DActivators%2520of%2520PKM2%2520in%2520cancer%2520metabolism%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1167%26epage%3D1178%26doi%3D10.4155%2Ffmc.14.70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobb, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, J.</span></span> <span> </span><span class="NLM_article-title">Variations in parthenolide content and daily dose of feverfew products</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1531</span>, <span class="refDoi"> DOI: 10.1093/ajhp/59.16.1527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1093%2Fajhp%2F59.16.1527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=12185827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvFSgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2002&pages=1527-1531&author=M.+H.+Nelsonauthor=S.+E.+Cobbauthor=J.+Shelton&title=Variations+in+parthenolide+content+and+daily+dose+of+feverfew+products&doi=10.1093%2Fajhp%2F59.16.1527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in parthenolide content and daily dose of feverfew products</span></div><div class="casAuthors">Nelson, Michael H.; Cobb, Sarah E.; Shelton, Jon</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1527-1531</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">Variations in the parthenolide content of feverfew products available to consumers were studied.  Feverfew products were analyzed for the content of parthenolide, the purported active component.  The actual wt. of feverfew was detd. only in those products contg. dried feverfew leaf.  The total daily doses of feverfew leaf and parthenolide were calcd. by using the instructions on each product label.  Parthenolide content was detd. by high-performance liq. chromatog.  The quantity of feverfew leaf in each capsule was similar to that stated on the label and ranged from 25 to 500 mg.  Parthenolide content per dosage form varied 150-fold (from 0.02 to 3.0 mg), while percent parthenolide varied 5.3-fold (from 0.14% to 0.74%).  If a person consumed the daily dose recommended on the label, intake of dried feverfew leaf would range from 225 to 2246 mg/day, a 10-fold variation, while intake of parthenolide would range from 0.06 to 9.7 mg/day, a 160-fold variation.  Large variations were obsd. in the parthenolide contents and daily intake as recommended by the labeling in com. feverfew products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOQGTp3fcXLbVg90H21EOLACvtfcHk0lgFUfHV23wA1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvFSgsL4%253D&md5=5cc7ac6e7ac2f571ceb0cf80bf1c9b9b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fajhp%2F59.16.1527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fajhp%252F59.16.1527%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DM.%2BH.%26aulast%3DCobb%26aufirst%3DS.%2BE.%26aulast%3DShelton%26aufirst%3DJ.%26atitle%3DVariations%2520in%2520parthenolide%2520content%2520and%2520daily%2520dose%2520of%2520feverfew%2520products%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2002%26volume%3D59%26spage%3D1527%26epage%3D1531%26doi%3D10.1093%2Fajhp%2F59.16.1527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghantous, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinjab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herceg, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwiche, N.</span></span> <span> </span><span class="NLM_article-title">Parthenolide: from plant shoots to cancer roots</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">905</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.drudis.2013.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=23688583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFGjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=894-905&author=A.+Ghantousauthor=A.+Sinjabauthor=Z.+Hercegauthor=N.+Darwiche&title=Parthenolide%3A+from+plant+shoots+to+cancer+roots&doi=10.1016%2Fj.drudis.2013.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Parthenolide: from plant shoots to cancer roots</span></div><div class="casAuthors">Ghantous, Akram; Sinjab, Ansam; Herceg, Zdenko; Darwiche, Nadine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17-18</span>),
    <span class="NLM_cas:pages">894-905</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Parthenolide (PTL), a sesquiterpene lactone (SL) originally purified from the shoots of feverfew (Tanacetum parthenium), has shown potent anticancer and anti-inflammatory activities.  It is currently being tested in cancer clin. trials.  Structure-activity relationship (SAR) studies of parthenolide revealed key chem. properties required for biol. activities and epigenetic mechanisms, and led to the derivatization of an orally bioavailable analog, dimethylamino-parthenolide (DMAPT).  Parthenolide is the first small mol. found to be selective against cancer stem cells (CSC), which it achieves by targeting specific signaling pathways and killing cancer from its roots.  In this review, we highlight the exciting journey of parthenolide, from plant shoots to cancer roots.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSNnHqQJd2UrVg90H21EOLACvtfcHk0lgFUfHV23wA1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFGjtbw%253D&md5=e87a1ab300093f8953879ee931d3cd42</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DGhantous%26aufirst%3DA.%26aulast%3DSinjab%26aufirst%3DA.%26aulast%3DHerceg%26aufirst%3DZ.%26aulast%3DDarwiche%26aufirst%3DN.%26atitle%3DParthenolide%253A%2520from%2520plant%2520shoots%2520to%2520cancer%2520roots%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D894%26epage%3D905%26doi%3D10.1016%2Fj.drudis.2013.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubuisi, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elofsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(01)00049-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2FS1074-5521%2801%2900049-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=11514225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtV2ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=759-766&author=B.+H.+Kwokauthor=B.+Kohauthor=M.+I.+Ndubuisiauthor=M.+Elofssonauthor=C.+M.+Crews&title=The+anti-inflammatory+natural+product+parthenolide+from+the+medicinal+herb+Feverfew+directly+binds+to+and+inhibits+IkappaB+kinase&doi=10.1016%2FS1074-5521%2801%2900049-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase</span></div><div class="casAuthors">Kwok, B. H. B.; Koh, B.; Ndubuisi, M. I.; Elofsson, M.; Crews, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">759-766</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Biol. active natural products continue to be useful in the exploration and control of intracellular signaling processes.  For example, the sesquiterpene lactone parthenolide from the anti-inflammatory medicinal herb Feverfew (Tanacetum parthenium) appears to inhibit the pro-inflammatory signaling pathway.  Parthenolide's direct mol. target, however, remains unknown.  We set out to identify the mol. mechanisms of parthenolide's anti-inflammatory activity.  A parthenolide affinity reagent was synthesized and shown to bind directly to and inhibit IB kinase (IKK), the kinase subunit known to play a crit. role in cytokine-mediated signaling.  Mutation of cysteine 179 in the activation loop of IKKβ abolished sensitivity towards parthenolide.  Moreover, we showed that parthenolide's in vitro and in vivo anti-inflammatory activity is mediated through the α-methylene γ-lactone moiety shared by other sesquiterpene lactones.  In recent years, the multi-subunit IKK complex has been shown to be responsible for cytokine-mediated stimulation of genes involved in inflammation and as such represents an attractive target for pharmaceutical intervention.  Our finding that parthenolide targets this kinase complex provides a possible mol. basis for the anti-inflammatory properties of parthenolide.  In addn., these results may be useful in the development of addnl. anti-inflammatory agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9wzcv0O9mwrVg90H21EOLACvtfcHk0lgFUfHV23wA1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtV2ku7k%253D&md5=bf8be7acdd42fd794f9ad10df20ffa5d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2801%2900049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252801%252900049-7%26sid%3Dliteratum%253Aachs%26aulast%3DKwok%26aufirst%3DB.%2BH.%26aulast%3DKoh%26aufirst%3DB.%26aulast%3DNdubuisi%26aufirst%3DM.%2BI.%26aulast%3DElofsson%26aufirst%3DM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DThe%2520anti-inflammatory%2520natural%2520product%2520parthenolide%2520from%2520the%2520medicinal%2520herb%2520Feverfew%2520directly%2520binds%2520to%2520and%2520inhibits%2520IkappaB%2520kinase%26jtitle%3DChem.%2520Biol.%26date%3D2001%26volume%3D8%26spage%3D759%26epage%3D766%26doi%3D10.1016%2FS1074-5521%2801%2900049-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnischky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span> <span> </span><span class="NLM_article-title">The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">4163</span>– <span class="NLM_lpage">4169</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-10-4135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1182%2Fblood-2004-10-4135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15687234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks12ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=4163-4169&author=M.+L.+Guzmanauthor=R.+M.+Rossiauthor=L.+Karnischkyauthor=X.+Liauthor=D.+R.+Petersonauthor=D.+S.+Howardauthor=C.+T.+Jordan&title=The+sesquiterpene+lactone+parthenolide+induces+apoptosis+of+human+acute+myelogenous+leukemia+stem+and+progenitor+cells&doi=10.1182%2Fblood-2004-10-4135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells</span></div><div class="casAuthors">Guzman, Monica L.; Rossi, Randall M.; Karnischky, Lilliana; Li, Xiaojie; Peterson, Derick R.; Howard, Dianna S.; Jordan, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4163-4169</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recent studies have described malignant stem cells as central to the initiation, growth, and potential relapse of acute and chronic myelogenous leukemia (AML and CML).  Because of their important role in pathogenesis, rare and biol. distinct leukemia stem cells (LSCs) represent a crit. target for therapeutic intervention.  However, to date, very few agents have been shown to directly target the LSC population.  The present studies demonstrate that parthenolide (PTL), a naturally occurring small mol., induces robust apoptosis in primary human AML cells and blast crisis CML (bcCML) cells while sparing normal hematopoietic cells.  Furthermore, anal. of progenitor cells using in vitro colony assays, as well as stem cells using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) xenograft model, show that PTL also preferentially targets AML progenitor and stem cell populations.  Notably, in comparison to the std. chemotherapy drug cytosine arabinoside (Ara-C), PTL is much more specific to leukemia cells.  The mol. mechanism of PTL-mediated apoptosis is strongly assocd. with inhibition of nuclear factor κ B (NF-κB), proapoptotic activation of p53, and increased reactive oxygen species (ROS).  On the basis of these findings, we propose that the activity of PTL triggers LSC-specific apoptosis and as such represents a potentially important new class of drugs for LSC-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBTKT6XR3lUbVg90H21EOLACvtfcHk0ljiQJQgmtQguQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks12ju74%253D&md5=4436e10afc798d6c233808acc3f0c0a2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-10-4135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-10-4135%26sid%3Dliteratum%253Aachs%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DRossi%26aufirst%3DR.%2BM.%26aulast%3DKarnischky%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DPeterson%26aufirst%3DD.%2BR.%26aulast%3DHoward%26aufirst%3DD.%2BS.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26atitle%3DThe%2520sesquiterpene%2520lactone%2520parthenolide%2520induces%2520apoptosis%2520of%2520human%2520acute%2520myelogenous%2520leukemia%2520stem%2520and%2520progenitor%2520cells%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D4163%26epage%3D4169%26doi%3D10.1182%2Fblood-2004-10-4135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Clair, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangnekar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Clair, W. H.</span></span> <span> </span><span class="NLM_article-title">The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2477</span>– <span class="NLM_lpage">2486</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1158%2F1535-7163.MCT-07-0186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=17876045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2477-2486&author=Y.+Sunauthor=D.+K.+St.+Clairauthor=F.+Fangauthor=G.+W.+Warrenauthor=V.+M.+Rangnekarauthor=P.+A.+Crooksauthor=W.+H.+St+Clair&title=The+radiosensitization+effect+of+parthenolide+in+prostate+cancer+cells+is+mediated+by+nuclear+factor-kappaB+inhibition+and+enhanced+by+the+presence+of+PTEN&doi=10.1158%2F1535-7163.MCT-07-0186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-κB inhibition and enhanced by the presence of PTEN</span></div><div class="casAuthors">Sun, Yulan; St. Clair, Daret K.; Fang, Fang; Warren, Graham W.; Rangnekar, Vivek M.; Crooks, Peter A.; St. Clair, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2477-2486</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Parthenolide has been shown to have anti-inflammatory and antitumor properties.  However, whether and how parthenolide enhances tumor sensitivity to radiation therapy are unknown.  In this study, we show that inhibition of the nuclear factor-κB (NF-κB) pathway is a common mechanism for the radiosensitization effect of parthenolide in prostate cancer cells LNCaP, DU145, and PC3.  Parthenolide inhibits radiation-induced NF-κB DNA-binding activity and the expression of its downstream target sod2, the gene coding for an important antiapoptotic and antioxidant enzyme (manganese superoxide dismutase) in the three prostate cancer cells.  Different susceptibilities to parthenolide's effect are obsd. in two radioresistant cancer cells, DU145 and PC3, with DU145 cells showing higher sensitivity.  This differential susceptibility to parthenolide is due, in part, to the fact that in addn. to NF-κB inhibition, parthenolide activates the phosphatidylinositol-3-kinase/Akt prosurvival pathway in both cell lines.  However, the activated Akt in DU145 cells is kept at a relatively low level compared with that in PC3 cells due to the presence of functional PTEN.  Transfection of wild-type PTEN into PTEN-null cells, PC3, confers the enhanced radiosensitization effect of parthenolide in PTEN-expressing cells.  When PTEN expression is knocked down in DU145 cells, the cells become more resistant to parthenolide's effect.  Taken together, these results suggest that parthenolide inhibits the NF-κB pathway and activates the phosphatidylinositol-3-kinase/Akt pathway in prostate cancer cells.  The radiosensitization effect of parthenolide is due, in part, to the inhibition of the NF-κB pathway.  The presence of PTEN enhances the radiosensitization effect of parthenolide, in part, by suppressing the abs. amt. of activated p-Akt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQgw3iQmgw1bVg90H21EOLACvtfcHk0ljiQJQgmtQguQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgur7J&md5=c5c94a18c84dcca3cc4803fa554014bb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0186%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSt.%2BClair%26aufirst%3DD.%2BK.%26aulast%3DFang%26aufirst%3DF.%26aulast%3DWarren%26aufirst%3DG.%2BW.%26aulast%3DRangnekar%26aufirst%3DV.%2BM.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26aulast%3DSt%2BClair%26aufirst%3DW.%2BH.%26atitle%3DThe%2520radiosensitization%2520effect%2520of%2520parthenolide%2520in%2520prostate%2520cancer%2520cells%2520is%2520mediated%2520by%2520nuclear%2520factor-kappaB%2520inhibition%2520and%2520enhanced%2520by%2520the%2520presence%2520of%2520PTEN%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2477%26epage%3D2486%26doi%3D10.1158%2F1535-7163.MCT-07-0186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.ejmech.2019.01.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=30739826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivFygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=445-469&author=W.+Geauthor=X.+Haoauthor=F.+Hanauthor=Z.+Liuauthor=T.+Wangauthor=M.+Wangauthor=N.+Chenauthor=Y.+Dingauthor=Y.+Chenauthor=Q.+Zhang&title=Synthesis+and+structure-activity+relationship+studies+of+parthenolide+derivatives+as+potential+anti-triple+negative+breast+cancer+agents&doi=10.1016%2Fj.ejmech.2019.01.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents</span></div><div class="casAuthors">Ge, Weizhi; Hao, Xin; Han, Fangzhi; Liu, Zhongquan; Wang, Tianpeng; Wang, Mengmeng; Chen, Ning; Ding, Yahui; Chen, Yue; Zhang, Quan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">445-469</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most aggressive cancers with a high recurrence rate and rapidly acquired drug resistance among various breast cancer subtypes.  There is no specific drug for treatment of TNBC.  Discovery of therapeutic agents with unique modes of actions is urgently needed.  In this study, a series of seventy parthenolide derivs. was designed, synthesized, and evaluated for their anti-TNBC activities.  Compd. I exhibited the most potent activity against different breast cancer cells with IC50 values ranging from 0.20 μM to 0.27 μM, which demonstrated 11.6- to 18.6-fold improvement comparing to that of the parent compd. parthenolide with IC50 values of 2.68-4.63 μM.  It is worth to note that I was more active than the pos. control drug ADR.  Moreover, compd. I could induce apoptosis of SUM-159 cells through mitochondria pathway and cause G1 phase arrest of SUM-159 cells.  These findings indicate that compd. I deserves further studies as a lead compd. for ultimate discovery of effective anti-TNBC drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW97WDAuIPtLVg90H21EOLACvtfcHk0ljiQJQgmtQguQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivFygtL8%253D&md5=32965e2aa3657b697c4d23f2cf7b63ce</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.058%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DW.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520parthenolide%2520derivatives%2520as%2520potential%2520anti-triple%2520negative%2520breast%2520cancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D166%26spage%3D445%26epage%3D469%26doi%3D10.1016%2Fj.ejmech.2019.01.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janganati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrelli, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penthala, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span> <span> </span><span class="NLM_article-title">Dimers of melampomagnolide B exhibit potent anticancer activity against hematological and solid tumor cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8896</span>– <span class="NLM_lpage">8906</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKlt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8896-8906&author=V.+Janganatiauthor=J.+Ponderauthor=C.+T.+Jordanauthor=M.+J.+Borrelliauthor=N.+R.+Penthalaauthor=P.+A.+Crooks&title=Dimers+of+melampomagnolide+B+exhibit+potent+anticancer+activity+against+hematological+and+solid+tumor+cells&doi=10.1021%2Facs.jmedchem.5b01187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells</span></div><div class="casAuthors">Janganati, Venumadhav; Ponder, Jessica; Jordan, Craig T.; Borrelli, Michael J.; Penthala, Narsimha Reddy; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8896-8906</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel carbamate and carbonate dimers of melampomagnolide B have been synthesized by reaction of the melampomagnolide-B-triazole carbamate synthon with various terminal diamino- and dihydroxyalkanes.  Dimeric carbamate products exhibited potent growth inhibition (GIC50 = 0.16-0.99 μM) against the majority of cell lines in the NCI panel of 60 human hematol. and solid tumor cell lines.  Compd. bis-E-(((1aR,7aS,10aS,10bS)-1a-Methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2',3' 9,10]cyclodeca[1,2-b]furan-5-yl)methyl)octane-1,8-diyldicarbamate (7f) and bis-E-(((1aR,7aS,10aS,10bS)-1a-Methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2',3':9,10] cyclodeca[1,2-b]furan-5-yl)methyl) carbonate (8) exhibited anticancer activity that was 300-fold and 1 × 106-fold more cytotoxic than DMAPT, resp., at a concn. of 10 μM against rat 9L-SF gliosarcoma cells.  Novel carbamate and carbonate dimers were also screened against M9-ENL1 and acute myelogenous leukemia (AML) primary cell lines and exhibited 2- to 10-fold more potent antileukemic activity against M9-ENL1 cells (EC50 = 0.57-2.90 μM) when compared to parthenolide (EC50 = 6.0) and showed potent antileukemic activity against five primary AML cell lines (EC50 = 0.76-7.3 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAnzBdDGGt0rVg90H21EOLACvtfcHk0lgRjxMQRl3uPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKlt7bE&md5=71183c44bde3a90e6e02e77392754928</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01187%26sid%3Dliteratum%253Aachs%26aulast%3DJanganati%26aufirst%3DV.%26aulast%3DPonder%26aufirst%3DJ.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DBorrelli%26aufirst%3DM.%2BJ.%26aulast%3DPenthala%26aufirst%3DN.%2BR.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DDimers%2520of%2520melampomagnolide%2520B%2520exhibit%2520potent%2520anticancer%2520activity%2520against%2520hematological%2520and%2520solid%2520tumor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8896%26epage%3D8906%26doi%3D10.1021%2Facs.jmedchem.5b01187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nasim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span> <span> </span><span class="NLM_article-title">Melampomagnolide B: a new antileukemic sesquiterpene</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bmc.2010.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21273084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFKhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1515-1519&author=S.+Nasimauthor=S.+Peiauthor=F.+K.+Hagenauthor=C.+T.+Jordanauthor=P.+A.+Crooks&title=Melampomagnolide+B%3A+a+new+antileukemic+sesquiterpene&doi=10.1016%2Fj.bmc.2010.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Melampomagnolide B: A new antileukemic sesquiterpene</span></div><div class="casAuthors">Nasim, Shama; Pei, Shan Shan; Hagen, Fred K.; Jordan, Craig T.; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1515-1519</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Melampomagnolide B has been identified as a new antileukemic sesquiterpene.  A biotin-conjugated deriv. of melampomagnolide B was designed and synthesized in order to elucidate its mechanism of action.  A study of the biochem. interactions of the biotin probe suggests that melampomagnolide B derives its remarkable selectivity for leukemic cells over normal hematopoietic cells from its unique ability to exploit biochem. differences between the two cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorkXTH9qgT2rVg90H21EOLACvtfcHk0lgRjxMQRl3uPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFKhtL0%253D&md5=610a8e982ad51571be7966cbac1fff80</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DNasim%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DF.%2BK.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DMelampomagnolide%2520B%253A%2520a%2520new%2520antileukemic%2520sesquiterpene%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1515%26epage%3D1519%26doi%3D10.1016%2Fj.bmc.2010.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, W.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, B.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Syntheses and biological evaluation of costunolide, parthenolide, and their fluorinated analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7007</span>– <span class="NLM_lpage">7020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00915</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00915" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gmsr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7007-7020&author=Z.-J.+Yangauthor=W.-Z.+Geauthor=Q.-Y.+Liauthor=Y.+Luauthor=J.-M.+Gongauthor=B.-J.+Kuangauthor=X.+Xiauthor=H.+Wuauthor=Q.+Zhangauthor=Y.+Chen&title=Syntheses+and+biological+evaluation+of+costunolide%2C+parthenolide%2C+and+their+fluorinated+analogues&doi=10.1021%2Facs.jmedchem.5b00915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and Biological Evaluation of Costunolide, Parthenolide, and Their Fluorinated Analogues</span></div><div class="casAuthors">Yang, Zhong-Jin; Ge, Wei-Zhi; Li, Qiu-Ying; Lu, Yaxin; Gong, Jian-Miao; Kuang, Bei-Jia; Xi, Xiaonan; Wu, Haiting; Zhang, Quan; Chen, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7007-7020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inspired by the biosynthesis of sesquiterpene lactones (SLs), herein we report the asym. total synthesis of the germacrane ring I.  The synthetic strategy features a selective aldol reaction between β,γ-unsatd. chiral sulfonylamide II and aldehyde III, as well as the intramol. α-alkylation of sulfone IV to construct a 10-membered carbocylic ring.  The key intermediate I can be used to prep. the natural products costunolide and parthenolide (PTL), which are the key precursors for transformation into other SLs.  Furthermore, the described synthetic sequences are amenable to the total synthesis of SL analogs, such as trifluoromethylated analogs V and VI.  Analogs V and VI maintained high activities against a series of cancer cell lines compared to their parent PTL and costunolide, resp.  In addn., V showed enhanced tolerance to acidic media compared with PTL.  To our surprise, PTL and V showed comparable half-lives in rat plasma and in the presence of human liver microsomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG-9MPHOGhMbVg90H21EOLACvtfcHk0lgRjxMQRl3uPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gmsr%252FF&md5=595543d5e8b515a14b7f93831b1f3bac</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00915%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.-J.%26aulast%3DGe%26aufirst%3DW.-Z.%26aulast%3DLi%26aufirst%3DQ.-Y.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DJ.-M.%26aulast%3DKuang%26aufirst%3DB.-J.%26aulast%3DXi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DSyntheses%2520and%2520biological%2520evaluation%2520of%2520costunolide%252C%2520parthenolide%252C%2520and%2520their%2520fluorinated%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7007%26epage%3D7020%26doi%3D10.1021%2Facs.jmedchem.5b00915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.07.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bmc.2005.07.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=16140536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1egsLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=83-91&author=D.+R.+Hwangauthor=Y.+S.+Wuauthor=C.+W.+Changauthor=T.+W.+Lienauthor=W.+C.+Chenauthor=U.+K.+Tanauthor=J.+T.+Hsuauthor=H.+P.+Hsieh&title=Synthesis+and+anti-viral+activity+of+a+series+of+sesquiterpene+lactones+and+analogues+in+the+subgenomic+HCV+replicon+system&doi=10.1016%2Fj.bmc.2005.07.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system</span></div><div class="casAuthors">Hwang, Der-Ren; Wu, Yu-Shan; Chang, Chun-Wei; Lien, Tzu-Wen; Chen, Wei-Cheng; Tan, Uan-Kang; Hsu, John T. A.; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a severe liver disease that often leads to liver cirrhosis and hepatocellular carcinoma (HCC).  Current therapy is inadequate to conquer this viral disease.  In this study, we identified parthenolide (1), an active component in feverfew, a popular remedy for fever and migraine, as a lead compd. with an EC50 value of 2.21 μM against HCV replication in a subgenomic RNA replicon assay system.  Parthenolide is able to potentiate the interferon α-exerted anti-HCV effect.  Several com. available sesquiterpene lactones (2-5) structurally analogous to parthenolide and a series of synthesized Michael-type adducts of parthenolide (12-18) also exhibit micromolar concns. for anti-HCV activities.  Structure-activity relationship was elucidated to reveal that the spatial arrangement of the terpenoid skeleton fused with an α-methylene-γ-lactone moiety produces maximal anti-HCV activity.  In addn., a strong anti-HCV potency indicates a possibility of secondary amino adducts (12-18) converting back to parthenolide or being replaced by the nucleophilic residues of proteins inside cells.  This work shows that screening of natural products is a viable and fast way for identifying novel mol. diversity as potential drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0_t6XNy2kX7Vg90H21EOLACvtfcHk0lhFCX6aP2zqjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1egsLjF&md5=3b2d5d9c4cdce1c5f5eb97368b261151</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.07.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.07.055%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.%2BS.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DLien%26aufirst%3DT.%2BW.%26aulast%3DChen%26aufirst%3DW.%2BC.%26aulast%3DTan%26aufirst%3DU.%2BK.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DSynthesis%2520and%2520anti-viral%2520activity%2520of%2520a%2520series%2520of%2520sesquiterpene%2520lactones%2520and%2520analogues%2520in%2520the%2520subgenomic%2520HCV%2520replicon%2520system%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D83%26epage%3D91%26doi%3D10.1016%2Fj.bmc.2005.07.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelakantan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span> <span> </span><span class="NLM_article-title">Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4346</span>– <span class="NLM_lpage">4349</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bmcl.2009.05.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19505822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4346-4349&author=S.+Neelakantanauthor=S.+Nasimauthor=M.+L.+Guzmanauthor=C.+T.+Jordanauthor=P.+A.+Crooks&title=Aminoparthenolides+as+novel+anti-leukemic+agents%3A+Discovery+of+the+NF-kappaB+inhibitor%2C+DMAPT+%28LC-1%29&doi=10.1016%2Fj.bmcl.2009.05.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)</span></div><div class="casAuthors">Neelakantan, Sundar; Nasim, Shama; Guzman, Monica L.; Jordan, Craig T.; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4346-4349</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of aminoparthenolide analogs were synthesized and evaluated for their anti-leukemic activity.  Eight compds. exhibited good anti-leukemic activity with LD50's in the low μM range (1.5-3.0 μM).  Compds. I, II and III were the most potent compds. in the series, causing greater than 90% cell death at 10 μM concn. against primary AML cells in culture, with LD50 values of 1.7, 1.8 and 1.6 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzFsAppmWkqbVg90H21EOLACvtfcHk0lhFCX6aP2zqjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGmu7w%253D&md5=aff3db6b1997e882d2474e120a1419fa</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DNeelakantan%26aufirst%3DS.%26aulast%3DNasim%26aufirst%3DS.%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DAminoparthenolides%2520as%2520novel%2520anti-leukemic%2520agents%253A%2520Discovery%2520of%2520the%2520NF-kappaB%2520inhibitor%252C%2520DMAPT%2520%2528LC-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4346%26epage%3D4349%26doi%3D10.1016%2Fj.bmcl.2009.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieberich, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alavanja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colby, D. A.</span></span> <span> </span><span class="NLM_article-title">Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as (19)F NMR probes in deuterium-free environments</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7934</span>– <span class="NLM_lpage">7941</span>, <span class="refDoi"> DOI: 10.1021/jm201114t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201114t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyjsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7934-7941&author=J.+R.+Woodsauthor=H.+Moauthor=A.+A.+Bieberichauthor=T.+Alavanjaauthor=D.+A.+Colby&title=Fluorinated+amino-derivatives+of+the+sesquiterpene+lactone%2C+parthenolide%2C+as+%2819%29F+NMR+probes+in+deuterium-free+environments&doi=10.1021%2Fjm201114t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorinated Amino-Derivatives of the Sesquiterpene Lactone, Parthenolide, as 19F NMR Probes in Deuterium-Free Environments</span></div><div class="casAuthors">Woods, James R.; Mo, Huaping; Bieberich, Andrew A.; Alavanja, Tanja; Colby, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7934-7941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and biol. activity of fluorinated amino-derivs. of the sesquiterpene lactone, parthenolide, are described.  A fluorinated aminoparthenolide analog with biol. activity similar to the parent natural product was discovered, and its x-ray structure was obtained.  This lead compd. was then studied using 19F NMR in the presence and absence of glutathione to obtain addnl. mechanism of action data, and it was found that the aminoparthenolide eliminates amine faster in the presence of glutathione than in the absence of glutathione.  The exact changes in concns. of fluorinated compd. and amine were quantified by a concn.-ref. method using 19F NMR; a major benefit of applying this strategy is that no deuterated solvents or internal stds. are required to obtain accurate concns.  These mechanistic data with glutathione may contribute to the conversion of the amino-deriv. to parthenolide, the active pharmacol. agent, in glutathione-rich cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot6UoKKPwq5bVg90H21EOLACvtfcHk0lhFCX6aP2zqjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyjsrrN&md5=cc78c225b5b20b2a8948846a1e1cc3ef</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm201114t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201114t%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DJ.%2BR.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DBieberich%26aufirst%3DA.%2BA.%26aulast%3DAlavanja%26aufirst%3DT.%26aulast%3DColby%26aufirst%3DD.%2BA.%26atitle%3DFluorinated%2520amino-derivatives%2520of%2520the%2520sesquiterpene%2520lactone%252C%2520parthenolide%252C%2520as%2520%252819%2529F%2520NMR%2520probes%2520in%2520deuterium-free%2520environments%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7934%26epage%3D7941%26doi%3D10.1021%2Fjm201114t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasiou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israelsen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattaini, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metallo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtney, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malstrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoumbourdis, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veith, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimacombe, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunt, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephanopoulos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auld, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnchembio.1060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=22922757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ght7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=839-847&author=D.+Anastasiouauthor=Y.+Yuauthor=W.+J.+Israelsenauthor=J.+K.+Jiangauthor=M.+B.+Boxerauthor=B.+S.+Hongauthor=W.+Tempelauthor=S.+Dimovauthor=M.+Shenauthor=A.+Jhaauthor=H.+Yangauthor=K.+R.+Mattainiauthor=C.+M.+Metalloauthor=B.+P.+Fiskeauthor=K.+D.+Courtneyauthor=S.+Malstromauthor=T.+M.+Khanauthor=C.+Kungauthor=A.+P.+Skoumbourdisauthor=H.+Veithauthor=N.+Southallauthor=M.+J.+Walshauthor=K.+R.+Brimacombeauthor=W.+Leisterauthor=S.+Y.+Luntauthor=Z.+R.+Johnsonauthor=K.+E.+Yenauthor=K.+Kuniiauthor=S.+M.+Davidsonauthor=H.+R.+Christofkauthor=C.+P.+Austinauthor=J.+Ingleseauthor=M.+H.+Harrisauthor=J.+M.+Asaraauthor=G.+Stephanopoulosauthor=F.+G.+Salituroauthor=S.+Jinauthor=L.+Dangauthor=D.+S.+Auldauthor=H.+W.+Parkauthor=L.+C.+Cantleyauthor=C.+J.+Thomasauthor=M.+G.+Vander+Heiden&title=Pyruvate+kinase+M2+activators+promote+tetramer+formation+and+suppress+tumorigenesis&doi=10.1038%2Fnchembio.1060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis</span></div><div class="casAuthors">Anastasiou, Dimitrios; Yu, Yimin; Israelsen, William J.; Jiang, Jian-Kang; Boxer, Matthew B.; Hong, Bum Soo; Tempel, Wolfram; Dimov, Svetoslav; Shen, Min; Jha, Abhishek; Yang, Hua; Mattaini, Katherine R.; Metallo, Christian M.; Fiske, Brian P.; Courtney, Kevin D.; Malstrom, Scott; Khan, Tahsin M.; Kung, Charles; Skoumbourdis, Amanda P.; Veith, Henrike; Southall, Noel; Walsh, Martin J.; Brimacombe, Kyle R.; Leister, William; Lunt, Sophia Y.; Johnson, Zachary R.; Yen, Katharine E.; Kunii, Kaiko; Davidson, Shawn M.; Christofk, Heather R.; Austin, Christopher P.; Inglese, James; Harris, Marian H.; Asara, John M.; Stephanopoulos, Gregory; Salituro, Francesco G.; Jin, Shengfang; Dang, Lenny; Auld, Douglas S.; Park, Hee-Won; Cantley, Lewis C.; Thomas, Craig J.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">839-847</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells engage in a metabolic program to enhance biosynthesis and support cell proliferation.  The regulatory properties of pyruvate kinase M2 (PKM2) influence altered glucose metab. in cancer.  The interaction of PKM2 with phosphotyrosine-contg. proteins inhibits enzyme activity and increases the availability of glycolytic metabolites to support cell proliferation.  This suggests that high pyruvate kinase activity may suppress tumor growth.  We show that expression of PKM1, the pyruvate kinase isoform with high constitutive activity, or exposure to published small-mol. PKM2 activators inhibits the growth of xenograft tumors.  Structural studies reveal that small-mol. activators bind PKM2 at the subunit interaction interface, a site that is distinct from that of the endogenous activator fructose-1,6-bisphosphate (FBP).  However, unlike FBP, binding of activators to PKM2 promotes a constitutively active enzyme state that is resistant to inhibition by tyrosine-phosphorylated proteins.  These data support the notion that small-mol. activation of PKM2 can interfere with anabolic metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMDIr6LPTxPbVg90H21EOLACvtfcHk0ljgInPKNgLdtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ght7rM&md5=20ae4953c6afd41458cf317933fd5d9d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1060%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasiou%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DIsraelsen%26aufirst%3DW.%2BJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DBoxer%26aufirst%3DM.%2BB.%26aulast%3DHong%26aufirst%3DB.%2BS.%26aulast%3DTempel%26aufirst%3DW.%26aulast%3DDimov%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DJha%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DMattaini%26aufirst%3DK.%2BR.%26aulast%3DMetallo%26aufirst%3DC.%2BM.%26aulast%3DFiske%26aufirst%3DB.%2BP.%26aulast%3DCourtney%26aufirst%3DK.%2BD.%26aulast%3DMalstrom%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DSkoumbourdis%26aufirst%3DA.%2BP.%26aulast%3DVeith%26aufirst%3DH.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DWalsh%26aufirst%3DM.%2BJ.%26aulast%3DBrimacombe%26aufirst%3DK.%2BR.%26aulast%3DLeister%26aufirst%3DW.%26aulast%3DLunt%26aufirst%3DS.%2BY.%26aulast%3DJohnson%26aufirst%3DZ.%2BR.%26aulast%3DYen%26aufirst%3DK.%2BE.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DDavidson%26aufirst%3DS.%2BM.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DInglese%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DM.%2BH.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DStephanopoulos%26aufirst%3DG.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DPark%26aufirst%3DH.%2BW.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DPyruvate%2520kinase%2520M2%2520activators%2520promote%2520tetramer%2520formation%2520and%2520suppress%2520tumorigenesis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D839%26epage%3D847%26doi%3D10.1038%2Fnchembio.1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanotto-Filho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalmolin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquali, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battastini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J. C.</span></span> <span> </span><span class="NLM_article-title">NFκB inhibitors induce cell death in glioblastomas</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2010.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bcp.2010.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21040711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ajtrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2011&pages=412-424&author=A.+Zanotto-Filhoauthor=E.+Braganholauthor=R.+Schr%C3%B6derauthor=L.+H.+de+Souzaauthor=R.+J.+Dalmolinauthor=M.+A.+Pasqualiauthor=D.+P.+Gelainauthor=A.+M.+Battastiniauthor=J.+C.+Moreira&title=NF%CE%BAB+inhibitors+induce+cell+death+in+glioblastomas&doi=10.1016%2Fj.bcp.2010.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">NFκB inhibitors induce cell death in glioblastomas</span></div><div class="casAuthors">Zanotto-Filho, Alfeu; Braganhol, Elizandra; Schroeder, Rafael; de Souza, Luis Henrique T.; Dalmolin, Rodrigo J. S.; Pasquali, Matheus A. Bittencourt; Gelain, Daniel Pens; Battastini, Ana Maria Oliveira; Moreira, Jose Claudio Fonseca</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">412-424</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Identification of novel target pathways in glioblastoma (GBM) remains crit. due to poor prognosis, inefficient therapies and recurrence assocd. with these tumors.  In this work, we evaluated the role of nuclear-factor-κ-B (NFκB) in the growth of GBM cells, and the potential of NFκB inhibitors as antiglioma agents.  NFκB pathway was found overstimulated in GBM cell lines and in tumor specimens compared to normal astrocytes and healthy brain tissues, resp.  Treatment of a panel of established GBM cell lines (U138MG, U87, U373 and C6) with pharmacol. NFκB inhibitors (BAY117082, parthenolide, MG132, curcumin and arsenic trioxide) and NFκB-p65 siRNA markedly decreased the viability of GBMs as compared to inhibitors of other signaling pathways such as MAPKs (ERK, JNK and p38), PKC, EGFR and PI3K/Akt.  In addn., NFκB inhibitors presented a low toxicity to normal astrocytes, indicating selectivity to cancerous cells.  In GBMs, mitochondrial dysfunction (membrane depolarization, bcl-xL downregulation and cytochrome c release) and arrest in the G2/M phase were obsd. at the early steps of NFκB inhibitors treatment.  These events preceded sub-G1 detection, apoptotic body formation and caspase-3 activation.  Also, NFκB was found overstimulated in cisplatin-resistant C6 cells, and treatment of GBMs with NFκB inhibitors overcame cisplatin resistance besides potentiating the effects of the chemotherapeutics, cisplatin and doxorubicin.  These findings support NFκB as a potential target to cell death induction in GBMs, and that the NFκB inhibitors may be considered for in vivo testing on animal models and possibly on GBM therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEYaZC-m_cx7Vg90H21EOLACvtfcHk0ljgInPKNgLdtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ajtrjN&md5=b2cabf0ff1d0b1d16885243ca785f779</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DZanotto-Filho%26aufirst%3DA.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DR.%26aulast%3Dde%2BSouza%26aufirst%3DL.%2BH.%26aulast%3DDalmolin%26aufirst%3DR.%2BJ.%26aulast%3DPasquali%26aufirst%3DM.%2BA.%26aulast%3DGelain%26aufirst%3DD.%2BP.%26aulast%3DBattastini%26aufirst%3DA.%2BM.%26aulast%3DMoreira%26aufirst%3DJ.%2BC.%26atitle%3DNF%25CE%25BAB%2520inhibitors%2520induce%2520cell%2520death%2520in%2520glioblastomas%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D81%26spage%3D412%26epage%3D424%26doi%3D10.1016%2Fj.bcp.2010.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1853</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2014.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.cellsig.2014.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=24686087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGlsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=1853-1862&author=P.+Yangauthor=Z.+Liauthor=R.+Fuauthor=H.+Wuauthor=Z.+Li&title=Pyruvate+kinase+M2+facilitates+colon+cancer+cell+migration+via+the+modulation+of+STAT3+signalling&doi=10.1016%2Fj.cellsig.2014.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling</span></div><div class="casAuthors">Yang, Peng; Li, Zongwei; Fu, Rong; Wu, Haili; Li, Zhuoyu</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1853-1862</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Understanding the mechanisms of colorectal cancer (CRC) metastatic progression is essential to reducing its morbidity and mortality.  Pyruvate kinase (PK) catalyzes the final step of glycolysis and has been identified as a crit. regulator of glucose consumption.  However, the mechanisms and roles of PKM1 and PKM2 in the regulation of CRC cell migration and cell adhesion remain elusive.  Here, we report that PKM2 rather than PKM1 drives CRC cell migration and cell adhesion, whereas PKM attenuation reverses these phenomena.  Furthermore, the overexpression of PKM2 significantly increases the expression of N-cadherin, MMP-2, MMP-9, STAT3, Snail-2, pFAK and active β1-integrin, while E-cadherin expression is suppressed.  More importantly, the results indicated that PKM2 overexpression facilitates STAT3 nuclear translocation, and it is required for PKM2 function in the regulation of migration and adhesion assocd. signalling.  In addn., the dimeric form of PKM2, which lacks the pyruvate kinase activities but possesses protein kinase activity, is crit. for CRC cell migration and cell adhesion.  Overall, this study suggests that PKM2 overexpression promotes CRC cell migration and cell adhesion by regulating STAT3-assocd. signalling and that PKM2 may serve as a therapeutic target for CRC metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhcHi48jxBILVg90H21EOLACvtfcHk0ljgInPKNgLdtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGlsb%252FL&md5=45eab56fbc5dc8fa531921ce50e005bb</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2014.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2014.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFu%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DPyruvate%2520kinase%2520M2%2520facilitates%2520colon%2520cancer%2520cell%2520migration%2520via%2520the%2520modulation%2520of%2520STAT3%2520signalling%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D1853%26epage%3D1862%26doi%3D10.1016%2Fj.cellsig.2014.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordula, T.</span></span> <span> </span><span class="NLM_article-title">Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1999.1948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1006%2Fbbrc.1999.1948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10623619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1GktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=2000&pages=329-333&author=R.+Sobotaauthor=M.+Szwedauthor=A.+Kaszaauthor=M.+Bugnoauthor=T.+Kordula&title=Parthenolide+inhibits+activation+of+signal+transducers+and+activators+of+transcription+%28STATs%29+induced+by+cytokines+of+the+IL-6+family&doi=10.1006%2Fbbrc.1999.1948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Parthenolide Inhibits Activation of Signal Transducers and Activators of Transcription (STATs) Induced by Cytokines of the IL-6 Family</span></div><div class="casAuthors">Sobota, Radoslaw; Szwed, Marcin; Kasza, Aneta; Bugno, Marcin; Kordula, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">329-333</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Progression of inflammatory processes correlates with the release of cell-derived mediators from the local site of inflammation.  These mediators, including cytokines of the IL-1 and IL-6 families, act on host cells and exert their action by activating their signal transduction pathways leading to specific target gene activation.  Parthenolide, a sesquiterpene lactone found in many medicinal plants, is an inhibitor of IL-1-type cytokine signaling that blocks the activation of NF-κB.  Here we show that parthenolide is also an effective inhibitor of IL-6-type cytokines.  It inhibits IL-6-type cytokine-induced gene expression by blocking STAT3 phosphorylation on Tyr705.  This prevents STAT3 dimerization necessary for its nuclear translocation and consequently STAT3-dependent gene expression.  This is a new mol. mechanism of parthenolide action that addnl. explains its anti-inflammatory activities.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3KCJLuFabKrVg90H21EOLACvtfcHk0ljsBtchzjsSsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1GktA%253D%253D&md5=e8dc1bf3d18338b8cf3ed0769cecc6ff</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1999.1948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1999.1948%26sid%3Dliteratum%253Aachs%26aulast%3DSobota%26aufirst%3DR.%26aulast%3DSzwed%26aufirst%3DM.%26aulast%3DKasza%26aufirst%3DA.%26aulast%3DBugno%26aufirst%3DM.%26aulast%3DKordula%26aufirst%3DT.%26atitle%3DParthenolide%2520inhibits%2520activation%2520of%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%2520%2528STATs%2529%2520induced%2520by%2520cytokines%2520of%2520the%2520IL-6%2520family%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2000%26volume%3D267%26spage%3D329%26epage%3D333%26doi%3D10.1006%2Fbbrc.1999.1948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3572</span>– <span class="NLM_lpage">3579</span>, <span class="refDoi"> DOI: 10.3892/ol.2018.7739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.3892%2Fol.2018.7739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=29467878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC1MrktVGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=3572-3579&author=H.+Liauthor=H.+Luauthor=M.+Lvauthor=Q.+Wangauthor=Y.+Sun&title=Parthenolide+facilitates+apoptosis+and+reverses+drug-resistance+of+human+gastric+carcinoma+cells+by+inhibiting+the+STAT3+signaling+pathway&doi=10.3892%2Fol.2018.7739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway</span></div><div class="casAuthors">Li Hua; Sun Yuping; Li Hua; Lu Hang; Lv Meng; Wang Qingsheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">3572-3579</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">In the present study, SGC-7901/DDP cells were treated with different concentrations of parthenolide (PN) (2.5-15 μmol/l), cisplatin (DDP) (1.25-15 μg/ml) and PN+DDP.  The proliferation inhibition rates were measured using an MTT assay, and the synergies of PN and DDP were analyzed.  The effect of PN and DDP on SGC-7901/DDP cell proliferation demonstrated a time- and concentration-dependent association, and a synergy between PN and DDP was identified.  DAPI staining and flow cytometry results indicated that 15 μmol/l PN significantly induced SGC-7901/DDP apoptosis and G1 phase arrest compared with the untreated control group.  Western blotting analysis results indicated that among the apoptosis-associated proteins, there were dose-dependent increases in the protein expression of apoptosis regulator BAX, cellular tumor antigen p53, cleaved caspase-3 and cleaved capase-9, and decreases in apoptosis regulator Bcl-2 and Bcl-xL protein expression levels.  Among the cell cycle-associated proteins, cyclin D1 expression was significantly decreased, cyclin-dependent kinase inhibitor 1 expression was significantly increased, and signal transducer and activator of transcription 3 (STAT3) activation was inhibited.  Scratch and Transwell assay results revealed that PN significantly inhibited SGC-7901/DDP cell migration, and invasion.  The present study demonstrated that PN induces SGC-7901/DDP apoptosis, inhibits SGC-7901/DDP proliferation, migration and invasion, and enhances the drug sensitivity of the cells to DDP.  The underlying mechanisms may be associated with inhibition of the STAT3 signaling pathway and regulation of the downstream apoptotic protein and cyclin expression levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrmXdAiWRkMdFxYDaSSP8XfW6udTcc2ea7wGe7OsjxmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrktVGmtA%253D%253D&md5=efb23320870893f96ff5e3515333e01b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3892%2Fol.2018.7739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2018.7739%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLv%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DParthenolide%2520facilitates%2520apoptosis%2520and%2520reverses%2520drug-resistance%2520of%2520human%2520gastric%2520carcinoma%2520cells%2520by%2520inhibiting%2520the%2520STAT3%2520signaling%2520pathway%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D15%26spage%3D3572%26epage%3D3579%26doi%3D10.3892%2Fol.2018.7739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palomer, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez-Guardia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vázquez-Carrera, M.</span></span> <span> </span><span class="NLM_article-title">The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e19724</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0019724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1371%2Fjournal.pone.0019724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21625432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=X.+Palomerauthor=D.+%C3%81lvarez-Guardiaauthor=M.+M.+Davidsonauthor=T.+O.+Chanauthor=A.+M.+Feldmanauthor=M.+V%C3%A1zquez-Carrera&title=The+interplay+between+NF-kappaB+and+E2F1+coordinately+regulates+inflammation+and+metabolism+in+human+cardiac+cells&doi=10.1371%2Fjournal.pone.0019724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The interplay between NF-κB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells</span></div><div class="casAuthors">Palomer, Xavier; Alvarez-Guardia, David; Davidson, Mercy M.; Chan, Tung O.; Feldman, Arthur M.; Vazquez-Carrera, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e19724</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Pyruvate dehydrogenase kinase 4 (PDK4) inhibition by nuclear factor-κB (NF-κB) is related to a shift towards increased glycolysis during cardiac pathol. processes such as cardiac hypertrophy and heart failure.  The transcription factors estrogen-related receptor-α (ERRα) and peroxisome proliferator-activated receptor (PPAR) regulate PDK4 expression through the potent transcriptional coactivator PPARγ coactivator-1α (PGC-1α).  NF-κB activation in AC16 cardiac cells inhibit ERRα and PPARβ/δ transcriptional activity, resulting in reduced PGC-1α and PDK4 expression, and an enhanced glucose oxidn. rate.  However, addn. of the NF-κB inhibitor parthenolide to these cells prevents the downregulation of PDK4 expression but not ERRα and PPARβ/δ DNA binding activity, thus suggesting that addnl. transcription factors are regulating PDK4.  Interestingly, a recent study has demonstrated that the transcription factor E2F1, which is crucial for cell cycle control, may regulate PDK4 expression.  Given that NF-κB may antagonize the transcriptional activity of E2F1 in cardiac myocytes, we sought to study whether inflammatory processes driven by NF-κB can downregulate PDK4 expression in human cardiac AC16 cells through E2F1 inhibition.  Protein coimmunopptn. indicated that PDK4 downregulation entailed enhanced phys. interaction between the p65 subunit of NF-κB and E2F1.  Chromatin immunopptn. analyses demonstrated that p65 translocation into the nucleus prevented the recruitment of E2F1 to the PDK4 promoter and its subsequent E2F1-dependent gene transcription.  Interestingly, the NF-κB inhibitor parthenolide prevented the inhibition of E2F1, while E2F1 overexpression reduced interleukin expression in stimulated cardiac cells.  Based on these findings, we propose that NF-κB acts as a mol. switch that regulates E2F1-dependent PDK4 gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosrmYcI4sovrVg90H21EOLACvtfcHk0ljsBtchzjsSsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslCrt70%253D&md5=02bebe411c8167456351898ac4903d6f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0019724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0019724%26sid%3Dliteratum%253Aachs%26aulast%3DPalomer%26aufirst%3DX.%26aulast%3D%25C3%2581lvarez-Guardia%26aufirst%3DD.%26aulast%3DDavidson%26aufirst%3DM.%2BM.%26aulast%3DChan%26aufirst%3DT.%2BO.%26aulast%3DFeldman%26aufirst%3DA.%2BM.%26aulast%3DV%25C3%25A1zquez-Carrera%26aufirst%3DM.%26atitle%3DThe%2520interplay%2520between%2520NF-kappaB%2520and%2520E2F1%2520coordinately%2520regulates%2520inflammation%2520and%2520metabolism%2520in%2520human%2520cardiac%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0019724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8757</span>– <span class="NLM_lpage">8769</span>, <span class="refDoi"> DOI: 10.1021/jm301064b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301064b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8757-8769&author=Q.+Zhangauthor=Y.+Luauthor=Y.+Dingauthor=J.+Zhaiauthor=Q.+Jiauthor=W.+Maauthor=M.+Yangauthor=H.+Fanauthor=J.+Longauthor=Z.+Tongauthor=Y.+Shiauthor=Y.+Jiaauthor=B.+Hanauthor=W.+Zhangauthor=C.+Qiuauthor=X.+Maauthor=Q.+Liauthor=Q.+Shiauthor=H.+Zhangauthor=D.+Liauthor=J.+Zhangauthor=J.+Linauthor=L.+Y.+Liauthor=Y.+Gaoauthor=Y.+Chen&title=Guaianolide+sesquiterpene+lactones%2C+a+source+to+discover+agents+that+selectively+inhibit+acute+myelogenous+leukemia+stem+and+progenitor+cells&doi=10.1021%2Fjm301064b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Guaianolide Sesquiterpene Lactones, a Source To Discover Agents That Selectively Inhibit Acute Myelogenous Leukemia Stem and Progenitor Cells</span></div><div class="casAuthors">Zhang, Quan; Lu, Yaxin; Ding, Yahui; Zhai, Jiadai; Ji, Qing; Ma, Weiwei; Yang, Ming; Fan, Hongxia; Long, Jing; Tong, Zhongsheng; Shi, Yehui; Jia, Yongsheng; Han, Bin; Zhang, Wenpeng; Qiu, Chuanjiang; Ma, Xiaoyan; Li, Qiuying; Shi, Qianqian; Zhang, Haoliang; Li, Dongmei; Zhang, Jing; Lin, Jianping; Li, Lu-Yuan; Gao, Yingdai; Chen, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8757-8769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mols. that can selectively target cancer stem cells (CSCs) remain rare currently and exhibit no common structural features.  Here, we report a series of guaianolide sesquiterpene lactones (GSLs) and their derivs. that can selectively eradicate acute myelogenous leukemia (AML) stem or progenitor cells.  Natural GSL compds. arglabin, an anticancer clin. drug, and micheliolide (MCL), are able to reduce the proportion of AML stem cells (CD34+CD38-) in primary AML cells.  Targeting of AML stem cells is further confirmed by a sharp redn. of colony-forming units of primary AML cells upon MCL treatment.  Moreover, the dimethylamino Michael adduct of MCL, I, slowly releases MCL in plasma and in vivo and demonstrates remarkable therapeutic efficacy in the nonobese diabetic/severe combined immunodeficiency AML models.  These findings indicate that GSL is an ample source for chem. agents against AML stem or progenitor cells and that GSL is potentially highly useful to explore anti-CSC approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps_V3OAFoCjrVg90H21EOLACvtfcHk0lgeutMPNs2p-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktbzN&md5=064c942ed395fc35e71155c45206a5bf</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm301064b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301064b%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DZhai%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DGuaianolide%2520sesquiterpene%2520lactones%252C%2520a%2520source%2520to%2520discover%2520agents%2520that%2520selectively%2520inhibit%2520acute%2520myelogenous%2520leukemia%2520stem%2520and%2520progenitor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8757%26epage%3D8769%26doi%3D10.1021%2Fjm301064b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Wedel-Parlow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wölte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galla, H. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2009.06305.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1111%2Fj.1471-4159.2009.06305.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19656257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ertLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2009&pages=111-118&author=M.+von%0AWedel-Parlowauthor=P.+W%C3%B6lteauthor=H.+J.+Galla&title=Regulation+of+major+efflux+transporters+under+inflammatory+conditions+at+the+blood-brain+barrier+in+vitro&doi=10.1111%2Fj.1471-4159.2009.06305.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro</span></div><div class="casAuthors">von Wedel-Parlow, Magdalena; Woelte, Philipp; Galla, Hans-Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">ATP-driven efflux transport proteins at the blood-brain barrier protect the healthy brain but impede pharmacotherapy of the disordered CNS.  To investigate the question how ATP-binding cassette (ABC)-transporters are regulated during inflammation or infection we analyzed the effects of the cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) on the expression of brain multi-drug resistance proteins in primary cultures of porcine brain capillary endothelial cells.  We found that TNF-α and IL-1β rapidly decrease Abcg2 (BMDP/BCRP) mRNA expression within 6 h.  After 24 and 48 h the mRNA level came back to control values.  The mRNA redn. at 6 h was counter-regulated by the anti-inflammatory glucocorticoid hydrocortisone.  Abcg2 protein levels were suppressed at prolonged stimulations but not after 6 h of stimulation which correlates with Abcg2 specific substrate uptake measurements.  Abcb1 (p-glycoprotein) protein expression was transiently increased after TNF-α addn. within 6 h of incubation followed by a redn. after 24 and 48 h whereas the Abcb1 mRNA levels were not changed.  IL-1β caused a continuous decrease in protein expression of both ABC-transporters.  Long-term treatment with an assumed TNF-α-downstream agent, the vasocon-strictor endothelin-1, induced Abcg2 protein expression but suppressed Abcb1.  Other efflux pumps like multi-drug resistance-assocd. proteins/Abcc were rarely affected.  The present results imply a complex regulation of the two most abundant ABC-transporters at the blood-brain barrier during early inflammation stages suggesting that Abcb1 (p-glycoprotein) is an early target of TNF-α-signaling counter-balanced by Abcg2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnAWI6G1Wpv7Vg90H21EOLACvtfcHk0lgeutMPNs2p-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ertLnJ&md5=68f955b8c59d15a53dc8444d8d6fb889</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2009.06305.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2009.06305.x%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BWedel-Parlow%26aufirst%3DM.%26aulast%3DW%25C3%25B6lte%26aufirst%3DP.%26aulast%3DGalla%26aufirst%3DH.%2BJ.%26atitle%3DRegulation%2520of%2520major%2520efflux%2520transporters%2520under%2520inflammatory%2520conditions%2520at%2520the%2520blood-brain%2520barrier%2520in%2520vitro%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D111%26spage%3D111%26epage%3D118%26doi%3D10.1111%2Fj.1471-4159.2009.06305.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasiou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulogiannis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auld, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">1278</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1126/science.1211485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1126%2Fscience.1211485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=22052977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCms7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=1278-1283&author=D.+Anastasiouauthor=G.+Poulogiannisauthor=J.+M.+Asaraauthor=M.+B.+Boxerauthor=J.+K.+Jiangauthor=M.+Shenauthor=G.+Bellingerauthor=A.+T.+Sasakiauthor=J.+W.+Locasaleauthor=D.+S.+Auldauthor=C.+J.+Thomasauthor=M.+G.+Vander+Heidenauthor=L.+C.+Cantley&title=Inhibition+of+pyruvate+kinase+M2+by+reactive+oxygen+species+contributes+to+cellular+antioxidant+responses&doi=10.1126%2Fscience.1211485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses</span></div><div class="casAuthors">Anastasiou, Dimitrios; Poulogiannis, George; Asara, John M.; Boxer, Matthew B.; Jiang, Jian-kang; Shen, Min; Bellinger, Gary; Sasaki, Atsuo T.; Locasale, Jason W.; Auld, Douglas S.; Thomas, Craig J.; Vander Heiden, Matthew G.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6060</span>),
    <span class="NLM_cas:pages">1278-1283</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Control of intracellular reactive oxygen species (ROS) concns. is crit. for cancer cell survival.  We show that, in human lung cancer cells, acute increases in intracellular concns. of ROS caused inhibition of the glycolytic enzyme pyruvate kinase M2 (PKM2) through oxidn. of Cys358.  This inhibition of PKM2 is required to divert glucose flux into the pentose phosphate pathway and thereby generate sufficient reducing potential for detoxification of ROS.  Lung cancer cells in which endogenous PKM2 was replaced with the Cys358 to Ser358 oxidn.-resistant mutant exhibited increased sensitivity to oxidative stress and impaired tumor formation in a xenograft model.  Besides promoting metabolic changes required for proliferation, the regulatory properties of PKM2 may confer an addnl. advantage to cancer cells by allowing them to withstand oxidative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9SgiOQxnKObVg90H21EOLACvtfcHk0lgeutMPNs2p-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCms7jK&md5=9c6ac78508f3c25cbad20d1f8a21b4dc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.1211485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1211485%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasiou%26aufirst%3DD.%26aulast%3DPoulogiannis%26aufirst%3DG.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DBoxer%26aufirst%3DM.%2BB.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DBellinger%26aufirst%3DG.%26aulast%3DSasaki%26aufirst%3DA.%2BT.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DInhibition%2520of%2520pyruvate%2520kinase%2520M2%2520by%2520reactive%2520oxygen%2520species%2520contributes%2520to%2520cellular%2520antioxidant%2520responses%26jtitle%3DScience%26date%3D2011%26volume%3D334%26spage%3D1278%26epage%3D1283%26doi%3D10.1126%2Fscience.1211485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blouin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakikhani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algire, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2009.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.canlet.2009.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19744772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1Wlu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2010&pages=246-253&author=M.+J.+Blouinauthor=Y.+Zhaoauthor=M.+Zakikhaniauthor=C.+Algireauthor=E.+Piuraauthor=M.+Pollak&title=Loss+of+function+of+PTEN+alters+the+relationship+between+glucose+concentration+and+cell+proliferation%2C+increases+glycolysis%2C+and+sensitizes+cells+to+2-deoxyglucose&doi=10.1016%2Fj.canlet.2009.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose</span></div><div class="casAuthors">Blouin, Marie-Jose; Zhao, Yunhua; Zakikhani, Mahvash; Algire, Carolyn; Piura, Esther; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-253</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">PTEN loss of function enhances proliferation, but effects on cellular energy metab. are less well characterized.  We used an inducible PTEN expression vector in a PTEN-null glioma cell line to examine this issue.  While proliferation of PTEN-pos. cells was insensitive to increases in glucose concn. beyond 2.5 mM, PTEN-null cells significantly increased proliferation with increasing glucose concn. across the normal physiol. range to ∼10 mM, coinciding with a shift to glycolysis and "glucose addiction".  This demonstrates that the impact of loss of function of PTEN is modified by glucose concn., and may be relevant to epidemiol. results linking hyperglycemia to cancer risk and cancer mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOn5gk3F6FTbVg90H21EOLACvtfcHk0ljnIfZamaJKIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1Wlu70%253D&md5=49be114e6c700aaffbbcc03a5e2ebc8a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DBlouin%26aufirst%3DM.%2BJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DAlgire%26aufirst%3DC.%26aulast%3DPiura%26aufirst%3DE.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DLoss%2520of%2520function%2520of%2520PTEN%2520alters%2520the%2520relationship%2520between%2520glucose%2520concentration%2520and%2520cell%2520proliferation%252C%2520increases%2520glycolysis%252C%2520and%2520sensitizes%2520cells%2520to%25202-deoxyglucose%26jtitle%3DCancer%2520Lett.%26date%3D2010%26volume%3D289%26spage%3D246%26epage%3D253%26doi%3D10.1016%2Fj.canlet.2009.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Cros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmerlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounarides, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span> <span> </span><span class="NLM_article-title">M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1073/pnas.1212780110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1073%2Fpnas.1212780110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=23267074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=489-494&author=M.+Cortes-Crosauthor=C.+Hemmerlinauthor=S.+Ferrettiauthor=J.+Zhangauthor=J.+S.+Gounaridesauthor=H.+Yinauthor=A.+Mullerauthor=A.+Haberkornauthor=P.+Cheneauthor=W.+R.+Sellersauthor=F.+Hofmann&title=M2+isoform+of+pyruvate+kinase+is+dispensable+for+tumor+maintenance+and+growth&doi=10.1073%2Fpnas.1212780110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth</span></div><div class="casAuthors">Cortes-Cros, Marta; Hemmerlin, Christelle; Ferretti, Stephane; Zhang, Juan; Gounarides, John S.; Yin, Hong; Muller, Alban; Haberkorn, Anne; Chene, Patrick; Sellers, William R.; Hofmann, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">489-494, S489/1-S489/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Many cancer cells have increased rates of aerobic glycolysis, a phenomenon termed the Warburg effect.  In addn., in tumors there is a predominance of expression of the M2 isoform of pyruvate kinase (PKM2).  PKM2 expression was previously shown to be necessary for aerobic glycolysis and to provide a growth advantage to tumors.  Here, the authors report that knockdown of PKM2 in tumor cells led to a decrease in the levels of pyruvate kinase activity and an increase in the pyruvate kinase substrate, phosphoenolpyruvate.  However, lactate prodn. from glucose, although reduced, was not fully inhibited.  Furthermore, the authors are unique in reporting increased serine and glycine biosynthesis from both glucose and glutamine following PKM2 knockdown.  Although PKM2 knockdown resulted in modest impairment of proliferation in vitro, the in vivo growth of established xenograft tumors was unaffected by PKM2 absence.  Thus, these findings indicate that PKM2 is dispensable for tumor maintenance and growth in vivo, suggesting that other metabolic pathways bypass its function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXJi5-fdQ7jLVg90H21EOLACvtfcHk0ljnIfZamaJKIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOhtLs%253D&md5=5284f54fbaa4dad9b067ee1b0394a7e1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1212780110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1212780110%26sid%3Dliteratum%253Aachs%26aulast%3DCortes-Cros%26aufirst%3DM.%26aulast%3DHemmerlin%26aufirst%3DC.%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGounarides%26aufirst%3DJ.%2BS.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DA.%26aulast%3DHaberkorn%26aufirst%3DA.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26atitle%3DM2%2520isoform%2520of%2520pyruvate%2520kinase%2520is%2520dispensable%2520for%2520tumor%2520maintenance%2520and%2520growth%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D489%26epage%3D494%26doi%3D10.1073%2Fpnas.1212780110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Israelsen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayton, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosios, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burga, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibbey, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Vizio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">PKM2 isoform-specifific deletion reveals a difffferential requirement for pyruvate kinase in tumor cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2013.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.cell.2013.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=24120138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sktr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2013&pages=397-409&author=W.+J.+Israelsenauthor=T.+L.+Daytonauthor=S.+M.+Davidsonauthor=B.+P.+Fiskeauthor=A.+M.+Hosiosauthor=G.+Bellingerauthor=J.+Liauthor=Y.+Yuauthor=M.+Sasakiauthor=J.+W.+Hornerauthor=L.+N.+Burgaauthor=J.+Xieauthor=M.+J.+Jurczakauthor=R.+A.+DePinhoauthor=C.+B.+Clishauthor=T.+Jacksauthor=R.+G.+Kibbeyauthor=G.+M.+Wulfauthor=D.+Di+Vizioauthor=G.+B.+Millsauthor=L.+C.+Cantleyauthor=M.+G.+Vander+Heiden&title=PKM2+isoform-specifific+deletion+reveals+a+difffferential+requirement+for+pyruvate+kinase+in+tumor+cells&doi=10.1016%2Fj.cell.2013.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells</span></div><div class="casAuthors">Israelsen, William J.; Dayton, Talya L.; Davidson, Shawn M.; Fiske, Brian P.; Hosios, Aaron M.; Bellinger, Gary; Li, Jie; Yu, Yimin; Sasaki, Mika; Horner, James W.; Burga, Laura N.; Xie, Jianxin; Jurczak, Michael J.; DePinho, Ronald A.; Clish, Clary B.; Jacks, Tyler; Kibbey, Richard G.; Wulf, Gerburg M.; Di Vizio, Dolores; Mills, Gordon B.; Cantley, Lewis C.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The pyruvate kinase M2 isoform (PKM2) is expressed in cancer and plays a role in regulating anabolic metab.  To det. whether PKM2 is required for tumor formation or growth, we generated mice with a conditional allele that abolishes PKM2 expression without disrupting PKM1 expression.  PKM2 deletion accelerated mammary tumor formation in a Brca1-loss-driven model of breast cancer.  PKM2 null tumors displayed heterogeneous PKM1 expression, with PKM1 found in nonproliferating tumor cells and no detectable pyruvate kinase expression in proliferating cells.  This suggests that PKM2 is not necessary for tumor cell proliferation and implies that the inactive state of PKM2 is assocd. with the proliferating cell population within tumors, whereas nonproliferating tumor cells require active pyruvate kinase.  Consistent with these findings, variable PKM2 expression and heterozygous PKM2 mutations are found in human tumors.  These data suggest that regulation of PKM2 activity supports the different metabolic requirements of proliferating and nonproliferating tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8md57TLpos7Vg90H21EOLACvtfcHk0ljnIfZamaJKIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sktr%252FI&md5=b2647ac4c5fa6a1fa03664adb60288ee</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DIsraelsen%26aufirst%3DW.%2BJ.%26aulast%3DDayton%26aufirst%3DT.%2BL.%26aulast%3DDavidson%26aufirst%3DS.%2BM.%26aulast%3DFiske%26aufirst%3DB.%2BP.%26aulast%3DHosios%26aufirst%3DA.%2BM.%26aulast%3DBellinger%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DM.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DBurga%26aufirst%3DL.%2BN.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DJurczak%26aufirst%3DM.%2BJ.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DKibbey%26aufirst%3DR.%2BG.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26aulast%3DDi%2BVizio%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DPKM2%2520isoform-specifific%2520deletion%2520reveals%2520a%2520difffferential%2520requirement%2520for%2520pyruvate%2520kinase%2520in%2520tumor%2520cells%26jtitle%3DCell%26date%3D2013%26volume%3D155%26spage%3D397%26epage%3D409%26doi%3D10.1016%2Fj.cell.2013.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendez-Lucas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschaharganeh, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvisi, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuneva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Glucose catabolism in liver tumors induced by c-MYC can be sustained by various PKM1/PKM2 ratios and pyruvate kinase activities</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4355</span>– <span class="NLM_lpage">4364</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-0498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1158%2F0008-5472.CAN-17-0498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=28630053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC1cnpvVajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4355-4364&author=A.+Mendez-Lucasauthor=X.+Liauthor=J.+Huauthor=L.+Cheauthor=X.+Songauthor=J.+Jiaauthor=J.+Wangauthor=C.+Xieauthor=P.+C.+Driscollauthor=D.+F.+Tschaharganehauthor=D.+F.+Calvisiauthor=M.+Yunevaauthor=X.+Chen&title=Glucose+catabolism+in+liver+tumors+induced+by+c-MYC+can+be+sustained+by+various+PKM1%2FPKM2+ratios+and+pyruvate+kinase+activities&doi=10.1158%2F0008-5472.CAN-17-0498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities</span></div><div class="casAuthors">Mendez-Lucas Andres; Driscoll Paul C; Yuneva Mariia; Li Xiaolei; Hu Junjie; Che Li; Song Xinhua; Jia Jiaoyuan; Wang Jingxiao; Xie Chencheng; Chen Xin; Li Xiaolei; Hu Junjie; Chen Xin; Jia Jiaoyuan; Xie Chencheng; Tschaharganeh Darjus F; Tschaharganeh Darjus F; Calvisi Diego F</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4355-4364</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Different pyruvate kinase isoforms are expressed in a tissue-specific manner, with pyruvate kinase M2 (PKM2) suggested to be the predominant isoform in proliferating cells and cancer cells.  Because of differential regulation of enzymatic activities, PKM2, but not PKM1, has been thought to favor cell proliferation.  However, the role of PKM2 in tumorigenesis has been recently challenged.  Here we report that increased glucose catabolism through glycolysis and increased pyruvate kinase activity in c-MYC-driven liver tumors are associated with increased expression of both PKM1 and PKM2 isoforms and decreased expression of the liver-specific isoform of pyruvate kinase, PKL.  Depletion of PKM2 at the time of c-MYC overexpression in murine livers did not affect c-MYC-induced tumorigenesis and resulted in liver tumor formation with decreased pyruvate kinase activity and decreased catabolism of glucose into alanine and the Krebs cycle.  An increased PKM1/PKM2 ratio by ectopic PKM1 expression further decreased glucose flux into serine biosynthesis and increased flux into lactate and the Krebs cycle, resulting in reduced total levels of serine.  However, these changes also did not affect c-MYC-induced liver tumor development.  These results suggest that increased expression of PKM2 is not required to support c-MYC-induced tumorigenesis in the liver and that various PKM1/PKM2 ratios and pyruvate kinase activities can sustain glucose catabolism required for this process.  Cancer Res; 77(16); 4355-64. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRX9xb9_t-_-LFU0A1HOshhfW6udTcc2eaHZo9wAln0MLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnpvVajtg%253D%253D&md5=f2e79aca961381e431827d62ad50c676</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0498%26sid%3Dliteratum%253Aachs%26aulast%3DMendez-Lucas%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DDriscoll%26aufirst%3DP.%2BC.%26aulast%3DTschaharganeh%26aufirst%3DD.%2BF.%26aulast%3DCalvisi%26aufirst%3DD.%2BF.%26aulast%3DYuneva%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DGlucose%2520catabolism%2520in%2520liver%2520tumors%2520induced%2520by%2520c-MYC%2520can%2520be%2520sustained%2520by%2520various%2520PKM1%252FPKM2%2520ratios%2520and%2520pyruvate%2520kinase%2520activities%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4355%26epage%3D4364%26doi%3D10.1158%2F0008-5472.CAN-17-0498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yulin Ren, <span class="NLM_string-name hlFld-ContribAuthor">A. Douglas Kinghorn</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15410-15448. <a href="https://doi.org/10.1021/acs.jmedchem.0c01449" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01449%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BPotential%252BAntitumor%252BAgents%252Bfrom%252Bthe%252BScaffolds%252Bof%252BPlant-Derived%252BTerpenoid%252BLactones%26aulast%3DRen%26aufirst%3DYulin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20082020%26date%3D08122020%26volume%3D63%26issue%3D24%26spage%3D15410%26epage%3D15448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdelhak  Ouled Aitouna</span>, <span class="hlFld-ContribAuthor ">ME.  Belghiti</span>, <span class="hlFld-ContribAuthor ">Aslı  Eşme</span>, <span class="hlFld-ContribAuthor ">E.  Anouar</span>, <span class="hlFld-ContribAuthor ">Anass  Ouled Aitouna</span>, <span class="hlFld-ContribAuthor ">A.  Zeroual</span>, <span class="hlFld-ContribAuthor ">M.  Salah</span>, <span class="hlFld-ContribAuthor ">A.  Chekroun</span>, <span class="hlFld-ContribAuthor ">H. El  Alaoui El Abdallaoui</span>, <span class="hlFld-ContribAuthor ">A.  Benharref</span>, <span class="hlFld-ContribAuthor ">N.  Mazoir</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical reactivities and molecular docking studies of parthenolide with the main protease of HEP-G2 and SARS-CoV-2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1243 </em>, 130705. <a href="https://doi.org/10.1016/j.molstruc.2021.130705" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130705</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130705%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DChemical%252Breactivities%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bparthenolide%252Bwith%252Bthe%252Bmain%252Bprotease%252Bof%252BHEP-G2%252Band%252BSARS-CoV-2%26aulast%3DOuled%2BAitouna%26aufirst%3DAbdelhak%26date%3D2021%26volume%3D1243%26spage%3D130705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhagyashri  Rathod</span>, <span class="hlFld-ContribAuthor ">Shivam  Chak</span>, <span class="hlFld-ContribAuthor ">Sagarkumar  Patel</span>, <span class="hlFld-ContribAuthor ">Amit  Shard</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (7)
                                     , 1121-1141. <a href="https://doi.org/10.1039/D1MD00045D" title="DOI URL">https://doi.org/10.1039/D1MD00045D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00045D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00045D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DTumor%252Bpyruvate%252Bkinase%252BM2%252Bmodulators%25253A%252Ba%252Bcomprehensive%252Baccount%252Bof%252Bactivators%252Band%252Binhibitors%252Bas%252Banticancer%252Bagents%26aulast%3DRathod%26aufirst%3DBhagyashri%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D7%26spage%3D1121%26epage%3D1141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Niraj Kumar  Panday</span>, <span class="hlFld-ContribAuthor ">Disha  Thakkar</span>, <span class="hlFld-ContribAuthor ">Sagarkumar  Patel</span>, <span class="hlFld-ContribAuthor ">Amit  Shard</span>, <span class="hlFld-ContribAuthor ">Pinaki  Sengupta</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolite profiling of IMID‐2, a novel anticancer molecule of piperazine derivative:
              In silico
              prediction,
              in vitro
              and
              in vivo
              metabolite characterization using UPLC–QTOF–MS/MS. </span><span class="cited-content_cbyCitation_journal-name">Biomedical Chromatography</span><span> <strong>2021,</strong> <em>35 </em>
                                    (6)
                                     <a href="https://doi.org/10.1002/bmc.5082" title="DOI URL">https://doi.org/10.1002/bmc.5082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bmc.5082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbmc.5082%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520Chromatography%26atitle%3DMetabolite%252Bprofiling%252Bof%252BIMID%2525E2%252580%2525902%25252C%252Ba%252Bnovel%252Banticancer%252Bmolecule%252Bof%252Bpiperazine%252Bderivative%25253A%252BIn%252Bsilico%252Bprediction%25252C%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bmetabolite%252Bcharacterization%252Busing%252BUPLC%2525E2%252580%252593QTOF%2525E2%252580%252593MS%25252FMS%26aulast%3DPanday%26aufirst%3DNiraj%2BKumar%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Binglin  Zeng</span>, <span class="hlFld-ContribAuthor ">Yu  Cheng</span>, <span class="hlFld-ContribAuthor ">Kailu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shuoxiao  Liu</span>, <span class="hlFld-ContribAuthor ">Longying  Shen</span>, <span class="hlFld-ContribAuthor ">Jinping  Hu</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Xiandao  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF-κB and STAT3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>111 </em>, 104973. <a href="https://doi.org/10.1016/j.bioorg.2021.104973" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104973</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104973%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bin%252Bvivo%252Banticancer%252Bactivity%252Bof%252Bnovel%252Bparthenolide%252Band%252Bmicheliolide%252Bderivatives%252Bas%252BNF-%2525CE%2525BAB%252Band%252BSTAT3%252Binhibitors%26aulast%3DZeng%26aufirst%3DBinglin%26date%3D2021%26volume%3D111%26spage%3D104973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajkumar  Patle</span>, <span class="hlFld-ContribAuthor ">Shital  Shinde</span>, <span class="hlFld-ContribAuthor ">Sagarkumar  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Maheshwari</span>, <span class="hlFld-ContribAuthor ">Heena  Jariyal</span>, <span class="hlFld-ContribAuthor ">Akshay  Srivastava</span>, <span class="hlFld-ContribAuthor ">Neelam  Chauhan</span>, <span class="hlFld-ContribAuthor ">Christoph  Globisch</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Rakesh K.  Tekade</span>, <span class="hlFld-ContribAuthor ">Amit  Shard</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of boronic acid-based potent activators of tumor pyruvate kinase M2 and development of gastroretentive nanoformulation for oral dosing. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>42 </em>, 128062. <a href="https://doi.org/10.1016/j.bmcl.2021.128062" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128062%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bboronic%252Bacid-based%252Bpotent%252Bactivators%252Bof%252Btumor%252Bpyruvate%252Bkinase%252BM2%252Band%252Bdevelopment%252Bof%252Bgastroretentive%252Bnanoformulation%252Bfor%252Boral%252Bdosing%26aulast%3DPatle%26aufirst%3DRajkumar%26date%3D2021%26volume%3D42%26spage%3D128062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susi  Zhu</span>, <span class="hlFld-ContribAuthor ">Yeye  Guo</span>, <span class="hlFld-ContribAuthor ">Xu  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Mingzhu  Yin</span>, <span class="hlFld-ContribAuthor ">Xiang  Chen</span>, <span class="hlFld-ContribAuthor ">Cong  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2021,</strong> <em>503 </em>, 240-248. <a href="https://doi.org/10.1016/j.canlet.2020.11.018" title="DOI URL">https://doi.org/10.1016/j.canlet.2020.11.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2020.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2020.11.018%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DPyruvate%252Bkinase%252BM2%252B%252528PKM2%252529%252Bin%252Bcancer%252Band%252Bcancer%252Btherapeutics%26aulast%3DZhu%26aufirst%3DSusi%26date%3D2021%26volume%3D503%26spage%3D240%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of PTL and TEPP-46.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>5</b>–<b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SeO<sub>2</sub>, <i>t</i>-BuOOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 4 d, 75%; (b) Dess–Martin periodinane, NaHCO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 90%; (c) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, 2-methyl-2-butene, <i>t</i>-BuOH, H<sub>2</sub>O, 0 °C, 1 h, 90%; (d) DMAP, DIC, CH<sub>2</sub>Cl<sub>2</sub>, 6.6–62.4%; (e) dimethylamine, THF, 1 h; fumaric acid, methanol, 71.2%.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Parthenolide dimers activated the pyruvate kinase activity of PKM2. (A) The relative enzyme activity of PKM2 after treatment with compounds at a concentration of 10 μM. (B–D) Recombinant PKM2 proteins were incubated with compound <b>5</b>, compound <b>6</b>, and compound <b>10</b> for 50 min at room temperature with different concentrations, and then the pyruvate kinase activity was monitored and the value of AC<sub>50</sub> calculated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Parthenolide dimers inhibited the proliferation of different GBM cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. IC<sub>50</sub> values of compound <b>5</b> against five kinds of cancer cells including glioma (U118), cervical carcinoma (HeLa), liver cancer (HepG2), breast cancer (SUM159), and lung cancer (A549).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>5</b> inhibited colony formation and induced apoptosis of different GBM cells. (A) The colony formation of U118 and U87 cells after treatment with compound <b>5</b> for 7 days. (B, C) The colony number of U118 and U87 cells after treatment with compound <b>5</b> was calculated. (D) Representative pictures of cell apoptosis with or without treatment with <b>5</b> for 48 h. (E, F) The percentage of cell apoptosis with or without treatment with <b>5</b> for 48 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>5</b> inhibited invasion and migration of different GBM cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>5</b> could directly bind to PKM2. (A, B) Molecular docking studies of dimeric PKM2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T5A">1T5A</a>) with parthenolide dimer <b>5</b>. (C) Compound <b>5</b> stabilized PKM2 at 42 °C, 49 °C, and 56 °C by thermal stability assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>5</b> promoted formation of tetrameric PKM2 and reduced nuclear translocation. (A) The protein expression of PKM2 after treatment with <b>5</b> for 48 h. (B, C) The protein levels of PKM2 in the nucleus and cytoplasm in U118 and U87 cells after treatment with <b>5</b> for 48 h. (D, E) The tetrameric formation of PKM2 was analyzed in U118 and U87 cells after being treated with <b>5</b> (0.5 μM and 1 μM), or TEPP-46 (10 μM) for 48 h using the chemical cross-linking assay. (F) The changes in PKM2 particle size were detected after treatment with <b>5</b> or TEPP-46.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>5</b> inhibited the STAT3 pathway. (A) The protein expression of P65 and IKKβ after treatment with compound <b>5</b> for 48 h. (B) The protein expression of p-IKKβ was analyzed after the treatment with compound <b>5</b> in U118 cells for 48 h. (C) The nuclear translocation of P65 was analyzed after the treatment with compound <b>5</b> in U118 cells for 48 h. (D) The protein expression of STAT3, p-STAT3, Bcl-xl, Bax, Bcl-2, E-cadherin, and vimentin was analyzed after the treatment with compound <b>5</b> for 48 h in U118 and U87 cells. (E) The protein level of STAT3 and PKD4 after being treated with compound <b>5</b> and PTL for 48 h at concentrations of 2 μM in U118 cells, and 5 μM in U87 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Induction of apoptosis of U87 and U118 by <b>5</b> was dependent on the expression of PKM2. (A) The protein level of PKM2 in U87 and U118 cells after stably expressing shNC or shPKM2 plasmid. (B, C) The antiproliferative effect of <b>5</b> on U118 and U87 cells with stably knocked down PKM2. (D) The representative pictures of cell apoptosis after treatment with <b>5</b> in U87 and U118 cells with stably knocked down PKM2. (E, F) The percentage of cell apoptosis after treatment with compound <b>5</b> in U87 and U118 cells with stably knocked down PKM2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Inhibition of invasion and migration of U87 and U118 cells by <b>5</b> was dependent on the expression of PKM2. (A) The representative pictures and number of invasion cells after treatment with <b>5</b> in stably knocked down PKM2 cells. (B) The representative pictures and number of migration cells after treatment with <b>5</b> in stably knocked down PKM2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Compound <b>16</b> inhibited GBM growth in vivo. (A) Images of the xenograft tumors derived from U118 cells. Compound <b>16</b> was administered twice a week intraperitoneally. siPKM2 was administered twice a week by intratumoral injection. (B) Tumor growth rate of control-, compound <b>16</b>-, siPKM2-, and compound <b>16</b>+siPKM2-treated mice. (C) The body weight change of control-, compound <b>16</b>-, siPKM2-, and compound <b>16</b>+siPKM2-treated mice. (D) Tumor weight of control-, compound <b>16</b>-, siPKM2-, and compound <b>16</b>+siPKM2-treated mice. (E) The protein level of Bax, Bcl-2, E-cadherin, STAT3, and vimentin in tumor tissue lysate obtained from vehicle control group and compound <b>16</b>-treated group. (F–I) The gene expression of E-cadherin, N-cadherin, Bcl-2, and STAT3 in tumor tissue derived from vehicle control group and compound <b>16</b>-treated group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. IHC analysis of the protein level of PKM2, Bax, Bcl-2, E-cadherin, vimentin, and p-STAT3 in control group, compound <b>16</b>-treated group, siPKM2 group, and compound <b>16</b>/siPKM2 group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/medium/jm9b01328_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. TEER values were measured for 7 h after treatment with TMZ or compound <b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01328/20200221/images/large/jm9b01328_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01328&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 54 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reifenberger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figarella-Branger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenee, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohgaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestler, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleihues, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, D. W.</span></span> <span> </span><span class="NLM_article-title">The 2016 World Health Organization classification of tumors of the central nervous system: a summary</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1007/s00401-016-1545-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1007%2Fs00401-016-1545-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=27157931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC28bnsVektA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2016&pages=803-820&author=D.+N.+Louisauthor=A.+Perryauthor=G.+Reifenbergerauthor=A.+Von+Deimlingauthor=D.+Figarella-Brangerauthor=W.+K.+Caveneeauthor=H.+Ohgakiauthor=O.+D.+Wiestlerauthor=P.+Kleihuesauthor=D.+W.+Ellison&title=The+2016+World+Health+Organization+classification+of+tumors+of+the+central+nervous+system%3A+a+summary&doi=10.1007%2Fs00401-016-1545-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary</span></div><div class="casAuthors">Louis David N; Perry Arie; Reifenberger Guido; Reifenberger Guido; von Deimling Andreas; von Deimling Andreas; Figarella-Branger Dominique; Cavenee Webster K; Ohgaki Hiroko; Wiestler Otmar D; Kleihues Paul; Ellison David W</div><div class="citationInfo"><span class="NLM_cas:title">Acta neuropathologica</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">803-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor.  For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era.  As such, the 2016 CNS WHO presents major restructuring of the diffuse gliomas, medulloblastomas and other embryonal tumors, and incorporates new entities that are defined by both histology and molecular features, including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, WNT-activated and medulloblastoma, SHH-activated; and embryonal tumour with multilayered rosettes, C19MC-altered.  The 2016 edition has added newly recognized neoplasms, and has deleted some entities, variants and patterns that no longer have diagnostic and/or biological relevance.  Other notable changes include the addition of brain invasion as a criterion for atypical meningioma and the introduction of a soft tissue-type grading system for the now combined entity of solitary fibrous tumor / hemangiopericytoma-a departure from the manner by which other CNS tumors are graded.  Overall, it is hoped that the 2016 CNS WHO will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7YzqOXqWReQqdek-gHSrIfW6udTcc2ea_SDwg4KJiALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bnsVektA%253D%253D&md5=f9ac51999bf1b171477b20ea0085c9e8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs00401-016-1545-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-016-1545-1%26sid%3Dliteratum%253Aachs%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DPerry%26aufirst%3DA.%26aulast%3DReifenberger%26aufirst%3DG.%26aulast%3DVon%2BDeimling%26aufirst%3DA.%26aulast%3DFigarella-Branger%26aufirst%3DD.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26aulast%3DOhgaki%26aufirst%3DH.%26aulast%3DWiestler%26aufirst%3DO.%2BD.%26aulast%3DKleihues%26aufirst%3DP.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26atitle%3DThe%25202016%2520World%2520Health%2520Organization%2520classification%2520of%2520tumors%2520of%2520the%2520central%2520nervous%2520system%253A%2520a%2520summary%26jtitle%3DActa%2520Neuropathol.%26date%3D2016%26volume%3D131%26spage%3D803%26epage%3D820%26doi%3D10.1007%2Fs00401-016-1545-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturiale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galzio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danieli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, A. A.</span></span> <span> </span><span class="NLM_article-title">The effect of re-operation on survival in patients with recurrent glioblastoma</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1743</span>– <span class="NLM_lpage">1748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=25750337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC2MnhvVyktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1743-1748&author=E.+Franceschiauthor=M.+Bartolottiauthor=A.+Tosoniauthor=S.+Bartoliniauthor=C.+Sturialeauthor=A.+Fioravantiauthor=E.+Pozzatiauthor=R.+Galzioauthor=A.+Talacchiauthor=L.+Volpinauthor=L.+Morandiauthor=D.+Danieliauthor=M.+Ermaniauthor=A.+A.+Brandes&title=The+effect+of+re-operation+on+survival+in+patients+with+recurrent+glioblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of re-operation on survival in patients with recurrent glioblastoma</span></div><div class="casAuthors">Franceschi Enrico; Bartolotti Marco; Tosoni Alicia; Bartolini Stefania; Brandes Alba A; Sturiale Carmelo; Fioravanti Antonio; Pozzati Eugenio; Galzio Renato; Talacchi Andrea; Volpin Lorenzo; Morandi Luca; Danieli Daniela; Ermani Mario</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1743-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Treatment options for glioblastoma (GBM) at recurrence have limited efficacy.  Re-surgery has been used for confirmation of recurrent disease and to provide relief of symptoms but the real impact on survival is unknown.  PATIENTS AND METHODS:  A retrospective analysis was performed for GBM patients followed between 01/2005 and 06/2010 at our Institution.  RESULTS:  Two hundred and thirty-two patients with recurrent GBM were evaluated.  One hundred and two patients (44%) were treated with re-surgery followed by chemotherapy and 130 patients (56%) with chemotherapy alone.  In multivariate analysis, no significant effect of re-surgery was found, with age (p=0.001), MGMT methylation (p=0.002) and PFS at 6 months (p=0.0001) being significant prognostic factors.  CONCLUSION:  Second surgery might have a limited impact in the clinical course of recurrent GBM patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOo1G9GMq1wEBuFdjgVNKSfW6udTcc2ebk3Zpb5PzoUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnhvVyktA%253D%253D&md5=c658d55ebb01f3dc8c8503376cd7044f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFranceschi%26aufirst%3DE.%26aulast%3DBartolotti%26aufirst%3DM.%26aulast%3DTosoni%26aufirst%3DA.%26aulast%3DBartolini%26aufirst%3DS.%26aulast%3DSturiale%26aufirst%3DC.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DPozzati%26aufirst%3DE.%26aulast%3DGalzio%26aufirst%3DR.%26aulast%3DTalacchi%26aufirst%3DA.%26aulast%3DVolpin%26aufirst%3DL.%26aulast%3DMorandi%26aufirst%3DL.%26aulast%3DDanieli%26aufirst%3DD.%26aulast%3DErmani%26aufirst%3DM.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26atitle%3DThe%2520effect%2520of%2520re-operation%2520on%2520survival%2520in%2520patients%2520with%2520recurrent%2520glioblastoma%26jtitle%3DAnticancer%2520Res.%26date%3D2015%26volume%3D35%26spage%3D1743%26epage%3D1748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrom, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittleman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondracek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolinsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroup, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruchko, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnholtz-Sloan, J. S.</span></span> <span> </span><span class="NLM_article-title">CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010</span>. <i>Neuro. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1093/neuonc/not151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1093%2Fneuonc%2Fnot151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=23284031" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1-56&author=Q.+T.+Ostromauthor=H.+Gittlemanauthor=P.+Farahauthor=A.+Ondracekauthor=Y.+Chenauthor=Y.+Wolinskyauthor=N.+E.+Stroupauthor=C.+Kruchkoauthor=J.+S.+Barnholtz-Sloan&title=CBTRUS+statistical+report%3A+primary+brain+and+central+nervous+system+tumors+diagnosed+in+the+United+States+in+2006%E2%80%932010&doi=10.1093%2Fneuonc%2Fnot151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnot151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnot151%26sid%3Dliteratum%253Aachs%26aulast%3DOstrom%26aufirst%3DQ.%2BT.%26aulast%3DGittleman%26aufirst%3DH.%26aulast%3DFarah%26aufirst%3DP.%26aulast%3DOndracek%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWolinsky%26aufirst%3DY.%26aulast%3DStroup%26aufirst%3DN.%2BE.%26aulast%3DKruchko%26aufirst%3DC.%26aulast%3DBarnholtz-Sloan%26aufirst%3DJ.%2BS.%26atitle%3DCBTRUS%2520statistical%2520report%253A%2520primary%2520brain%2520and%2520central%2520nervous%2520system%2520tumors%2520diagnosed%2520in%2520the%2520United%2520States%2520in%25202006%25E2%2580%25932010%26jtitle%3DNeuro.%2520Oncol.%26date%3D2013%26volume%3D15%26spage%3D1%26epage%3D56%26doi%3D10.1093%2Fneuonc%2Fnot151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abi-Said, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourney, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokaslan, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMonte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutcheon, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassenbusch, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawaya, R.</span></span> <span> </span><span class="NLM_article-title">A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival</span>. <i>J. Neurosurg.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.3171/jns.2001.95.2.0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.3171%2Fjns.2001.95.2.0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=11780887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FlsFGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2001&pages=190-198&author=M.+Lacroixauthor=D.+Abi-Saidauthor=D.+R.+Fourneyauthor=Z.+L.+Gokaslanauthor=W.+Shiauthor=F.+DeMonteauthor=F.+F.+Langauthor=I.+E.+McCutcheonauthor=S.+J.+Hassenbuschauthor=E.+Hollandauthor=K.+Hessauthor=C.+Michaelauthor=D.+Millerauthor=R.+Sawaya&title=A+multivariate+analysis+of+416+patients+with+glioblastoma+multiforme%3A+prognosis%2C+extent+of+resection%2C+and+survival&doi=10.3171%2Fjns.2001.95.2.0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival</span></div><div class="casAuthors">Lacroix M; Abi-Said D; Fourney D R; Gokaslan Z L; Shi W; DeMonte F; Lang F F; McCutcheon I E; Hassenbusch S J; Holland E; Hess K; Michael C; Miller D; Sawaya R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurosurgery</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">190-8</span>
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    </div><div class="casAbstract">OBJECT:  The extent of tumor resection that should be undertaken in patients with glioblastoma multiforme (GBM) remains controversial.  The purpose of this study was to identify significant independent predictors of survival in these patients and to determine whether the extent of resection was associated with increased survival time.  METHODS:  The authors retrospectively analyzed 416 consecutive patients with histologically proven GBM who underwent tumor resection at the authors' institution between June 1993 and June 1999.  Volumetric data and other tumor characteristics identified on magnetic resonance (MR) imaging were collected prospectively.  CONCLUSIONS:  Five independent predictors of survival were identified: age, Karnofsky Performance Scale (KPS) score, extent of resection, and the degree of necrosis and enhancement on preoperative MR imaging studies.  A significant survival advantage was associated with resection of 98% or more of the tumor volume (median survival 13 months, 95% confidence interval [CI] 11.4-14.6 months), compared with 8.8 months (95% CI 7.4-10.2 months; p < 0.0001) for resections of less than 98%.  Using an outcome scale ranging from 0 to 5 based on age, KPS score, and tumor necrosis on MR imaging, we observed significantly longer survival in patients with lower scores (1-3) who underwent aggressive resections, and a trend toward slightly longer survival was found in patients with higher scores (4-5).  Gross-total tumor resection is associated with longer survival in patients with GBM, especially when other predictive variables are favorable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxfgUiUw3arqqcneEtCi92fW6udTcc2ebk3Zpb5PzoUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FlsFGitA%253D%253D&md5=4f82792eeb0f0f63c6aca3124c774088</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3171%2Fjns.2001.95.2.0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3171%252Fjns.2001.95.2.0190%26sid%3Dliteratum%253Aachs%26aulast%3DLacroix%26aufirst%3DM.%26aulast%3DAbi-Said%26aufirst%3DD.%26aulast%3DFourney%26aufirst%3DD.%2BR.%26aulast%3DGokaslan%26aufirst%3DZ.%2BL.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DDeMonte%26aufirst%3DF.%26aulast%3DLang%26aufirst%3DF.%2BF.%26aulast%3DMcCutcheon%26aufirst%3DI.%2BE.%26aulast%3DHassenbusch%26aufirst%3DS.%2BJ.%26aulast%3DHolland%26aufirst%3DE.%26aulast%3DHess%26aufirst%3DK.%26aulast%3DMichael%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSawaya%26aufirst%3DR.%26atitle%3DA%2520multivariate%2520analysis%2520of%2520416%2520patients%2520with%2520glioblastoma%2520multiforme%253A%2520prognosis%252C%2520extent%2520of%2520resection%252C%2520and%2520survival%26jtitle%3DJ.%2520Neurosurg.%26date%3D2001%26volume%3D95%26spage%3D190%26epage%3D198%26doi%3D10.3171%2Fjns.2001.95.2.0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang-Xuan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpentier, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delattre, J.-Y.</span></span> <span> </span><span class="NLM_article-title">Primary brain tumours in adults</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(03)12328-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2FS0140-6736%2803%2912328-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=12559880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FltVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2003&pages=323-331&author=A.+Behinauthor=K.+Hoang-Xuanauthor=A.+F.+Carpentierauthor=J.-Y.+Delattre&title=Primary+brain+tumours+in+adults&doi=10.1016%2FS0140-6736%2803%2912328-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Primary brain tumours in adults</span></div><div class="casAuthors">Behin Anthony; Hoang-Xuan Khe; Carpentier Antoine F; Delattre Jean-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">9354</span>),
    <span class="NLM_cas:pages">323-31</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">The most frequent primary brain tumours in adults are gliomas and primary CNS lymphomas.  In gliomas, molecular genetic analysis plays an increasing part in classification and treatment planning, a feature well illustrated by the chemosensitive oligodendrogliomas.  Unfortunately, management of glioblastoma is still mainly palliative.  Incidence of primary CNS lymphoma has increased strikingly in the past 20 years; substantial progress has been achieved in patients who are immunocompetent with the addition of methotrexate-based chemotherapy to radiotherapy, but the potential neurotoxic effects of this combination in elderly patients is worrisome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8yCAPPun1X5Pq5LRczm8ffW6udTcc2eZTztb7DNyZqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FltVCltQ%253D%253D&md5=38588e3ab15d4f4a8c1e3379c94f06e1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2803%2912328-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252803%252912328-8%26sid%3Dliteratum%253Aachs%26aulast%3DBehin%26aufirst%3DA.%26aulast%3DHoang-Xuan%26aufirst%3DK.%26aulast%3DCarpentier%26aufirst%3DA.%2BF.%26aulast%3DDelattre%26aufirst%3DJ.-Y.%26atitle%3DPrimary%2520brain%2520tumours%2520in%2520adults%26jtitle%3DLancet%26date%3D2003%26volume%3D361%26spage%3D323%26epage%3D331%26doi%3D10.1016%2FS0140-6736%2803%2912328-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nieder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosu, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andratschke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molls, M.</span></span> <span> </span><span class="NLM_article-title">Treatment of malignant gliomas: Radiotherapy, chemotherapy and integration of new targeted agents</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1586/14737175.4.4.691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1586%2F14737175.4.4.691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15853588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlSmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=691-703&author=C.+Niederauthor=A.+L.+Grosuauthor=M.+P.+Mehtaauthor=N.+Andratschkeauthor=M.+Molls&title=Treatment+of+malignant+gliomas%3A+Radiotherapy%2C+chemotherapy+and+integration+of+new+targeted+agents&doi=10.1586%2F14737175.4.4.691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of malignant gliomas: Radiotherapy, chemotherapy and integration of new targeted agents</span></div><div class="casAuthors">Nieder, Carsten; Grosu, Anca L.; Mehta, Minesh P.; Andratschke, Nicolaus; Molls, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">691-703</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Progress in the biol. and mol. characterization of gliomas and studies of factors assocd. with tumor growth and progression have led to translational research projects and the development of rational new approaches regarding prognostic models, better prediction of response to treatment and innovative therapeutic strategies.  This review summarizes the available data on established and emerging prognostic factors and prognostic scores, and discusses their limitations as well as their potential influence on future therapeutic efforts.  Recent developments in std. treatment options (i.e., surgery, radiotherapy and chemotherapy) are reviewed.  Exptl. data indicate that inhibition of several signaling pathways (e.g., epidermal growth factor, transforming growth factor-β and phosphatidylinositol 3 kinase) may represent a promising therapeutic strategy.  Some inhibitory agents (i.e., drugs, antibodies and antisense oligonucleotides) have now entered clin. trials, mainly for recurrent gliomas and a small no. are being tested in combination with radiotherapy.  Early results of such approaches are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp69CJ3jfTdorVg90H21EOLACvtfcHk0lh4JU5JE1_Iaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlSmsLo%253D&md5=65ceab2d3f9328b44398733d45c31c5d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1586%2F14737175.4.4.691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.4.4.691%26sid%3Dliteratum%253Aachs%26aulast%3DNieder%26aufirst%3DC.%26aulast%3DGrosu%26aufirst%3DA.%2BL.%26aulast%3DMehta%26aufirst%3DM.%2BP.%26aulast%3DAndratschke%26aufirst%3DN.%26aulast%3DMolls%26aufirst%3DM.%26atitle%3DTreatment%2520of%2520malignant%2520gliomas%253A%2520Radiotherapy%252C%2520chemotherapy%2520and%2520integration%2520of%2520new%2520targeted%2520agents%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2004%26volume%3D4%26spage%3D691%26epage%3D703%26doi%3D10.1586%2F14737175.4.4.691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stupp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Bent, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taphoorn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdahn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curschmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzer, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwin, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allgeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairncross, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirimanoff, R. O.</span></span> <span> </span><span class="NLM_article-title">Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa043330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1056%2FNEJMoa043330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15758009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Wksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=987-996&author=R.+Stuppauthor=W.+P.+Masonauthor=M.+J.+van+den%0ABentauthor=M.+Wellerauthor=B.+Fisherauthor=M.+J.+Taphoornauthor=K.+Belangerauthor=A.+A.+Brandesauthor=C.+Marosiauthor=U.+Bogdahnauthor=J.+Curschmannauthor=R.+C.+Janzerauthor=S.+K.+Ludwinauthor=T.+Gorliaauthor=A.+Allgeierauthor=D.+Lacombeauthor=J.+G.+Cairncrossauthor=E.+Eisenhauerauthor=R.+O.+Mirimanoff&title=Radiotherapy+plus+concomitant+and+adjuvant+Temozolomide+for+glioblastoma&doi=10.1056%2FNEJMoa043330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</span></div><div class="casAuthors">Stupp, Roger; Mason, Warren P.; van den Bent, Martin J.; Weller, Michael; Fisher, Barbara; Taphoorn, Martin J. B.; Belanger, Karl; Brandes, Alba A.; Marosi, Christine; Bogdahn, Ulrich; Curschmann, Jurgen; Janzer, Robert C.; Ludwin, Samuel K.; Gorlia, Thierry; Allgeier, Anouk; Lacombe, Denis; Cairncross, J. Gregory; Eisenhauer, Elizabeth; Mirimanoff, Rene O.; Forsyth, P.; Fulton, D.; Kirby, S.; Wong, R.; Fenton, D.; Fisher, B.; Cairncross, G.; Whitlock, P.; Belanger, K.; Burdette-Radoux, S.; Gertler, S.; Saunders, S.; Laing, K.; Siddiqui, J.; Martin, L. A.; Gulavita, S.; Perry, J.; Mason, W.; Thiessen, B.; Pai, H.; Alam, Z. Y.; Eisenstat, D.; Mingrone, W.; Hofer, S.; Pesce, G.; Curschmann, J.; Dietrich, P. Y.; Stupp, R.; Mirimanoff, R. O.; Thum, P.; Baumert, B.; Ryan, G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">987-996</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal.  The current std. of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy.  In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety.  METHODS Patients with newly diagnosed, histol. confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradn. in daily fractions of 2 Gy given 5 days per wk for 6 wk, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per wk from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).  The primary end point was overall survival.  RESULTS A total of 573 patients from 85 centers underwent randomization.  The median age was 56 years, and 84 % of patients had undergone debulking surgery.  At a median follow-up of 28 mo, the median survival was 14.6 mo with radiotherapy plus temozolomide and 12.1 mo with radiotherapy alone.  The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 % confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test).  The two-year survival rate was 26.5 % with radiotherapy plus temozolomide and 10.4 % with radiotherapy alone.  Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematol. toxic effects in 7 % of patients.  Conclusions The addn. of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clin. meaningful and statistically significant survival benefit with minimal addnl. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdNLD2mISWE7Vg90H21EOLACvtfcHk0lh4JU5JE1_Iaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Wksbk%253D&md5=28546eb2e78f7346974d7d029c9fa916</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043330%26sid%3Dliteratum%253Aachs%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DW.%2BP.%26aulast%3Dvan%2Bden%2BBent%26aufirst%3DM.%2BJ.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DTaphoorn%26aufirst%3DM.%2BJ.%26aulast%3DBelanger%26aufirst%3DK.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26aulast%3DMarosi%26aufirst%3DC.%26aulast%3DBogdahn%26aufirst%3DU.%26aulast%3DCurschmann%26aufirst%3DJ.%26aulast%3DJanzer%26aufirst%3DR.%2BC.%26aulast%3DLudwin%26aufirst%3DS.%2BK.%26aulast%3DGorlia%26aufirst%3DT.%26aulast%3DAllgeier%26aufirst%3DA.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DCairncross%26aufirst%3DJ.%2BG.%26aulast%3DEisenhauer%26aufirst%3DE.%26aulast%3DMirimanoff%26aufirst%3DR.%2BO.%26atitle%3DRadiotherapy%2520plus%2520concomitant%2520and%2520adjuvant%2520Temozolomide%2520for%2520glioblastoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D987%26epage%3D996%26doi%3D10.1056%2FNEJMoa043330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Small molecule kinase inhibitors for the treatment of brain cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10030</span>– <span class="NLM_lpage">10066</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10030-10066&author=T.+P.+Heffron&title=Small+molecule+kinase+inhibitors+for+the+treatment+of+brain+cancer&doi=10.1021%2Facs.jmedchem.6b00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer</span></div><div class="casAuthors">Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10030-10066</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In addn. to each of the factors that govern the identification of a successful oncol. drug candidate, drug discovery aimed at treating neurol. cancer must also consider the presence of the blood-brain barrier (BBB).  The high level of expression of efflux transporters (e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp)) at the BBB limits many small mols. from freely reaching the brain, where neurooncol. malignancies reside.  Furthermore, many of the targets identified for the potential treatment of central nervous system (CNS) malignancies suggest that kinase inhibitors, capable of penetrating the BBB to reach their target, would be desirable.  This Perspective discusses the unmet need for neurooncol. treatments, the appeal of kinase targets in this space, and a summary of what is known about free brain penetration of clin. inhibitors of kinases that are of interest for the treatment of brain cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqij86WIpk16LVg90H21EOLACvtfcHk0lg7loEFA4Sg9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOjt77E&md5=7e184f17a60658174cb44a9fbadc8dfd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DSmall%2520molecule%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520brain%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10030%26epage%3D10066%26doi%3D10.1021%2Facs.jmedchem.6b00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darefsky, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, J. T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrow, R.</span></span> <span> </span><span class="NLM_article-title">Adult glioblastoma multiforme survival in the Temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2172</span>, <span class="refDoi"> DOI: 10.1002/cncr.26494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1002%2Fcncr.26494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21882183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC38zlsFagtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=2163-2172&author=A.+S.+Darefskyauthor=J.+T.+Kingauthor=R.+Dubrow&title=Adult+glioblastoma+multiforme+survival+in+the+Temozolomide+era%3A+a+population-based+analysis+of+Surveillance%2C+Epidemiology%2C+and+End+Results+registries&doi=10.1002%2Fcncr.26494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries</span></div><div class="casAuthors">Darefsky Amy S; King Joseph T Jr; Dubrow Robert</div><div class="citationInfo"><span class="NLM_cas:title">Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2163-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Survival after a glioblastoma multiforme (GBM) diagnosis remained static during the several decades before 1999.  We hypothesized that the progressive increase in temozolomide use for GBM treatment that began in 1999 in the United States would be paralleled by a corresponding improvement in survival.  METHODS:  We included 19,674 GBM cases, ages 20 years or greater, diagnosed 1993 to 2007 in the population-based Surveillance, Epidemiology, and End Results Program database.  We used proportional hazards models to calculate calendar period hazard ratios (HR) and 95% confidence intervals (CI), adjusted for demographic covariates.  We compared survival across periods using the Kaplan-Meier method.  RESULTS:  Starting with cases diagnosed in 1999 to 2001, we observed a progressive decrease in HRs compared with cases diagnosed in 1993 to 1995.  The multivariate-adjusted HR for 2005 to 2007 versus 1993 to 1995 was 0.69 (95% CI, 0.65-0.72).  Age-stratified analyses revealed that this progressive decrease occurred in all age groups except 80+ years.  Two-year survival increased from 7% among cases diagnosed in 1993 to 1995 and 1996 to 1998 to 9% among cases diagnosed in 1999 to 2001, 13% in 2002 to 2004, and 17% in 2005 to 2007.  The disparity in survival between young and old patients increased in the temozolomide era, with 2-year survival of 39% among cases diagnosed at ages 20 to 44 years and 1% among cases diagnosed at 80+ years in 2005 to 2007.  CONCLUSIONS:  We observed a modest, but meaningful, population-based survival improvement for GBM patients in the United States.  Widespread adoption of temozolomide represents the most likely explanation, although other treatment advances, such as increased extent of surgical resection, also may have played a role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8CSz82skSzjC850By6mxpfW6udTcc2eZ0wF46-yr9Crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zlsFagtQ%253D%253D&md5=a555a44bcfbe7065dc9d09824ae72562</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fcncr.26494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.26494%26sid%3Dliteratum%253Aachs%26aulast%3DDarefsky%26aufirst%3DA.%2BS.%26aulast%3DKing%26aufirst%3DJ.%2BT.%26aulast%3DDubrow%26aufirst%3DR.%26atitle%3DAdult%2520glioblastoma%2520multiforme%2520survival%2520in%2520the%2520Temozolomide%2520era%253A%2520a%2520population-based%2520analysis%2520of%2520Surveillance%252C%2520Epidemiology%252C%2520and%2520End%2520Results%2520registries%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26spage%3D2163%26epage%3D2172%26doi%3D10.1002%2Fcncr.26494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Outschoorn, U. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peiris-Pages, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestell, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotgia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span> <span> </span><span class="NLM_article-title">Cancer metabolism: a therapeutic perspective</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2016.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnrclinonc.2016.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=27141887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsF2qu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=11-31&author=U.+E.+Martinez-Outschoornauthor=M.+Peiris-Pagesauthor=R.+G.+Pestellauthor=F.+Sotgiaauthor=M.+P.+Lisanti&title=Cancer+metabolism%3A+a+therapeutic+perspective&doi=10.1038%2Fnrclinonc.2016.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer metabolism: a therapeutic perspective</span></div><div class="casAuthors">Martinez-Outschoorn, Ubaldo E.; Peiris-Pages, Maria; Pestell, Richard G.; Sotgia, Federica; Lisanti, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-31</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Awareness that the metabolic phenotype of cells within tumors is heterogeneous - and distinct from that of their normal counterparts - is growing.  In general, tumor cells metabolize glucose, lactate, pyruvate, hydroxybutyrate, acetate, glutamine, and fatty acids at much higher rates than their nontumor equiv.; however, the metabolic ecol. of tumors is complex because they contain multiple metabolic compartments, which are linked by the transfer of these catabolites.  This metabolic variability and flexibility enables tumor cells to generate ATP as an energy source, while maintaining the redn.-oxidn. (redox) balance and committing resources to biosynthesis - processes that are essential for cell survival, growth, and proliferation.  Importantly, exptl. evidence indicates that metabolic coupling between cell populations with different, complementary metabolic profiles can induce cancer progression.  Thus, targeting the metabolic differences between tumor and normal cells holds promise as a novel anticancer strategy.  In this Review, we discuss how cancer cells reprogramme their metab. and that of other cells within the tumor microenvironment in order to survive and propagate, thus driving disease progression; in particular, we highlight potential metabolic vulnerabilities that might be targeted therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNuUI8-igjaLVg90H21EOLACvtfcHk0lg7loEFA4Sg9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsF2qu7g%253D&md5=a4f92ba92569fca1d35e20ec7acb9394</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2016.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2016.60%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Outschoorn%26aufirst%3DU.%2BE.%26aulast%3DPeiris-Pages%26aufirst%3DM.%26aulast%3DPestell%26aufirst%3DR.%2BG.%26aulast%3DSotgia%26aufirst%3DF.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26atitle%3DCancer%2520metabolism%253A%2520a%2520therapeutic%2520perspective%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D11%26epage%3D31%26doi%3D10.1038%2Fnrclinonc.2016.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer metabolism: a therapeutic window opens</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1038/nrd3504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnrd3504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21878982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSltb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=671-684&author=M.+G.+Vander%0AHeiden&title=Targeting+cancer+metabolism%3A+a+therapeutic+window+opens&doi=10.1038%2Fnrd3504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer metabolism: a therapeutic window opens</span></div><div class="casAuthors">Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">671-684</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genetic events in cancer activate signalling pathways that alter cell metab.  Clin. evidence has linked cell metab. with cancer outcomes.  Together, these observations have raised interest in targeting metabolic enzymes for cancer therapy, but they have also raised concerns that these therapies would have unacceptable effects on normal cells.  However, some of the first cancer therapies that were developed target the specific metabolic needs of cancer cells and remain effective agents in the clinic today.  Research into how changes in cell metab. promote tumor growth has accelerated in recent years.  This has refocused efforts to target metabolic dependencies of cancer cells as a selective anticancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdwef_xmbtRrVg90H21EOLACvtfcHk0liGDyQksEOs9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSltb3J&md5=5051a52f70ba7dd0cd99cf6ffce7f4c6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd3504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3504%26sid%3Dliteratum%253Aachs%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DTargeting%2520cancer%2520metabolism%253A%2520a%2520therapeutic%2520window%2520opens%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D671%26epage%3D684%26doi%3D10.1038%2Fnrd3504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNicola, G. M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in cancer metabolism: a technological perspective</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">31</span>, <span class="refDoi"> DOI: 10.1038/s12276-018-0027-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fs12276-018-0027-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=29657324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC1MjivV2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=31&author=Y.+P.+Kangauthor=N.+P.+Wardauthor=G.+M.+DeNicola&title=Recent+advances+in+cancer+metabolism%3A+a+technological+perspective&doi=10.1038%2Fs12276-018-0027-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in cancer metabolism: a technological perspective</span></div><div class="casAuthors">Kang Yun Pyo; Ward Nathan P; DeNicola Gina M</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & molecular medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer cells are highly dependent on metabolic pathways to sustain both their proliferation and adaption to harsh microenvironments.  Thus, understanding the metabolic reprogramming that occurs in tumors can provide critical insights for the development of therapies targeting metabolism.  In this review, we will discuss recent advancements in metabolomics and other multidisciplinary techniques that have led to the discovery of novel metabolic pathways and mechanisms in diverse cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfl2bVO8UffAwxfk_AGB-EfW6udTcc2eacai8yjAr46Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjivV2rtg%253D%253D&md5=f340410bf7acc31a200c4f012cff648c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs12276-018-0027-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-018-0027-z%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%2BP.%26aulast%3DWard%26aufirst%3DN.%2BP.%26aulast%3DDeNicola%26aufirst%3DG.%2BM.%26atitle%3DRecent%2520advances%2520in%2520cancer%2520metabolism%253A%2520a%2520technological%2520perspective%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2018%26volume%3D50%26spage%3D31%26doi%3D10.1038%2Fs12276-018-0027-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boros, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-N. P.</span></span> <span> </span><span class="NLM_article-title">Metabolic profifiling of cell growth and death in cancer: applications in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(02)02179-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2FS1359-6446%2802%2902179-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=11893545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVWhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=364-372&author=L.+G.+Borosauthor=M.+Cascanteauthor=W.-N.+P.+Lee&title=Metabolic+profifiling+of+cell+growth+and+death+in+cancer%3A+applications+in+drug+discovery&doi=10.1016%2FS1359-6446%2802%2902179-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic profiling of cell growth and death in cancer: applications in drug discovery</span></div><div class="casAuthors">Boros, Laszlo G.; Cascante, Marta; Lee, Wai-Nang Paul</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">364-372</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabolic profiling using stable-isotope tracer technol. enables the measurement of substrate redistribution within major metabolic pathways in living cells.  This technique has demonstrated that transformed human cells exhibit profound metabolic shifts and that some anti-cancer drugs produce their effects by forcing the reversion of these metabolic changes.  By revealing tumor-specific metabolic shifts in tumor cells, metabolic profiling enables drug developers to identify the metabolic steps that control cell proliferation, thus aiding the identification of new anti-cancer targets and screening of lead compds. for anti-proliferative metabolic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyu4s3EPCxtrVg90H21EOLACvtfcHk0lgJ9gJJDIMy7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVWhsbg%253D&md5=24c1ccaddac0d9e5a0154d738535ad94</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2802%2902179-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252802%252902179-7%26sid%3Dliteratum%253Aachs%26aulast%3DBoros%26aufirst%3DL.%2BG.%26aulast%3DCascante%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DW.-N.%2BP.%26atitle%3DMetabolic%2520profifiling%2520of%2520cell%2520growth%2520and%2520death%2520in%2520cancer%253A%2520applications%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2002%26volume%3D7%26spage%3D364%26epage%3D372%26doi%3D10.1016%2FS1359-6446%2802%2902179-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warburg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negelein, E.</span></span> <span> </span><span class="NLM_article-title">The metabolism of tumors in the body</span>. <i>J. Gen. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1927</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1085/jgp.8.6.519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1085%2Fjgp.8.6.519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19872213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADyaB2sXitlyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1927&pages=519-530&author=O.+Warburgauthor=F.+Windauthor=E.+Negelein&title=The+metabolism+of+tumors+in+the+body&doi=10.1085%2Fjgp.8.6.519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of tumors in the body</span></div><div class="casAuthors">Warburg, O.; Wind, F.; Negelein, E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Physiology</span>
        (<span class="NLM_cas:date">1927</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519-30</span>CODEN:
                <span class="NLM_cas:coden">JGPLAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-1295</span>.
    </div><div class="casAbstract">See C. A. 20, 2364.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqArKTpFMYzGbVg90H21EOLACvtfcHk0lgJ9gJJDIMy7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaB2sXitlyhuw%253D%253D&md5=4706b45fc56643446d1c1a45f491213b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1085%2Fjgp.8.6.519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1085%252Fjgp.8.6.519%26sid%3Dliteratum%253Aachs%26aulast%3DWarburg%26aufirst%3DO.%26aulast%3DWind%26aufirst%3DF.%26aulast%3DNegelein%26aufirst%3DE.%26atitle%3DThe%2520metabolism%2520of%2520tumors%2520in%2520the%2520body%26jtitle%3DJ.%2520Gen.%2520Physiol.%26date%3D1927%26volume%3D8%26spage%3D519%26epage%3D530%26doi%3D10.1085%2Fjgp.8.6.519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gatenby, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, R. J.</span></span> <span> </span><span class="NLM_article-title">Why do cancers have high aerobic glycolysis?</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1038/nrc1478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnrc1478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15516961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFegt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=891-899&author=R.+A.+Gatenbyauthor=R.+J.+Gillies&title=Why+do+cancers+have+high+aerobic+glycolysis%3F&doi=10.1038%2Fnrc1478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Why do cancers have high aerobic glycolysis?</span></div><div class="casAuthors">Gatenby, Robert A.; Gillies, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  If carcinogenesis occurs by somatic evolution, then common components of the cancer phenotype result from active selection and must, therefore, confer a significant growth advantage.  A near-universal property of primary and metastatic cancers is upregulation of glycolysis, resulting in increased glucose consumption, which can be obsd. with clin. tumor imaging.  We propose that persistent metab. of glucose to lactate even in aerobic conditions is an adaptation to intermittent hypoxia in pre-malignant lesions.  However, upregulation of glycolysis leads to microenvironmental acidosis requiring evolution to phenotypes resistant to acid-induced cell toxicity.  Subsequent cell populations with upregulated glycolysis and acid resistance have a powerful growth advantage, which promotes unconstrained proliferation and invasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCkeoJiIxH7Vg90H21EOLACvtfcHk0lgJ9gJJDIMy7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFegt7w%253D&md5=0584954722468b0bfaa5821fa17f2db5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc1478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1478%26sid%3Dliteratum%253Aachs%26aulast%3DGatenby%26aufirst%3DR.%2BA.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26atitle%3DWhy%2520do%2520cancers%2520have%2520high%2520aerobic%2520glycolysis%253F%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D891%26epage%3D899%26doi%3D10.1038%2Fnrc1478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valentini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speranza, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span> <span> </span><span class="NLM_article-title">The allosteric regulation of pyruvate kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">18145</span>– <span class="NLM_lpage">18152</span>, <span class="refDoi"> DOI: 10.1074/jbc.M001870200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1074%2Fjbc.M001870200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10751408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlymtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=18145-18152&author=G.+Valentiniauthor=L.+Chiarelliauthor=R.+Fortinauthor=M.+L.+Speranzaauthor=A.+Galizziauthor=A.+Mattevi&title=The+allosteric+regulation+of+pyruvate+kinase&doi=10.1074%2Fjbc.M001870200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The allosteric regulation of pyruvate kinase. A site-directed mutagenesis study</span></div><div class="casAuthors">Valentini, Giovanna; Chiarelli, Laurent; Fortin, Riccardo; Speranza, Maria L.; Galizzi, Alessandro; Mattevi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">18145-18152</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Pyruvate kinase (PK) is crit. for the regulation of the glycolytic pathway.  The regulatory properties of Escherichia coli were investigated by mutating six charged residues involved in interdomain salt bridges (Arg271, Arg292, Asp297, and Lys413) and in the binding of the allosteric activator (Lys382 and Arg431).  Arg271 and Lys413 are located at the interface between A and C domains within one subunit.  The R271L and K413Q mutant enzymes exhibit altered kinetic properties.  In K413Q, there is partial enzyme activation, whereas R271L is characterized by a bias toward the T-state in the allosteric equil.  In the T-state, Arg292 and Asp297 form an intersubunit salt bridge.  The mutants R292D and D297R are totally inactive.  The crystal structure of R292D reveals that the mutant enzyme retains the T-state quaternary structure.  However, the mutation induces a reorganization of the interface with the creation of a network of interactions similar to that obsd. in the crystal structures of R-state yeast and M1 PK proteins.  Furthermore, in the R292D structure, two loops that are part of the active site are disordered.  The K382Q and R431E mutations were designed to probe the binding site for fructose 1,6-bisphosphate, the allosteric activator.  R431E exhibits only slight changes in the regulatory properties.  Conversely, K382Q displays a highly altered responsiveness to the activator, suggesting that Lys382 is involved in both activator binding and allosteric transition mechanism.  Taken together, these results support the notion that domain interfaces are crit. for the allosteric transition.  They couple changes in the tertiary and quaternary structures to alterations in the geometry of the fructose 1,6-bisphosphate and substrate binding sites.  These site-directed mutagenesis data are discussed in the light of the mol. basis for the hereditary nonspherocytic hemolytic anemia, which is caused by mutations in human erythrocyte PK gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB0YeFSAkn2bVg90H21EOLACvtfcHk0lgJ9gJJDIMy7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlymtL0%253D&md5=bb560dbaa21eba0e557e753b2261018b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M001870200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M001870200%26sid%3Dliteratum%253Aachs%26aulast%3DValentini%26aufirst%3DG.%26aulast%3DChiarelli%26aufirst%3DL.%26aulast%3DFortin%26aufirst%3DR.%26aulast%3DSperanza%26aufirst%3DM.%2BL.%26aulast%3DGalizzi%26aufirst%3DA.%26aulast%3DMattevi%26aufirst%3DA.%26atitle%3DThe%2520allosteric%2520regulation%2520of%2520pyruvate%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D18145%26epage%3D18152%26doi%3D10.1074%2Fjbc.M001870200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">The multifaceted regulation and functions of PKM2 in tumor progression</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1846</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.bbcan.2014.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bbcan.2014.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=25064846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1OrtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1846&publication_year=2014&pages=285-296&author=Z.+Liauthor=P.+Yangauthor=Z.+Li&title=The+multifaceted+regulation+and+functions+of+PKM2+in+tumor+progression&doi=10.1016%2Fj.bbcan.2014.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted regulation and functions of PKM2 in tumor progression</span></div><div class="casAuthors">Li, Zongwei; Yang, Peng; Li, Zhuoyu</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1846</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-296</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo metabolic rewiring from oxidative phosphorylation towards aerobic glycolysis to maintain the increased anabolic requirements for cell proliferation.  It is widely accepted that specific expression of the M2 type pyruvate kinase (PKM2) in tumor cells contributes to this aerobic glycolysis phenotype.  To date, researchers have uncovered myriad forms of functional regulation for PKM2, which confers a growth advantage on the tumor cells to enable them to adapt to various microenvironmental signals.  Here the richness of our understanding on the modulations and functions of PKM2 in tumor progression is reviewed, and some new insights into the paradoxical expression and functional differences of PKM2 in distinct cancer types are offered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKAFPW-94IkbVg90H21EOLACvtfcHk0ljLZkZhiBZo4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1OrtbzF&md5=d7eddc5c0f4c977e385f234ba3e03545</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2014.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2014.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DThe%2520multifaceted%2520regulation%2520and%2520functions%2520of%2520PKM2%2520in%2520tumor%2520progression%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2014%26volume%3D1846%26spage%3D285%26epage%3D296%26doi%3D10.1016%2Fj.bbcan.2014.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Israelsen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase: function, regulation and role in cancer</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2015.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.semcdb.2015.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=26277545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGgtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=43-51&author=W.+J.+Israelsenauthor=M.+G.+Vander+Heiden&title=Pyruvate+kinase%3A+function%2C+regulation+and+role+in+cancer&doi=10.1016%2Fj.semcdb.2015.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase: Function, regulation and role in cancer</span></div><div class="casAuthors">Israelsen, William J.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cell & Developmental Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">SCDBFX</span>;
        ISSN:<span class="NLM_cas:issn">1084-9521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pyruvate kinase is an enzyme that catalyzes the conversion of phosphoenolpyruvate and ADP to pyruvate and ATP in glycolysis and plays a role in regulating cell metab.  There are four mammalian pyruvate kinase isoforms with unique tissue expression patterns and regulatory properties.  The M2 isoform of pyruvate kinase (PKM2) supports anabolic metab. and is expressed both in cancer and normal tissue.  The enzymic activity of PKM2 is allosterically regulated by both intracellular signaling pathways and metabolites; PKM2 thus integrates signaling and metabolic inputs to modulate glucose metab. according to the needs of the cell.  Recent advances have increased our understanding of metabolic regulation by pyruvate kinase, raised new questions, and suggested the possibility of non-canonical PKM2 functions to regulate gene expression and cell cycle progression via protein-protein interactions and protein kinase activity.  Here we review the structure, function, and regulation of pyruvate kinase and discuss how these properties enable regulation of PKM2 for cell proliferation and tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrylgQY9GHGw7Vg90H21EOLACvtfcHk0ljLZkZhiBZo4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGgtbzP&md5=b8bbed5fa7653fc200d3a290268212d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2015.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2015.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DIsraelsen%26aufirst%3DW.%2BJ.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DPyruvate%2520kinase%253A%2520function%252C%2520regulation%2520and%2520role%2520in%2520cancer%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2015%26volume%3D43%26spage%3D43%26epage%3D51%26doi%3D10.1016%2Fj.semcdb.2015.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span> <span> </span><span class="NLM_article-title">PKM2 and cancer: the function of PKM2 beyond glycolysis</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1980</span>– <span class="NLM_lpage">1986</span>, <span class="refDoi"> DOI: 10.3892/ol.2016.4168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.3892%2Fol.2016.4168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=26998110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmt12gsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1980-1986&author=G.+Dongauthor=Q.+Maoauthor=W.+Xiaauthor=Y.+Xuauthor=J.+Wangauthor=L.+Xuauthor=F.+Jiang&title=PKM2+and+cancer%3A+the+function+of+PKM2+beyond+glycolysis&doi=10.3892%2Fol.2016.4168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PKM2 and cancer: The function of PKM2 beyond glycolysis (Review)</span></div><div class="casAuthors">Dong, Gaochao; Mao, Qixing; Xia, Wenjie; Xu, Youtao; Wang, Jie; Xu, Lin; Jiang, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1980-1986</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1082</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Metabolic reprogramming is a hallmark of cancer cells and is used by cancer cells for growth and survival.  Pyruvate kinase muscle isoenzyme M2 (PKM2) is a limiting glycolytic enzyme that catalyzes the final step in glycolysis, which is key in tumor metab. and growth.  The present review discusses the expression and regulation of PKM2, and reports the dominant role that PKM2 plays in glycolysis to achieve the nutrient demands of cancer cell proliferation.  In addn., the present study discusses the non-metabolic function of PKM2, and its role as a coactivator and protein kinase, which contributes to tumorigenesis.  Furthermore, conflicting studies concerning the role of PKM2 as a therapeutic target are reviewed.  The improved understanding of PKM2 may provide a noval approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6iyPmfctlibVg90H21EOLACvtfcHk0ljLZkZhiBZo4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmt12gsL0%253D&md5=c82505c1572efe541656f773dc4374d0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3892%2Fol.2016.4168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2016.4168%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DF.%26atitle%3DPKM2%2520and%2520cancer%253A%2520the%2520function%2520of%2520PKM2%2520beyond%2520glycolysis%26jtitle%3DOncol.%2520Lett.%26date%3D2016%26volume%3D11%26spage%3D1980%26epage%3D1986%26doi%3D10.3892%2Fol.2016.4168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerszten, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>452</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nature06734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnature06734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=18337823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1Gnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=452&publication_year=2008&pages=230-233&author=H.+R.+Christofkauthor=M.+G.+Vander+Heidenauthor=M.+H.+Harrisauthor=A.+Ramanathanauthor=R.+E.+Gersztenauthor=R.+Weiauthor=M.+D.+Flemingauthor=S.+L.+Schreiberauthor=L.+C.+Cantley&title=The+M2+splice+isoform+of+pyruvate+kinase+is+important+for+cancer+metabolism+and+tumour+growth&doi=10.1038%2Fnature06734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth</span></div><div class="casAuthors">Christofk, Heather R.; Vander Heiden, Matthew G.; Harris, Marian H.; Ramanathan, Arvind; Gerszten, Robert E.; Wei, Ru; Fleming, Mark D.; Schreiber, Stuart L.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">452</span>
        (<span class="NLM_cas:issue">7184</span>),
    <span class="NLM_cas:pages">230-233</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many tumor cells have elevated rates of glucose uptake but reduced rates of oxidative phosphorylation.  This persistence of high lactate prodn. by tumors in the presence of oxygen, known as aerobic glycolysis, was first noted by Otto Warburg more than 75 yr ago.  How tumor cells establish this altered metabolic phenotype and whether it is essential for tumorigenesis is as yet unknown.  Here we show that a single switch in a splice isoform of the glycolytic enzyme pyruvate kinase is necessary for the shift in cellular metab. to aerobic glycolysis and that this promotes tumorigenesis.  Tumor cells have been shown to express exclusively the embryonic M2 isoform of pyruvate kinase.  Here we use short hairpin RNA to knockdown pyruvate kinase M2 expression in human cancer cell lines and replace it with pyruvate kinase M1.  Switching pyruvate kinase expression to the M1 (adult) isoform leads to reversal of the Warburg effect, as judged by reduced lactate prodn. and increased oxygen consumption, and this correlates with a reduced ability to form tumors in nude mouse xenografts.  These results demonstrate that M2 expression is necessary for aerobic glycolysis and that this metabolic phenotype provides a selective growth advantage for tumor cells in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvmgcXNsSjpbVg90H21EOLACvtfcHk0lghBy5YtgPlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1Gnu74%253D&md5=e7e6b7cc09477e1f9d270018d1c38be4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnature06734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06734%26sid%3Dliteratum%253Aachs%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DHarris%26aufirst%3DM.%2BH.%26aulast%3DRamanathan%26aufirst%3DA.%26aulast%3DGerszten%26aufirst%3DR.%2BE.%26aulast%3DWei%26aufirst%3DR.%26aulast%3DFleming%26aufirst%3DM.%2BD.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520M2%2520splice%2520isoform%2520of%2520pyruvate%2520kinase%2520is%2520important%2520for%2520cancer%2520metabolism%2520and%2520tumour%2520growth%26jtitle%3DNature%26date%3D2008%26volume%3D452%26spage%3D230%26epage%3D233%26doi%3D10.1038%2Fnature06734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vander
Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">Understanding the Warburg effect: the metabolic requirements of cell proliferation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1126/science.1160809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1126%2Fscience.1160809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19460998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1029-1033&author=M.+G.+Vander%0AHeidenauthor=L.+C.+Cantleyauthor=C.+B.+Thompson&title=Understanding+the+Warburg+effect%3A+the+metabolic+requirements+of+cell+proliferation&doi=10.1126%2Fscience.1160809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation</span></div><div class="casAuthors">Vander Heiden, Matthew G.; Cantley, Lewis C.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5930</span>),
    <span class="NLM_cas:pages">1029-1033</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed "the Warburg effect".  Aerobic glycolysis is an inefficient way to generate ATP, however, and the advantage it confers to cancer cells has been unclear.  Here we propose that the metab. of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell.  Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-assocd. mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP prodn.  A better understanding of the mechanistic links between cellular metab. and growth control may ultimately lead to better treatments for human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGvLHGQ9TX77Vg90H21EOLACvtfcHk0lghBy5YtgPlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsbg%253D&md5=f927402a43cdca471c3f4874dcbeb943</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1160809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1160809%26sid%3Dliteratum%253Aachs%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DUnderstanding%2520the%2520Warburg%2520effect%253A%2520the%2520metabolic%2520requirements%2520of%2520cell%2520proliferation%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1029%26epage%3D1033%26doi%3D10.1126%2Fscience.1160809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span> <span> </span><span class="NLM_article-title">PKM2 contributes to cancer metabolism</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2014.01.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.canlet.2014.01.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=24508027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2015&pages=184-191&author=N.+Wongauthor=D.+Ojoauthor=J.+Yanauthor=D.+Tang&title=PKM2+contributes+to+cancer+metabolism&doi=10.1016%2Fj.canlet.2014.01.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">PKM2 contributes to cancer metabolism</span></div><div class="casAuthors">Wong, Nicholas; Ojo, Diane; Yan, Judy; Tang, Damu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2_Part_A</span>),
    <span class="NLM_cas:pages">184-191</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Reprogramming of cell metab. is essential for tumorigenesis, and is regulated by a complex network, in which PKM2 plays a crit. role.  PKM2 exists as an inactive monomer, less active dimer and active tetramer.  While dimeric PKM2 diverts glucose metab. towards anabolism through aerobic glycolysis, tetrameric PKM2 promotes the flux of glucose-derived carbons for ATP prodn. via oxidative phosphorylation.  Equil. of the PKM2 dimers and tetramers is crit. for tumorigenesis, and is controlled by multiple factors.  The PKM2 dimer also promotes aerobic glycolysis by modulating transcriptional regulation.  We will discuss the current understanding of PKM2 in regulating cancer metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxTIgwuY8YnLVg90H21EOLACvtfcHk0lghBy5YtgPlKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVart7c%253D&md5=8562ddc23e089703d976d165b3a2bb3b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.01.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.01.031%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DN.%26aulast%3DOjo%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DD.%26atitle%3DPKM2%2520contributes%2520to%2520cancer%2520metabolism%26jtitle%3DCancer%2520Lett.%26date%3D2015%26volume%3D356%26spage%3D184%26epage%3D191%26doi%3D10.1016%2Fj.canlet.2014.01.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span> <span> </span><span class="NLM_article-title">Tissue-specifific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">8202</span>– <span class="NLM_lpage">8210</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.18632%2Foncotarget.1159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=24077665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FitFamsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=8202-8210&author=S.+Desaiauthor=M.+Dingauthor=B.+Wangauthor=Z.+Luauthor=Q.+Zhaoauthor=K.+Shawauthor=W.+K.+Yungauthor=J.+N.+Weinsteinauthor=M.+Tanauthor=J.+Yao&title=Tissue-specifific+isoform+switch+and+DNA+hypomethylation+of+the+pyruvate+kinase+PKM+gene+in+human+cancers&doi=10.18632%2Foncotarget.1159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers</span></div><div class="casAuthors">Desai Shruti; Tan Ming; Ding Minming; Wang Bin; Lu Zhimin; Yung W K Alfred; Yao Jun; Zhao Qi; Shaw Kenna; Weinstein John N</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8202-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The M2 isoform of pyruvate kinase (PKM2) plays an important role in aerobic glycolysis and is a mediator of the Warburg effect in tumors.  It was previously thought that tumor cells switch expression of PKM from normal tissue-expressed PKM1 to tumor-specific PKM2 via an alternative splicing mechanism.  This view was challenged by a recent report demonstrating that PKM2 is already the major PKM isoform expressed in many differentiated normal tissues.  Here, through analyses on sixteen tumor types using the cancer genome atlas RNA-Seq and exon array datasets, we confirmed that isoform switch from PKM1 to PKM2 occurred in glioblastomas but not in other tumor types examined.  Despite lacking of isoform switches, PKM2 expression was found to be increased in all cancer types examined, and correlated strongly to poor prognosis in head and neck cancers.  We further demonstrated that elevated PKM2 expression correlated well with the hypomethylation status of intron 1 of the PKM gene in multiple cancer types, suggesting epigenetic regulation by DNA methylation as a major mechanism in controlling PKM transcription in tumors.  Our study suggests that isoform switch of PKM1 to PKM2 in cancers is tissue-specific and targeting PKM2 activity in tumors remains a promising approach for clinical intervention of multiple cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWoKJoTs3QNtts4TFFB11gfW6udTcc2eajW4xqan6jnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FitFamsg%253D%253D&md5=fb78a92711d9c581c1e5d50d73037ef2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1159%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DShaw%26aufirst%3DK.%26aulast%3DYung%26aufirst%3DW.%2BK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DJ.%26atitle%3DTissue-specifific%2520isoform%2520switch%2520and%2520DNA%2520hypomethylation%2520of%2520the%2520pyruvate%2520kinase%2520PKM%2520gene%2520in%2520human%2520cancers%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D8202%26epage%3D8210%26doi%3D10.18632%2Foncotarget.1159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Veelen, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staal, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbiest, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlug, A. M.</span></span> <span> </span><span class="NLM_article-title">Alanine inhibition of pyruvate kinase in gliomas and meningiomas. A diagnostic tool in surgery for gliomas?</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(77)90308-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2FS0140-6736%2877%2990308-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=70592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADyaE2s3ltlOmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1977&pages=384-385&author=C.+W.+van%0AVeelenauthor=G.+E.+Staalauthor=H.+Verbiestauthor=A.+M.+Vlug&title=Alanine+inhibition+of+pyruvate+kinase+in+gliomas+and+meningiomas.+A+diagnostic+tool+in+surgery+for+gliomas%3F&doi=10.1016%2FS0140-6736%2877%2990308-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Alanine inhibition of pyruvate kinase in gliomas and meningiomas. A diagnostic tool in surgery for gliomas?</span></div><div class="casAuthors">van Veelen C W; Staal G E; Verbiest H; Vlug A M</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8034</span>),
    <span class="NLM_cas:pages">384-5</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">In gliomas a shift was found in the composition of enzymes, manifested by abnormal inhibition of pyruvate kinase by alanine.  This study demonstrates the appearance of the MII-type isoenzyme in various gliomas.  This MII type is also found in meningiomas but not in normal brain tissue.  The method of enzyme examination described may be valuable as a diagnostic aid in the surgery of gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS23fTQs9fVTn6CEoQgWY10fW6udTcc2ea5CWvSaaqBmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2s3ltlOmug%253D%253D&md5=2ac721a67cd7993e95395d6a8710a997</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2877%2990308-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252877%252990308-7%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVeelen%26aufirst%3DC.%2BW.%26aulast%3DStaal%26aufirst%3DG.%2BE.%26aulast%3DVerbiest%26aufirst%3DH.%26aulast%3DVlug%26aufirst%3DA.%2BM.%26atitle%3DAlanine%2520inhibition%2520of%2520pyruvate%2520kinase%2520in%2520gliomas%2520and%2520meningiomas.%2520A%2520diagnostic%2520tool%2520in%2520surgery%2520for%2520gliomas%253F%26jtitle%3DLancet%26date%3D1977%26volume%3D2%26spage%3D384%26epage%3D385%26doi%3D10.1016%2FS0140-6736%2877%2990308-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaneton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddocks, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chokkathukalam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankevics, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holding, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vousden, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, E.</span></span> <span> </span><span class="NLM_article-title">Serine is a natural ligand and allosteric activator of pyruvate kinase M2</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1038/nature11540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnature11540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=23064226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2012&pages=458-462&author=B.+Chanetonauthor=P.+Hillmannauthor=L.+Zhengauthor=A.+C.+Martinauthor=O.+D.+Maddocksauthor=A.+Chokkathukalamauthor=J.+E.+Coyleauthor=A.+Jankevicsauthor=F.+P.+Holdingauthor=K.+H.+Vousdenauthor=C.+Frezzaauthor=M.+O%E2%80%99Reillyauthor=E.+Gottlieb&title=Serine+is+a+natural+ligand+and+allosteric+activator+of+pyruvate+kinase+M2&doi=10.1038%2Fnature11540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Serine is a natural ligand and allosteric activator of pyruvate kinase M2</span></div><div class="casAuthors">Chaneton, Barbara; Hillmann, Petra; Zheng, Liang; Martin, Agnes C. L.; Maddocks, Oliver D. K.; Chokkathukalam, Achuthanunni; Coyle, Joseph E.; Jankevics, Andris; Holding, Finn P.; Vousden, Karen H.; Frezza, Christian; O'Reilly, Marc; Gottlieb, Eyal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">7424</span>),
    <span class="NLM_cas:pages">458-462</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells exhibit several unique metabolic phenotypes that are crit. for cell growth and proliferation.  Specifically, they overexpress the M2 isoform of the tightly regulated enzyme, pyruvate kinase (PKM2), which controls glycolytic flux, and are highly dependent on the de novo biosynthesis of serine and glycine.  Here, the authors describe a new rheostat-like mechanistic relation between PKM2 activity and serine biosynthesis.  The authors show that serine can bind to and activate human PKM2, and that PKM2 activity in cells is reduced in response to serine deprivation.  This redn. in PKM2 activity shifts cells to a fuel-efficient mode in which more pyruvate is diverted to the mitochondria and more glucose-derived carbon is channeled into serine biosynthesis to support cell proliferation.  By activating PKM2, serine supports aerobic glycolysis and lactate prodn., events that are crit. for cancer growth and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGong16lcMeQXbVg90H21EOLACvtfcHk0lgtgNxtwmPCcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rsL7K&md5=4f4af944baaded05fa4bc93c4c2eb181</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature11540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11540%26sid%3Dliteratum%253Aachs%26aulast%3DChaneton%26aufirst%3DB.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DMartin%26aufirst%3DA.%2BC.%26aulast%3DMaddocks%26aufirst%3DO.%2BD.%26aulast%3DChokkathukalam%26aufirst%3DA.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DJankevics%26aufirst%3DA.%26aulast%3DHolding%26aufirst%3DF.%2BP.%26aulast%3DVousden%26aufirst%3DK.%2BH.%26aulast%3DFrezza%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DGottlieb%26aufirst%3DE.%26atitle%3DSerine%2520is%2520a%2520natural%2520ligand%2520and%2520allosteric%2520activator%2520of%2520pyruvate%2520kinase%2520M2%26jtitle%3DNature%26date%3D2012%26volume%3D491%26spage%3D458%26epage%3D462%26doi%3D10.1038%2Fnature11540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Israelsen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase: function, regulation and role in cancer</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2015.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.semcdb.2015.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=26277545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGgtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=43-51&author=W.+J.+Israelsenauthor=M.+G.+Vander+Heiden&title=Pyruvate+kinase%3A+function%2C+regulation+and+role+in+cancer&doi=10.1016%2Fj.semcdb.2015.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase: Function, regulation and role in cancer</span></div><div class="casAuthors">Israelsen, William J.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cell & Developmental Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">SCDBFX</span>;
        ISSN:<span class="NLM_cas:issn">1084-9521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pyruvate kinase is an enzyme that catalyzes the conversion of phosphoenolpyruvate and ADP to pyruvate and ATP in glycolysis and plays a role in regulating cell metab.  There are four mammalian pyruvate kinase isoforms with unique tissue expression patterns and regulatory properties.  The M2 isoform of pyruvate kinase (PKM2) supports anabolic metab. and is expressed both in cancer and normal tissue.  The enzymic activity of PKM2 is allosterically regulated by both intracellular signaling pathways and metabolites; PKM2 thus integrates signaling and metabolic inputs to modulate glucose metab. according to the needs of the cell.  Recent advances have increased our understanding of metabolic regulation by pyruvate kinase, raised new questions, and suggested the possibility of non-canonical PKM2 functions to regulate gene expression and cell cycle progression via protein-protein interactions and protein kinase activity.  Here we review the structure, function, and regulation of pyruvate kinase and discuss how these properties enable regulation of PKM2 for cell proliferation and tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrylgQY9GHGw7Vg90H21EOLACvtfcHk0lgtgNxtwmPCcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGgtbzP&md5=b8bbed5fa7653fc200d3a290268212d7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2015.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2015.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DIsraelsen%26aufirst%3DW.%2BJ.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DPyruvate%2520kinase%253A%2520function%252C%2520regulation%2520and%2520role%2520in%2520cancer%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2015%26volume%3D43%26spage%3D43%26epage%3D51%26doi%3D10.1016%2Fj.semcdb.2015.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazurek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschek, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrodt, E.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase type M2 and its role in tumor growth and spreading</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2005.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.semcancer.2005.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15908230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVKntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=300-308&author=S.+Mazurekauthor=C.+B.+Boschekauthor=F.+Hugoauthor=E.+Eigenbrodt&title=Pyruvate+kinase+type+M2+and+its+role+in+tumor+growth+and+spreading&doi=10.1016%2Fj.semcancer.2005.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase type M2 and its role in tumor growth and spreading</span></div><div class="casAuthors">Mazurek, Sybille; Boschek, C. Bruce; Hugo, Ferdinand; Eigenbrodt, Erich</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">300-308</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proliferating cells and tumor cells in particular express the pyruvate kinase isoenzyme type M2 (M2-PK).  Within the tumor metabolome M2-PK regulates the proportions of glucose carbons that are channelled to synthetic processes (inactive dimeric form) or used for glycolytic energy prodn. (highly active tetrameric form, a component of the glycolytic enzyme complex).  In tumor cells, the dimeric form of M2-PK (Tumor M2-PK) is always predominant.  The dimerization is caused by direct interaction of M2-PK with certain oncoproteins.  The switch between the tetrameric and dimeric form of M2-PK allows tumor cells to survive in environments with varying oxygen und nutrient supply.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAGWFw-vXg7Vg90H21EOLACvtfcHk0ljrlJ3HOzvv0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVKntbw%253D&md5=617c052dfc629ac074acc006f90947b3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2005.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2005.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DMazurek%26aufirst%3DS.%26aulast%3DBoschek%26aufirst%3DC.%2BB.%26aulast%3DHugo%26aufirst%3DF.%26aulast%3DEigenbrodt%26aufirst%3DE.%26atitle%3DPyruvate%2520kinase%2520type%2520M2%2520and%2520its%2520role%2520in%2520tumor%2520growth%2520and%2520spreading%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2005%26volume%3D15%26spage%3D300%26epage%3D308%26doi%3D10.1016%2Fj.semcancer.2005.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y. H.</span></span> <span> </span><span class="NLM_article-title">PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">846</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.18632%2Foncotarget.2749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=25514599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC2MznvFKrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=846-861&author=W.+R.+Liuauthor=M.+X.+Tianauthor=L.+X.+Yangauthor=Y.+L.+Linauthor=L.+Jinauthor=Z.+B.+Dingauthor=Y.+H.+Shenauthor=Y.+F.+Pengauthor=D.+M.+Gaoauthor=J.+Zhouauthor=S.+J.+Qiuauthor=Z.+Daiauthor=R.+Heauthor=J.+Fanauthor=Y.+H.+Shi&title=PKM2+promotes+metastasis+by+recruiting+myeloid-derived+suppressor+cells+and+indicates+poor+prognosis+for+hepatocellular+carcinoma&doi=10.18632%2Foncotarget.2749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma</span></div><div class="casAuthors">Liu Wei-Ren; Tian Meng-Xin; Yang Liu-Xiao; Jin Lei; Ding Zhen-Bin; Shen Ying-Hao; Peng Yuan-Fei; Gao Dong-Mei; Zhou Jian; Qiu Shuang-Jian; Dai Zhi; Fan Jia; Shi Ying-Hong; Lin Yu-Li; He Rui; Zhou Jian; Fan Jia</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">846-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pyruvate kinase M2 (PKM2) is a member of the pyruvate kinase family.  Recent work has defined the "non-metabolic" functions of PKM2.  However, the role of PKM2 in HCC remains unclear.  To investigate the role of PKM2 in tumor growth, invasion and the prognosis of hepatocellular carcinoma (HCC), PKM2 expression was measured in HCC cell lines and tissues using qRT-PCR, western blot, and immunofluorescence assays.  In in vitro experiments, PKM2 was knocked down using a short hairpin RNA lentivirus vector, and tumor cell behavior and the downstream signaling pathways and chemokine were analyzed.  For the analysis of in vivo tumor growth, intratumoral and peritumoral lymphocyte infiltration were examined in nude mice.  The prognostic value of PKM2 was analyzed by immunohistochemistry in two cohorts including 721 HCC patients.  Together, our data obtained from cell lines, tumorigenicity studies, and primary HCC samples illustrate an oncogenic role for PKM2 in tumors.  Moreover, PKM2 may serve as a novel prognostic indicator for HCC patients after curative resection, targeted therapy aimed at PKM2 may represent an effective treatment approach for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWhnKWAUjbzEewzGPswiWOfW6udTcc2eb0vh_pbe_7nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MznvFKrug%253D%253D&md5=7388ac1f54d8183cb264888e169513e5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2749%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%2BR.%26aulast%3DTian%26aufirst%3DM.%2BX.%26aulast%3DYang%26aufirst%3DL.%2BX.%26aulast%3DLin%26aufirst%3DY.%2BL.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DZ.%2BB.%26aulast%3DShen%26aufirst%3DY.%2BH.%26aulast%3DPeng%26aufirst%3DY.%2BF.%26aulast%3DGao%26aufirst%3DD.%2BM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DS.%2BJ.%26aulast%3DDai%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%2BH.%26atitle%3DPKM2%2520promotes%2520metastasis%2520by%2520recruiting%2520myeloid-derived%2520suppressor%2520cells%2520and%2520indicates%2520poor%2520prognosis%2520for%2520hepatocellular%2520carcinoma%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D846%26epage%3D861%26doi%3D10.18632%2Foncotarget.2749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span> <span> </span><span class="NLM_article-title">Activators of PKM2 in cancer metabolism</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1167</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.70</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.4155%2Ffmc.14.70" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=25078136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1167-1178&author=S.+L.+Warnerauthor=K.+J.+Carpenterauthor=D.+J.+Bearss&title=Activators+of+PKM2+in+cancer+metabolism&doi=10.4155%2Ffmc.14.70"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Activators of PKM2 in cancer metabolism</span></div><div class="casAuthors">Warner, Steven L.; Carpenter, Kent J.; Bearss, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1167-1178</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Pyruvate kinase converts phosphoenolpyruvate to pyruvate, catalyzing the rate-limiting step of glycolysis.  The M1 isoenzyme of pyruvate kinase (PKM1) is found in adult tissues; whereas, PKM2 is a splicesome variant found in embryonic and cancer cells.  PKM2 expression in malignant cells is a result of the tumor microenvironment and is responsible for maintaining a glycolytic phenotype.  PKM2 has other nonmetabolic functions in malignant cells, including transcriptional coactivation and protein kinase activity.  PKM2 activators have antitumor properties by inducing tetramerization of two PKM2 dimers causing PKM2 to function like PKM1.  Restoring PKM2 to PKM1-like levels of activity causes reversal of the Warburg effect in cancer cells.  PKM2 activators have therapeutic potential in the treatment of cancer and other metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsWUMVHeRw87Vg90H21EOLACvtfcHk0ljrlJ3HOzvv0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyjurnN&md5=276eca6bcf45a7d9ff677e27f6c7b6c0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.70%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DCarpenter%26aufirst%3DK.%2BJ.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26atitle%3DActivators%2520of%2520PKM2%2520in%2520cancer%2520metabolism%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1167%26epage%3D1178%26doi%3D10.4155%2Ffmc.14.70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobb, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, J.</span></span> <span> </span><span class="NLM_article-title">Variations in parthenolide content and daily dose of feverfew products</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1531</span>, <span class="refDoi"> DOI: 10.1093/ajhp/59.16.1527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1093%2Fajhp%2F59.16.1527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=12185827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvFSgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2002&pages=1527-1531&author=M.+H.+Nelsonauthor=S.+E.+Cobbauthor=J.+Shelton&title=Variations+in+parthenolide+content+and+daily+dose+of+feverfew+products&doi=10.1093%2Fajhp%2F59.16.1527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in parthenolide content and daily dose of feverfew products</span></div><div class="casAuthors">Nelson, Michael H.; Cobb, Sarah E.; Shelton, Jon</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1527-1531</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">Variations in the parthenolide content of feverfew products available to consumers were studied.  Feverfew products were analyzed for the content of parthenolide, the purported active component.  The actual wt. of feverfew was detd. only in those products contg. dried feverfew leaf.  The total daily doses of feverfew leaf and parthenolide were calcd. by using the instructions on each product label.  Parthenolide content was detd. by high-performance liq. chromatog.  The quantity of feverfew leaf in each capsule was similar to that stated on the label and ranged from 25 to 500 mg.  Parthenolide content per dosage form varied 150-fold (from 0.02 to 3.0 mg), while percent parthenolide varied 5.3-fold (from 0.14% to 0.74%).  If a person consumed the daily dose recommended on the label, intake of dried feverfew leaf would range from 225 to 2246 mg/day, a 10-fold variation, while intake of parthenolide would range from 0.06 to 9.7 mg/day, a 160-fold variation.  Large variations were obsd. in the parthenolide contents and daily intake as recommended by the labeling in com. feverfew products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOQGTp3fcXLbVg90H21EOLACvtfcHk0ljrlJ3HOzvv0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvFSgsL4%253D&md5=5cc7ac6e7ac2f571ceb0cf80bf1c9b9b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fajhp%2F59.16.1527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fajhp%252F59.16.1527%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DM.%2BH.%26aulast%3DCobb%26aufirst%3DS.%2BE.%26aulast%3DShelton%26aufirst%3DJ.%26atitle%3DVariations%2520in%2520parthenolide%2520content%2520and%2520daily%2520dose%2520of%2520feverfew%2520products%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2002%26volume%3D59%26spage%3D1527%26epage%3D1531%26doi%3D10.1093%2Fajhp%2F59.16.1527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghantous, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinjab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herceg, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwiche, N.</span></span> <span> </span><span class="NLM_article-title">Parthenolide: from plant shoots to cancer roots</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">905</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.drudis.2013.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=23688583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFGjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=894-905&author=A.+Ghantousauthor=A.+Sinjabauthor=Z.+Hercegauthor=N.+Darwiche&title=Parthenolide%3A+from+plant+shoots+to+cancer+roots&doi=10.1016%2Fj.drudis.2013.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Parthenolide: from plant shoots to cancer roots</span></div><div class="casAuthors">Ghantous, Akram; Sinjab, Ansam; Herceg, Zdenko; Darwiche, Nadine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17-18</span>),
    <span class="NLM_cas:pages">894-905</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Parthenolide (PTL), a sesquiterpene lactone (SL) originally purified from the shoots of feverfew (Tanacetum parthenium), has shown potent anticancer and anti-inflammatory activities.  It is currently being tested in cancer clin. trials.  Structure-activity relationship (SAR) studies of parthenolide revealed key chem. properties required for biol. activities and epigenetic mechanisms, and led to the derivatization of an orally bioavailable analog, dimethylamino-parthenolide (DMAPT).  Parthenolide is the first small mol. found to be selective against cancer stem cells (CSC), which it achieves by targeting specific signaling pathways and killing cancer from its roots.  In this review, we highlight the exciting journey of parthenolide, from plant shoots to cancer roots.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSNnHqQJd2UrVg90H21EOLACvtfcHk0ljpldDeWWcYhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFGjtbw%253D&md5=e87a1ab300093f8953879ee931d3cd42</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DGhantous%26aufirst%3DA.%26aulast%3DSinjab%26aufirst%3DA.%26aulast%3DHerceg%26aufirst%3DZ.%26aulast%3DDarwiche%26aufirst%3DN.%26atitle%3DParthenolide%253A%2520from%2520plant%2520shoots%2520to%2520cancer%2520roots%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D894%26epage%3D905%26doi%3D10.1016%2Fj.drudis.2013.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndubuisi, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elofsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1016/S1074-5521(01)00049-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2FS1074-5521%2801%2900049-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=11514225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtV2ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=759-766&author=B.+H.+Kwokauthor=B.+Kohauthor=M.+I.+Ndubuisiauthor=M.+Elofssonauthor=C.+M.+Crews&title=The+anti-inflammatory+natural+product+parthenolide+from+the+medicinal+herb+Feverfew+directly+binds+to+and+inhibits+IkappaB+kinase&doi=10.1016%2FS1074-5521%2801%2900049-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase</span></div><div class="casAuthors">Kwok, B. H. B.; Koh, B.; Ndubuisi, M. I.; Elofsson, M.; Crews, C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">759-766</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Biol. active natural products continue to be useful in the exploration and control of intracellular signaling processes.  For example, the sesquiterpene lactone parthenolide from the anti-inflammatory medicinal herb Feverfew (Tanacetum parthenium) appears to inhibit the pro-inflammatory signaling pathway.  Parthenolide's direct mol. target, however, remains unknown.  We set out to identify the mol. mechanisms of parthenolide's anti-inflammatory activity.  A parthenolide affinity reagent was synthesized and shown to bind directly to and inhibit IB kinase (IKK), the kinase subunit known to play a crit. role in cytokine-mediated signaling.  Mutation of cysteine 179 in the activation loop of IKKβ abolished sensitivity towards parthenolide.  Moreover, we showed that parthenolide's in vitro and in vivo anti-inflammatory activity is mediated through the α-methylene γ-lactone moiety shared by other sesquiterpene lactones.  In recent years, the multi-subunit IKK complex has been shown to be responsible for cytokine-mediated stimulation of genes involved in inflammation and as such represents an attractive target for pharmaceutical intervention.  Our finding that parthenolide targets this kinase complex provides a possible mol. basis for the anti-inflammatory properties of parthenolide.  In addn., these results may be useful in the development of addnl. anti-inflammatory agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9wzcv0O9mwrVg90H21EOLACvtfcHk0ljpldDeWWcYhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtV2ku7k%253D&md5=bf8be7acdd42fd794f9ad10df20ffa5d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2801%2900049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252801%252900049-7%26sid%3Dliteratum%253Aachs%26aulast%3DKwok%26aufirst%3DB.%2BH.%26aulast%3DKoh%26aufirst%3DB.%26aulast%3DNdubuisi%26aufirst%3DM.%2BI.%26aulast%3DElofsson%26aufirst%3DM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DThe%2520anti-inflammatory%2520natural%2520product%2520parthenolide%2520from%2520the%2520medicinal%2520herb%2520Feverfew%2520directly%2520binds%2520to%2520and%2520inhibits%2520IkappaB%2520kinase%26jtitle%3DChem.%2520Biol.%26date%3D2001%26volume%3D8%26spage%3D759%26epage%3D766%26doi%3D10.1016%2FS1074-5521%2801%2900049-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnischky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span> <span> </span><span class="NLM_article-title">The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">4163</span>– <span class="NLM_lpage">4169</span>, <span class="refDoi"> DOI: 10.1182/blood-2004-10-4135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1182%2Fblood-2004-10-4135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=15687234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks12ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=4163-4169&author=M.+L.+Guzmanauthor=R.+M.+Rossiauthor=L.+Karnischkyauthor=X.+Liauthor=D.+R.+Petersonauthor=D.+S.+Howardauthor=C.+T.+Jordan&title=The+sesquiterpene+lactone+parthenolide+induces+apoptosis+of+human+acute+myelogenous+leukemia+stem+and+progenitor+cells&doi=10.1182%2Fblood-2004-10-4135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells</span></div><div class="casAuthors">Guzman, Monica L.; Rossi, Randall M.; Karnischky, Lilliana; Li, Xiaojie; Peterson, Derick R.; Howard, Dianna S.; Jordan, Craig T.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4163-4169</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recent studies have described malignant stem cells as central to the initiation, growth, and potential relapse of acute and chronic myelogenous leukemia (AML and CML).  Because of their important role in pathogenesis, rare and biol. distinct leukemia stem cells (LSCs) represent a crit. target for therapeutic intervention.  However, to date, very few agents have been shown to directly target the LSC population.  The present studies demonstrate that parthenolide (PTL), a naturally occurring small mol., induces robust apoptosis in primary human AML cells and blast crisis CML (bcCML) cells while sparing normal hematopoietic cells.  Furthermore, anal. of progenitor cells using in vitro colony assays, as well as stem cells using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) xenograft model, show that PTL also preferentially targets AML progenitor and stem cell populations.  Notably, in comparison to the std. chemotherapy drug cytosine arabinoside (Ara-C), PTL is much more specific to leukemia cells.  The mol. mechanism of PTL-mediated apoptosis is strongly assocd. with inhibition of nuclear factor κ B (NF-κB), proapoptotic activation of p53, and increased reactive oxygen species (ROS).  On the basis of these findings, we propose that the activity of PTL triggers LSC-specific apoptosis and as such represents a potentially important new class of drugs for LSC-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBTKT6XR3lUbVg90H21EOLACvtfcHk0ljpldDeWWcYhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks12ju74%253D&md5=4436e10afc798d6c233808acc3f0c0a2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-10-4135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-10-4135%26sid%3Dliteratum%253Aachs%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DRossi%26aufirst%3DR.%2BM.%26aulast%3DKarnischky%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DPeterson%26aufirst%3DD.%2BR.%26aulast%3DHoward%26aufirst%3DD.%2BS.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26atitle%3DThe%2520sesquiterpene%2520lactone%2520parthenolide%2520induces%2520apoptosis%2520of%2520human%2520acute%2520myelogenous%2520leukemia%2520stem%2520and%2520progenitor%2520cells%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D4163%26epage%3D4169%26doi%3D10.1182%2Fblood-2004-10-4135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Clair, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangnekar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Clair, W. H.</span></span> <span> </span><span class="NLM_article-title">The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2477</span>– <span class="NLM_lpage">2486</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1158%2F1535-7163.MCT-07-0186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=17876045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2477-2486&author=Y.+Sunauthor=D.+K.+St.+Clairauthor=F.+Fangauthor=G.+W.+Warrenauthor=V.+M.+Rangnekarauthor=P.+A.+Crooksauthor=W.+H.+St+Clair&title=The+radiosensitization+effect+of+parthenolide+in+prostate+cancer+cells+is+mediated+by+nuclear+factor-kappaB+inhibition+and+enhanced+by+the+presence+of+PTEN&doi=10.1158%2F1535-7163.MCT-07-0186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-κB inhibition and enhanced by the presence of PTEN</span></div><div class="casAuthors">Sun, Yulan; St. Clair, Daret K.; Fang, Fang; Warren, Graham W.; Rangnekar, Vivek M.; Crooks, Peter A.; St. Clair, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2477-2486</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Parthenolide has been shown to have anti-inflammatory and antitumor properties.  However, whether and how parthenolide enhances tumor sensitivity to radiation therapy are unknown.  In this study, we show that inhibition of the nuclear factor-κB (NF-κB) pathway is a common mechanism for the radiosensitization effect of parthenolide in prostate cancer cells LNCaP, DU145, and PC3.  Parthenolide inhibits radiation-induced NF-κB DNA-binding activity and the expression of its downstream target sod2, the gene coding for an important antiapoptotic and antioxidant enzyme (manganese superoxide dismutase) in the three prostate cancer cells.  Different susceptibilities to parthenolide's effect are obsd. in two radioresistant cancer cells, DU145 and PC3, with DU145 cells showing higher sensitivity.  This differential susceptibility to parthenolide is due, in part, to the fact that in addn. to NF-κB inhibition, parthenolide activates the phosphatidylinositol-3-kinase/Akt prosurvival pathway in both cell lines.  However, the activated Akt in DU145 cells is kept at a relatively low level compared with that in PC3 cells due to the presence of functional PTEN.  Transfection of wild-type PTEN into PTEN-null cells, PC3, confers the enhanced radiosensitization effect of parthenolide in PTEN-expressing cells.  When PTEN expression is knocked down in DU145 cells, the cells become more resistant to parthenolide's effect.  Taken together, these results suggest that parthenolide inhibits the NF-κB pathway and activates the phosphatidylinositol-3-kinase/Akt pathway in prostate cancer cells.  The radiosensitization effect of parthenolide is due, in part, to the inhibition of the NF-κB pathway.  The presence of PTEN enhances the radiosensitization effect of parthenolide, in part, by suppressing the abs. amt. of activated p-Akt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQgw3iQmgw1bVg90H21EOLACvtfcHk0ljB2P9ncVBYXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgur7J&md5=c5c94a18c84dcca3cc4803fa554014bb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0186%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSt.%2BClair%26aufirst%3DD.%2BK.%26aulast%3DFang%26aufirst%3DF.%26aulast%3DWarren%26aufirst%3DG.%2BW.%26aulast%3DRangnekar%26aufirst%3DV.%2BM.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26aulast%3DSt%2BClair%26aufirst%3DW.%2BH.%26atitle%3DThe%2520radiosensitization%2520effect%2520of%2520parthenolide%2520in%2520prostate%2520cancer%2520cells%2520is%2520mediated%2520by%2520nuclear%2520factor-kappaB%2520inhibition%2520and%2520enhanced%2520by%2520the%2520presence%2520of%2520PTEN%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2477%26epage%3D2486%26doi%3D10.1158%2F1535-7163.MCT-07-0186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.ejmech.2019.01.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=30739826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivFygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=445-469&author=W.+Geauthor=X.+Haoauthor=F.+Hanauthor=Z.+Liuauthor=T.+Wangauthor=M.+Wangauthor=N.+Chenauthor=Y.+Dingauthor=Y.+Chenauthor=Q.+Zhang&title=Synthesis+and+structure-activity+relationship+studies+of+parthenolide+derivatives+as+potential+anti-triple+negative+breast+cancer+agents&doi=10.1016%2Fj.ejmech.2019.01.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents</span></div><div class="casAuthors">Ge, Weizhi; Hao, Xin; Han, Fangzhi; Liu, Zhongquan; Wang, Tianpeng; Wang, Mengmeng; Chen, Ning; Ding, Yahui; Chen, Yue; Zhang, Quan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">445-469</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most aggressive cancers with a high recurrence rate and rapidly acquired drug resistance among various breast cancer subtypes.  There is no specific drug for treatment of TNBC.  Discovery of therapeutic agents with unique modes of actions is urgently needed.  In this study, a series of seventy parthenolide derivs. was designed, synthesized, and evaluated for their anti-TNBC activities.  Compd. I exhibited the most potent activity against different breast cancer cells with IC50 values ranging from 0.20 μM to 0.27 μM, which demonstrated 11.6- to 18.6-fold improvement comparing to that of the parent compd. parthenolide with IC50 values of 2.68-4.63 μM.  It is worth to note that I was more active than the pos. control drug ADR.  Moreover, compd. I could induce apoptosis of SUM-159 cells through mitochondria pathway and cause G1 phase arrest of SUM-159 cells.  These findings indicate that compd. I deserves further studies as a lead compd. for ultimate discovery of effective anti-TNBC drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW97WDAuIPtLVg90H21EOLACvtfcHk0ljB2P9ncVBYXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivFygtL8%253D&md5=32965e2aa3657b697c4d23f2cf7b63ce</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.058%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DW.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520parthenolide%2520derivatives%2520as%2520potential%2520anti-triple%2520negative%2520breast%2520cancer%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D166%26spage%3D445%26epage%3D469%26doi%3D10.1016%2Fj.ejmech.2019.01.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janganati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrelli, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penthala, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span> <span> </span><span class="NLM_article-title">Dimers of melampomagnolide B exhibit potent anticancer activity against hematological and solid tumor cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8896</span>– <span class="NLM_lpage">8906</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKlt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8896-8906&author=V.+Janganatiauthor=J.+Ponderauthor=C.+T.+Jordanauthor=M.+J.+Borrelliauthor=N.+R.+Penthalaauthor=P.+A.+Crooks&title=Dimers+of+melampomagnolide+B+exhibit+potent+anticancer+activity+against+hematological+and+solid+tumor+cells&doi=10.1021%2Facs.jmedchem.5b01187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells</span></div><div class="casAuthors">Janganati, Venumadhav; Ponder, Jessica; Jordan, Craig T.; Borrelli, Michael J.; Penthala, Narsimha Reddy; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8896-8906</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel carbamate and carbonate dimers of melampomagnolide B have been synthesized by reaction of the melampomagnolide-B-triazole carbamate synthon with various terminal diamino- and dihydroxyalkanes.  Dimeric carbamate products exhibited potent growth inhibition (GIC50 = 0.16-0.99 μM) against the majority of cell lines in the NCI panel of 60 human hematol. and solid tumor cell lines.  Compd. bis-E-(((1aR,7aS,10aS,10bS)-1a-Methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2',3' 9,10]cyclodeca[1,2-b]furan-5-yl)methyl)octane-1,8-diyldicarbamate (7f) and bis-E-(((1aR,7aS,10aS,10bS)-1a-Methyl-8-methylene-9-oxo-1a,2,3,6,7,7a,8,9,10a,10b-decahydrooxireno[2',3':9,10] cyclodeca[1,2-b]furan-5-yl)methyl) carbonate (8) exhibited anticancer activity that was 300-fold and 1 × 106-fold more cytotoxic than DMAPT, resp., at a concn. of 10 μM against rat 9L-SF gliosarcoma cells.  Novel carbamate and carbonate dimers were also screened against M9-ENL1 and acute myelogenous leukemia (AML) primary cell lines and exhibited 2- to 10-fold more potent antileukemic activity against M9-ENL1 cells (EC50 = 0.57-2.90 μM) when compared to parthenolide (EC50 = 6.0) and showed potent antileukemic activity against five primary AML cell lines (EC50 = 0.76-7.3 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAnzBdDGGt0rVg90H21EOLACvtfcHk0ljB2P9ncVBYXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKlt7bE&md5=71183c44bde3a90e6e02e77392754928</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01187%26sid%3Dliteratum%253Aachs%26aulast%3DJanganati%26aufirst%3DV.%26aulast%3DPonder%26aufirst%3DJ.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DBorrelli%26aufirst%3DM.%2BJ.%26aulast%3DPenthala%26aufirst%3DN.%2BR.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DDimers%2520of%2520melampomagnolide%2520B%2520exhibit%2520potent%2520anticancer%2520activity%2520against%2520hematological%2520and%2520solid%2520tumor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8896%26epage%3D8906%26doi%3D10.1021%2Facs.jmedchem.5b01187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nasim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span> <span> </span><span class="NLM_article-title">Melampomagnolide B: a new antileukemic sesquiterpene</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bmc.2010.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21273084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFKhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1515-1519&author=S.+Nasimauthor=S.+Peiauthor=F.+K.+Hagenauthor=C.+T.+Jordanauthor=P.+A.+Crooks&title=Melampomagnolide+B%3A+a+new+antileukemic+sesquiterpene&doi=10.1016%2Fj.bmc.2010.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Melampomagnolide B: A new antileukemic sesquiterpene</span></div><div class="casAuthors">Nasim, Shama; Pei, Shan Shan; Hagen, Fred K.; Jordan, Craig T.; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1515-1519</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Melampomagnolide B has been identified as a new antileukemic sesquiterpene.  A biotin-conjugated deriv. of melampomagnolide B was designed and synthesized in order to elucidate its mechanism of action.  A study of the biochem. interactions of the biotin probe suggests that melampomagnolide B derives its remarkable selectivity for leukemic cells over normal hematopoietic cells from its unique ability to exploit biochem. differences between the two cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorkXTH9qgT2rVg90H21EOLACvtfcHk0lgnA53MQ-3__A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFKhtL0%253D&md5=610a8e982ad51571be7966cbac1fff80</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DNasim%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DF.%2BK.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DMelampomagnolide%2520B%253A%2520a%2520new%2520antileukemic%2520sesquiterpene%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1515%26epage%3D1519%26doi%3D10.1016%2Fj.bmc.2010.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, W.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, B.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Syntheses and biological evaluation of costunolide, parthenolide, and their fluorinated analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7007</span>– <span class="NLM_lpage">7020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00915</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00915" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gmsr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7007-7020&author=Z.-J.+Yangauthor=W.-Z.+Geauthor=Q.-Y.+Liauthor=Y.+Luauthor=J.-M.+Gongauthor=B.-J.+Kuangauthor=X.+Xiauthor=H.+Wuauthor=Q.+Zhangauthor=Y.+Chen&title=Syntheses+and+biological+evaluation+of+costunolide%2C+parthenolide%2C+and+their+fluorinated+analogues&doi=10.1021%2Facs.jmedchem.5b00915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and Biological Evaluation of Costunolide, Parthenolide, and Their Fluorinated Analogues</span></div><div class="casAuthors">Yang, Zhong-Jin; Ge, Wei-Zhi; Li, Qiu-Ying; Lu, Yaxin; Gong, Jian-Miao; Kuang, Bei-Jia; Xi, Xiaonan; Wu, Haiting; Zhang, Quan; Chen, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7007-7020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inspired by the biosynthesis of sesquiterpene lactones (SLs), herein we report the asym. total synthesis of the germacrane ring I.  The synthetic strategy features a selective aldol reaction between β,γ-unsatd. chiral sulfonylamide II and aldehyde III, as well as the intramol. α-alkylation of sulfone IV to construct a 10-membered carbocylic ring.  The key intermediate I can be used to prep. the natural products costunolide and parthenolide (PTL), which are the key precursors for transformation into other SLs.  Furthermore, the described synthetic sequences are amenable to the total synthesis of SL analogs, such as trifluoromethylated analogs V and VI.  Analogs V and VI maintained high activities against a series of cancer cell lines compared to their parent PTL and costunolide, resp.  In addn., V showed enhanced tolerance to acidic media compared with PTL.  To our surprise, PTL and V showed comparable half-lives in rat plasma and in the presence of human liver microsomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG-9MPHOGhMbVg90H21EOLACvtfcHk0lgnA53MQ-3__A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gmsr%252FF&md5=595543d5e8b515a14b7f93831b1f3bac</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00915%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.-J.%26aulast%3DGe%26aufirst%3DW.-Z.%26aulast%3DLi%26aufirst%3DQ.-Y.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DJ.-M.%26aulast%3DKuang%26aufirst%3DB.-J.%26aulast%3DXi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DSyntheses%2520and%2520biological%2520evaluation%2520of%2520costunolide%252C%2520parthenolide%252C%2520and%2520their%2520fluorinated%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7007%26epage%3D7020%26doi%3D10.1021%2Facs.jmedchem.5b00915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.07.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bmc.2005.07.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=16140536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1egsLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=83-91&author=D.+R.+Hwangauthor=Y.+S.+Wuauthor=C.+W.+Changauthor=T.+W.+Lienauthor=W.+C.+Chenauthor=U.+K.+Tanauthor=J.+T.+Hsuauthor=H.+P.+Hsieh&title=Synthesis+and+anti-viral+activity+of+a+series+of+sesquiterpene+lactones+and+analogues+in+the+subgenomic+HCV+replicon+system&doi=10.1016%2Fj.bmc.2005.07.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system</span></div><div class="casAuthors">Hwang, Der-Ren; Wu, Yu-Shan; Chang, Chun-Wei; Lien, Tzu-Wen; Chen, Wei-Cheng; Tan, Uan-Kang; Hsu, John T. A.; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a severe liver disease that often leads to liver cirrhosis and hepatocellular carcinoma (HCC).  Current therapy is inadequate to conquer this viral disease.  In this study, we identified parthenolide (1), an active component in feverfew, a popular remedy for fever and migraine, as a lead compd. with an EC50 value of 2.21 μM against HCV replication in a subgenomic RNA replicon assay system.  Parthenolide is able to potentiate the interferon α-exerted anti-HCV effect.  Several com. available sesquiterpene lactones (2-5) structurally analogous to parthenolide and a series of synthesized Michael-type adducts of parthenolide (12-18) also exhibit micromolar concns. for anti-HCV activities.  Structure-activity relationship was elucidated to reveal that the spatial arrangement of the terpenoid skeleton fused with an α-methylene-γ-lactone moiety produces maximal anti-HCV activity.  In addn., a strong anti-HCV potency indicates a possibility of secondary amino adducts (12-18) converting back to parthenolide or being replaced by the nucleophilic residues of proteins inside cells.  This work shows that screening of natural products is a viable and fast way for identifying novel mol. diversity as potential drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0_t6XNy2kX7Vg90H21EOLACvtfcHk0lgnA53MQ-3__A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1egsLjF&md5=3b2d5d9c4cdce1c5f5eb97368b261151</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.07.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.07.055%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.%2BS.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DLien%26aufirst%3DT.%2BW.%26aulast%3DChen%26aufirst%3DW.%2BC.%26aulast%3DTan%26aufirst%3DU.%2BK.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DSynthesis%2520and%2520anti-viral%2520activity%2520of%2520a%2520series%2520of%2520sesquiterpene%2520lactones%2520and%2520analogues%2520in%2520the%2520subgenomic%2520HCV%2520replicon%2520system%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D83%26epage%3D91%26doi%3D10.1016%2Fj.bmc.2005.07.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelakantan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span> <span> </span><span class="NLM_article-title">Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4346</span>– <span class="NLM_lpage">4349</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bmcl.2009.05.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19505822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4346-4349&author=S.+Neelakantanauthor=S.+Nasimauthor=M.+L.+Guzmanauthor=C.+T.+Jordanauthor=P.+A.+Crooks&title=Aminoparthenolides+as+novel+anti-leukemic+agents%3A+Discovery+of+the+NF-kappaB+inhibitor%2C+DMAPT+%28LC-1%29&doi=10.1016%2Fj.bmcl.2009.05.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)</span></div><div class="casAuthors">Neelakantan, Sundar; Nasim, Shama; Guzman, Monica L.; Jordan, Craig T.; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4346-4349</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of aminoparthenolide analogs were synthesized and evaluated for their anti-leukemic activity.  Eight compds. exhibited good anti-leukemic activity with LD50's in the low μM range (1.5-3.0 μM).  Compds. I, II and III were the most potent compds. in the series, causing greater than 90% cell death at 10 μM concn. against primary AML cells in culture, with LD50 values of 1.7, 1.8 and 1.6 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzFsAppmWkqbVg90H21EOLACvtfcHk0lh5PLXTPA3xTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGmu7w%253D&md5=aff3db6b1997e882d2474e120a1419fa</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DNeelakantan%26aufirst%3DS.%26aulast%3DNasim%26aufirst%3DS.%26aulast%3DGuzman%26aufirst%3DM.%2BL.%26aulast%3DJordan%26aufirst%3DC.%2BT.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DAminoparthenolides%2520as%2520novel%2520anti-leukemic%2520agents%253A%2520Discovery%2520of%2520the%2520NF-kappaB%2520inhibitor%252C%2520DMAPT%2520%2528LC-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4346%26epage%3D4349%26doi%3D10.1016%2Fj.bmcl.2009.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieberich, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alavanja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colby, D. A.</span></span> <span> </span><span class="NLM_article-title">Fluorinated amino-derivatives of the sesquiterpene lactone, parthenolide, as (19)F NMR probes in deuterium-free environments</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7934</span>– <span class="NLM_lpage">7941</span>, <span class="refDoi"> DOI: 10.1021/jm201114t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201114t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyjsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7934-7941&author=J.+R.+Woodsauthor=H.+Moauthor=A.+A.+Bieberichauthor=T.+Alavanjaauthor=D.+A.+Colby&title=Fluorinated+amino-derivatives+of+the+sesquiterpene+lactone%2C+parthenolide%2C+as+%2819%29F+NMR+probes+in+deuterium-free+environments&doi=10.1021%2Fjm201114t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorinated Amino-Derivatives of the Sesquiterpene Lactone, Parthenolide, as 19F NMR Probes in Deuterium-Free Environments</span></div><div class="casAuthors">Woods, James R.; Mo, Huaping; Bieberich, Andrew A.; Alavanja, Tanja; Colby, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7934-7941</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and biol. activity of fluorinated amino-derivs. of the sesquiterpene lactone, parthenolide, are described.  A fluorinated aminoparthenolide analog with biol. activity similar to the parent natural product was discovered, and its x-ray structure was obtained.  This lead compd. was then studied using 19F NMR in the presence and absence of glutathione to obtain addnl. mechanism of action data, and it was found that the aminoparthenolide eliminates amine faster in the presence of glutathione than in the absence of glutathione.  The exact changes in concns. of fluorinated compd. and amine were quantified by a concn.-ref. method using 19F NMR; a major benefit of applying this strategy is that no deuterated solvents or internal stds. are required to obtain accurate concns.  These mechanistic data with glutathione may contribute to the conversion of the amino-deriv. to parthenolide, the active pharmacol. agent, in glutathione-rich cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot6UoKKPwq5bVg90H21EOLACvtfcHk0lh5PLXTPA3xTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyjsrrN&md5=cc78c225b5b20b2a8948846a1e1cc3ef</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm201114t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201114t%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DJ.%2BR.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DBieberich%26aufirst%3DA.%2BA.%26aulast%3DAlavanja%26aufirst%3DT.%26aulast%3DColby%26aufirst%3DD.%2BA.%26atitle%3DFluorinated%2520amino-derivatives%2520of%2520the%2520sesquiterpene%2520lactone%252C%2520parthenolide%252C%2520as%2520%252819%2529F%2520NMR%2520probes%2520in%2520deuterium-free%2520environments%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7934%26epage%3D7941%26doi%3D10.1021%2Fjm201114t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasiou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israelsen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattaini, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metallo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtney, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malstrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoumbourdis, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veith, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimacombe, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunt, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephanopoulos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auld, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1038%2Fnchembio.1060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=22922757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ght7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=839-847&author=D.+Anastasiouauthor=Y.+Yuauthor=W.+J.+Israelsenauthor=J.+K.+Jiangauthor=M.+B.+Boxerauthor=B.+S.+Hongauthor=W.+Tempelauthor=S.+Dimovauthor=M.+Shenauthor=A.+Jhaauthor=H.+Yangauthor=K.+R.+Mattainiauthor=C.+M.+Metalloauthor=B.+P.+Fiskeauthor=K.+D.+Courtneyauthor=S.+Malstromauthor=T.+M.+Khanauthor=C.+Kungauthor=A.+P.+Skoumbourdisauthor=H.+Veithauthor=N.+Southallauthor=M.+J.+Walshauthor=K.+R.+Brimacombeauthor=W.+Leisterauthor=S.+Y.+Luntauthor=Z.+R.+Johnsonauthor=K.+E.+Yenauthor=K.+Kuniiauthor=S.+M.+Davidsonauthor=H.+R.+Christofkauthor=C.+P.+Austinauthor=J.+Ingleseauthor=M.+H.+Harrisauthor=J.+M.+Asaraauthor=G.+Stephanopoulosauthor=F.+G.+Salituroauthor=S.+Jinauthor=L.+Dangauthor=D.+S.+Auldauthor=H.+W.+Parkauthor=L.+C.+Cantleyauthor=C.+J.+Thomasauthor=M.+G.+Vander+Heiden&title=Pyruvate+kinase+M2+activators+promote+tetramer+formation+and+suppress+tumorigenesis&doi=10.1038%2Fnchembio.1060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis</span></div><div class="casAuthors">Anastasiou, Dimitrios; Yu, Yimin; Israelsen, William J.; Jiang, Jian-Kang; Boxer, Matthew B.; Hong, Bum Soo; Tempel, Wolfram; Dimov, Svetoslav; Shen, Min; Jha, Abhishek; Yang, Hua; Mattaini, Katherine R.; Metallo, Christian M.; Fiske, Brian P.; Courtney, Kevin D.; Malstrom, Scott; Khan, Tahsin M.; Kung, Charles; Skoumbourdis, Amanda P.; Veith, Henrike; Southall, Noel; Walsh, Martin J.; Brimacombe, Kyle R.; Leister, William; Lunt, Sophia Y.; Johnson, Zachary R.; Yen, Katharine E.; Kunii, Kaiko; Davidson, Shawn M.; Christofk, Heather R.; Austin, Christopher P.; Inglese, James; Harris, Marian H.; Asara, John M.; Stephanopoulos, Gregory; Salituro, Francesco G.; Jin, Shengfang; Dang, Lenny; Auld, Douglas S.; Park, Hee-Won; Cantley, Lewis C.; Thomas, Craig J.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">839-847</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells engage in a metabolic program to enhance biosynthesis and support cell proliferation.  The regulatory properties of pyruvate kinase M2 (PKM2) influence altered glucose metab. in cancer.  The interaction of PKM2 with phosphotyrosine-contg. proteins inhibits enzyme activity and increases the availability of glycolytic metabolites to support cell proliferation.  This suggests that high pyruvate kinase activity may suppress tumor growth.  We show that expression of PKM1, the pyruvate kinase isoform with high constitutive activity, or exposure to published small-mol. PKM2 activators inhibits the growth of xenograft tumors.  Structural studies reveal that small-mol. activators bind PKM2 at the subunit interaction interface, a site that is distinct from that of the endogenous activator fructose-1,6-bisphosphate (FBP).  However, unlike FBP, binding of activators to PKM2 promotes a constitutively active enzyme state that is resistant to inhibition by tyrosine-phosphorylated proteins.  These data support the notion that small-mol. activation of PKM2 can interfere with anabolic metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMDIr6LPTxPbVg90H21EOLACvtfcHk0lh5PLXTPA3xTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ght7rM&md5=20ae4953c6afd41458cf317933fd5d9d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1060%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasiou%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DIsraelsen%26aufirst%3DW.%2BJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DBoxer%26aufirst%3DM.%2BB.%26aulast%3DHong%26aufirst%3DB.%2BS.%26aulast%3DTempel%26aufirst%3DW.%26aulast%3DDimov%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DJha%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DMattaini%26aufirst%3DK.%2BR.%26aulast%3DMetallo%26aufirst%3DC.%2BM.%26aulast%3DFiske%26aufirst%3DB.%2BP.%26aulast%3DCourtney%26aufirst%3DK.%2BD.%26aulast%3DMalstrom%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DSkoumbourdis%26aufirst%3DA.%2BP.%26aulast%3DVeith%26aufirst%3DH.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DWalsh%26aufirst%3DM.%2BJ.%26aulast%3DBrimacombe%26aufirst%3DK.%2BR.%26aulast%3DLeister%26aufirst%3DW.%26aulast%3DLunt%26aufirst%3DS.%2BY.%26aulast%3DJohnson%26aufirst%3DZ.%2BR.%26aulast%3DYen%26aufirst%3DK.%2BE.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DDavidson%26aufirst%3DS.%2BM.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DInglese%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DM.%2BH.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DStephanopoulos%26aufirst%3DG.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DPark%26aufirst%3DH.%2BW.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DPyruvate%2520kinase%2520M2%2520activators%2520promote%2520tetramer%2520formation%2520and%2520suppress%2520tumorigenesis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D839%26epage%3D847%26doi%3D10.1038%2Fnchembio.1060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanotto-Filho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalmolin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquali, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battastini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J. C.</span></span> <span> </span><span class="NLM_article-title">NFκB inhibitors induce cell death in glioblastomas</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2010.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.bcp.2010.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21040711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ajtrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2011&pages=412-424&author=A.+Zanotto-Filhoauthor=E.+Braganholauthor=R.+Schr%C3%B6derauthor=L.+H.+de+Souzaauthor=R.+J.+Dalmolinauthor=M.+A.+Pasqualiauthor=D.+P.+Gelainauthor=A.+M.+Battastiniauthor=J.+C.+Moreira&title=NF%CE%BAB+inhibitors+induce+cell+death+in+glioblastomas&doi=10.1016%2Fj.bcp.2010.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">NFκB inhibitors induce cell death in glioblastomas</span></div><div class="casAuthors">Zanotto-Filho, Alfeu; Braganhol, Elizandra; Schroeder, Rafael; de Souza, Luis Henrique T.; Dalmolin, Rodrigo J. S.; Pasquali, Matheus A. Bittencourt; Gelain, Daniel Pens; Battastini, Ana Maria Oliveira; Moreira, Jose Claudio Fonseca</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">412-424</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Identification of novel target pathways in glioblastoma (GBM) remains crit. due to poor prognosis, inefficient therapies and recurrence assocd. with these tumors.  In this work, we evaluated the role of nuclear-factor-κ-B (NFκB) in the growth of GBM cells, and the potential of NFκB inhibitors as antiglioma agents.  NFκB pathway was found overstimulated in GBM cell lines and in tumor specimens compared to normal astrocytes and healthy brain tissues, resp.  Treatment of a panel of established GBM cell lines (U138MG, U87, U373 and C6) with pharmacol. NFκB inhibitors (BAY117082, parthenolide, MG132, curcumin and arsenic trioxide) and NFκB-p65 siRNA markedly decreased the viability of GBMs as compared to inhibitors of other signaling pathways such as MAPKs (ERK, JNK and p38), PKC, EGFR and PI3K/Akt.  In addn., NFκB inhibitors presented a low toxicity to normal astrocytes, indicating selectivity to cancerous cells.  In GBMs, mitochondrial dysfunction (membrane depolarization, bcl-xL downregulation and cytochrome c release) and arrest in the G2/M phase were obsd. at the early steps of NFκB inhibitors treatment.  These events preceded sub-G1 detection, apoptotic body formation and caspase-3 activation.  Also, NFκB was found overstimulated in cisplatin-resistant C6 cells, and treatment of GBMs with NFκB inhibitors overcame cisplatin resistance besides potentiating the effects of the chemotherapeutics, cisplatin and doxorubicin.  These findings support NFκB as a potential target to cell death induction in GBMs, and that the NFκB inhibitors may be considered for in vivo testing on animal models and possibly on GBM therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEYaZC-m_cx7Vg90H21EOLACvtfcHk0liyN_nuR3CGBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ajtrjN&md5=b2cabf0ff1d0b1d16885243ca785f779</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DZanotto-Filho%26aufirst%3DA.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DR.%26aulast%3Dde%2BSouza%26aufirst%3DL.%2BH.%26aulast%3DDalmolin%26aufirst%3DR.%2BJ.%26aulast%3DPasquali%26aufirst%3DM.%2BA.%26aulast%3DGelain%26aufirst%3DD.%2BP.%26aulast%3DBattastini%26aufirst%3DA.%2BM.%26aulast%3DMoreira%26aufirst%3DJ.%2BC.%26atitle%3DNF%25CE%25BAB%2520inhibitors%2520induce%2520cell%2520death%2520in%2520glioblastomas%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D81%26spage%3D412%26epage%3D424%26doi%3D10.1016%2Fj.bcp.2010.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1853</span>– <span class="NLM_lpage">1862</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2014.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.cellsig.2014.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=24686087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGlsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=1853-1862&author=P.+Yangauthor=Z.+Liauthor=R.+Fuauthor=H.+Wuauthor=Z.+Li&title=Pyruvate+kinase+M2+facilitates+colon+cancer+cell+migration+via+the+modulation+of+STAT3+signalling&doi=10.1016%2Fj.cellsig.2014.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling</span></div><div class="casAuthors">Yang, Peng; Li, Zongwei; Fu, Rong; Wu, Haili; Li, Zhuoyu</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1853-1862</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Understanding the mechanisms of colorectal cancer (CRC) metastatic progression is essential to reducing its morbidity and mortality.  Pyruvate kinase (PK) catalyzes the final step of glycolysis and has been identified as a crit. regulator of glucose consumption.  However, the mechanisms and roles of PKM1 and PKM2 in the regulation of CRC cell migration and cell adhesion remain elusive.  Here, we report that PKM2 rather than PKM1 drives CRC cell migration and cell adhesion, whereas PKM attenuation reverses these phenomena.  Furthermore, the overexpression of PKM2 significantly increases the expression of N-cadherin, MMP-2, MMP-9, STAT3, Snail-2, pFAK and active β1-integrin, while E-cadherin expression is suppressed.  More importantly, the results indicated that PKM2 overexpression facilitates STAT3 nuclear translocation, and it is required for PKM2 function in the regulation of migration and adhesion assocd. signalling.  In addn., the dimeric form of PKM2, which lacks the pyruvate kinase activities but possesses protein kinase activity, is crit. for CRC cell migration and cell adhesion.  Overall, this study suggests that PKM2 overexpression promotes CRC cell migration and cell adhesion by regulating STAT3-assocd. signalling and that PKM2 may serve as a therapeutic target for CRC metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhcHi48jxBILVg90H21EOLACvtfcHk0liyN_nuR3CGBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGlsb%252FL&md5=45eab56fbc5dc8fa531921ce50e005bb</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2014.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2014.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFu%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DPyruvate%2520kinase%2520M2%2520facilitates%2520colon%2520cancer%2520cell%2520migration%2520via%2520the%2520modulation%2520of%2520STAT3%2520signalling%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D1853%26epage%3D1862%26doi%3D10.1016%2Fj.cellsig.2014.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kordula, T.</span></span> <span> </span><span class="NLM_article-title">Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1999.1948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1006%2Fbbrc.1999.1948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10623619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1GktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=2000&pages=329-333&author=R.+Sobotaauthor=M.+Szwedauthor=A.+Kaszaauthor=M.+Bugnoauthor=T.+Kordula&title=Parthenolide+inhibits+activation+of+signal+transducers+and+activators+of+transcription+%28STATs%29+induced+by+cytokines+of+the+IL-6+family&doi=10.1006%2Fbbrc.1999.1948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Parthenolide Inhibits Activation of Signal Transducers and Activators of Transcription (STATs) Induced by Cytokines of the IL-6 Family</span></div><div class="casAuthors">Sobota, Radoslaw; Szwed, Marcin; Kasza, Aneta; Bugno, Marcin; Kordula, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">329-333</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Progression of inflammatory processes correlates with the release of cell-derived mediators from the local site of inflammation.  These mediators, including cytokines of the IL-1 and IL-6 families, act on host cells and exert their action by activating their signal transduction pathways leading to specific target gene activation.  Parthenolide, a sesquiterpene lactone found in many medicinal plants, is an inhibitor of IL-1-type cytokine signaling that blocks the activation of NF-κB.  Here we show that parthenolide is also an effective inhibitor of IL-6-type cytokines.  It inhibits IL-6-type cytokine-induced gene expression by blocking STAT3 phosphorylation on Tyr705.  This prevents STAT3 dimerization necessary for its nuclear translocation and consequently STAT3-dependent gene expression.  This is a new mol. mechanism of parthenolide action that addnl. explains its anti-inflammatory activities.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3KCJLuFabKrVg90H21EOLACvtfcHk0liyN_nuR3CGBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1GktA%253D%253D&md5=e8dc1bf3d18338b8cf3ed0769cecc6ff</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1999.1948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1999.1948%26sid%3Dliteratum%253Aachs%26aulast%3DSobota%26aufirst%3DR.%26aulast%3DSzwed%26aufirst%3DM.%26aulast%3DKasza%26aufirst%3DA.%26aulast%3DBugno%26aufirst%3DM.%26aulast%3DKordula%26aufirst%3DT.%26atitle%3DParthenolide%2520inhibits%2520activation%2520of%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%2520%2528STATs%2529%2520induced%2520by%2520cytokines%2520of%2520the%2520IL-6%2520family%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2000%26volume%3D267%26spage%3D329%26epage%3D333%26doi%3D10.1006%2Fbbrc.1999.1948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3572</span>– <span class="NLM_lpage">3579</span>, <span class="refDoi"> DOI: 10.3892/ol.2018.7739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.3892%2Fol.2018.7739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=29467878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC1MrktVGmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=3572-3579&author=H.+Liauthor=H.+Luauthor=M.+Lvauthor=Q.+Wangauthor=Y.+Sun&title=Parthenolide+facilitates+apoptosis+and+reverses+drug-resistance+of+human+gastric+carcinoma+cells+by+inhibiting+the+STAT3+signaling+pathway&doi=10.3892%2Fol.2018.7739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway</span></div><div class="casAuthors">Li Hua; Sun Yuping; Li Hua; Lu Hang; Lv Meng; Wang Qingsheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">3572-3579</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">In the present study, SGC-7901/DDP cells were treated with different concentrations of parthenolide (PN) (2.5-15 μmol/l), cisplatin (DDP) (1.25-15 μg/ml) and PN+DDP.  The proliferation inhibition rates were measured using an MTT assay, and the synergies of PN and DDP were analyzed.  The effect of PN and DDP on SGC-7901/DDP cell proliferation demonstrated a time- and concentration-dependent association, and a synergy between PN and DDP was identified.  DAPI staining and flow cytometry results indicated that 15 μmol/l PN significantly induced SGC-7901/DDP apoptosis and G1 phase arrest compared with the untreated control group.  Western blotting analysis results indicated that among the apoptosis-associated proteins, there were dose-dependent increases in the protein expression of apoptosis regulator BAX, cellular tumor antigen p53, cleaved caspase-3 and cleaved capase-9, and decreases in apoptosis regulator Bcl-2 and Bcl-xL protein expression levels.  Among the cell cycle-associated proteins, cyclin D1 expression was significantly decreased, cyclin-dependent kinase inhibitor 1 expression was significantly increased, and signal transducer and activator of transcription 3 (STAT3) activation was inhibited.  Scratch and Transwell assay results revealed that PN significantly inhibited SGC-7901/DDP cell migration, and invasion.  The present study demonstrated that PN induces SGC-7901/DDP apoptosis, inhibits SGC-7901/DDP proliferation, migration and invasion, and enhances the drug sensitivity of the cells to DDP.  The underlying mechanisms may be associated with inhibition of the STAT3 signaling pathway and regulation of the downstream apoptotic protein and cyclin expression levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrmXdAiWRkMdFxYDaSSP8XfW6udTcc2eZKe-uC48xMhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrktVGmtA%253D%253D&md5=efb23320870893f96ff5e3515333e01b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3892%2Fol.2018.7739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2018.7739%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLv%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DParthenolide%2520facilitates%2520apoptosis%2520and%2520reverses%2520drug-resistance%2520of%2520human%2520gastric%2520carcinoma%2520cells%2520by%2520inhibiting%2520the%2520STAT3%2520signaling%2520pathway%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D15%26spage%3D3572%26epage%3D3579%26doi%3D10.3892%2Fol.2018.7739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palomer, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez-Guardia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vázquez-Carrera, M.</span></span> <span> </span><span class="NLM_article-title">The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e19724</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0019724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1371%2Fjournal.pone.0019724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=21625432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=X.+Palomerauthor=D.+%C3%81lvarez-Guardiaauthor=M.+M.+Davidsonauthor=T.+O.+Chanauthor=A.+M.+Feldmanauthor=M.+V%C3%A1zquez-Carrera&title=The+interplay+between+NF-kappaB+and+E2F1+coordinately+regulates+inflammation+and+metabolism+in+human+cardiac+cells&doi=10.1371%2Fjournal.pone.0019724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The interplay between NF-κB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells</span></div><div class="casAuthors">Palomer, Xavier; Alvarez-Guardia, David; Davidson, Mercy M.; Chan, Tung O.; Feldman, Arthur M.; Vazquez-Carrera, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e19724</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Pyruvate dehydrogenase kinase 4 (PDK4) inhibition by nuclear factor-κB (NF-κB) is related to a shift towards increased glycolysis during cardiac pathol. processes such as cardiac hypertrophy and heart failure.  The transcription factors estrogen-related receptor-α (ERRα) and peroxisome proliferator-activated receptor (PPAR) regulate PDK4 expression through the potent transcriptional coactivator PPARγ coactivator-1α (PGC-1α).  NF-κB activation in AC16 cardiac cells inhibit ERRα and PPARβ/δ transcriptional activity, resulting in reduced PGC-1α and PDK4 expression, and an enhanced glucose oxidn. rate.  However, addn. of the NF-κB inhibitor parthenolide to these cells prevents the downregulation of PDK4 expression but not ERRα and PPARβ/δ DNA binding activity, thus suggesting that addnl. transcription factors are regulating PDK4.  Interestingly, a recent study has demonstrated that the transcription factor E2F1, which is crucial for cell cycle control, may regulate PDK4 expression.  Given that NF-κB may antagonize the transcriptional activity of E2F1 in cardiac myocytes, we sought to study whether inflammatory processes driven by NF-κB can downregulate PDK4 expression in human cardiac AC16 cells through E2F1 inhibition.  Protein coimmunopptn. indicated that PDK4 downregulation entailed enhanced phys. interaction between the p65 subunit of NF-κB and E2F1.  Chromatin immunopptn. analyses demonstrated that p65 translocation into the nucleus prevented the recruitment of E2F1 to the PDK4 promoter and its subsequent E2F1-dependent gene transcription.  Interestingly, the NF-κB inhibitor parthenolide prevented the inhibition of E2F1, while E2F1 overexpression reduced interleukin expression in stimulated cardiac cells.  Based on these findings, we propose that NF-κB acts as a mol. switch that regulates E2F1-dependent PDK4 gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosrmYcI4sovrVg90H21EOLACvtfcHk0liJZcr7zkE7ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslCrt70%253D&md5=02bebe411c8167456351898ac4903d6f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0019724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0019724%26sid%3Dliteratum%253Aachs%26aulast%3DPalomer%26aufirst%3DX.%26aulast%3D%25C3%2581lvarez-Guardia%26aufirst%3DD.%26aulast%3DDavidson%26aufirst%3DM.%2BM.%26aulast%3DChan%26aufirst%3DT.%2BO.%26aulast%3DFeldman%26aufirst%3DA.%2BM.%26aulast%3DV%25C3%25A1zquez-Carrera%26aufirst%3DM.%26atitle%3DThe%2520interplay%2520between%2520NF-kappaB%2520and%2520E2F1%2520coordinately%2520regulates%2520inflammation%2520and%2520metabolism%2520in%2520human%2520cardiac%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0019724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8757</span>– <span class="NLM_lpage">8769</span>, <span class="refDoi"> DOI: 10.1021/jm301064b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301064b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8757-8769&author=Q.+Zhangauthor=Y.+Luauthor=Y.+Dingauthor=J.+Zhaiauthor=Q.+Jiauthor=W.+Maauthor=M.+Yangauthor=H.+Fanauthor=J.+Longauthor=Z.+Tongauthor=Y.+Shiauthor=Y.+Jiaauthor=B.+Hanauthor=W.+Zhangauthor=C.+Qiuauthor=X.+Maauthor=Q.+Liauthor=Q.+Shiauthor=H.+Zhangauthor=D.+Liauthor=J.+Zhangauthor=J.+Linauthor=L.+Y.+Liauthor=Y.+Gaoauthor=Y.+Chen&title=Guaianolide+sesquiterpene+lactones%2C+a+source+to+discover+agents+that+selectively+inhibit+acute+myelogenous+leukemia+stem+and+progenitor+cells&doi=10.1021%2Fjm301064b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Guaianolide Sesquiterpene Lactones, a Source To Discover Agents That Selectively Inhibit Acute Myelogenous Leukemia Stem and Progenitor Cells</span></div><div class="casAuthors">Zhang, Quan; Lu, Yaxin; Ding, Yahui; Zhai, Jiadai; Ji, Qing; Ma, Weiwei; Yang, Ming; Fan, Hongxia; Long, Jing; Tong, Zhongsheng; Shi, Yehui; Jia, Yongsheng; Han, Bin; Zhang, Wenpeng; Qiu, Chuanjiang; Ma, Xiaoyan; Li, Qiuying; Shi, Qianqian; Zhang, Haoliang; Li, Dongmei; Zhang, Jing; Lin, Jianping; Li, Lu-Yuan; Gao, Yingdai; Chen, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8757-8769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mols. that can selectively target cancer stem cells (CSCs) remain rare currently and exhibit no common structural features.  Here, we report a series of guaianolide sesquiterpene lactones (GSLs) and their derivs. that can selectively eradicate acute myelogenous leukemia (AML) stem or progenitor cells.  Natural GSL compds. arglabin, an anticancer clin. drug, and micheliolide (MCL), are able to reduce the proportion of AML stem cells (CD34+CD38-) in primary AML cells.  Targeting of AML stem cells is further confirmed by a sharp redn. of colony-forming units of primary AML cells upon MCL treatment.  Moreover, the dimethylamino Michael adduct of MCL, I, slowly releases MCL in plasma and in vivo and demonstrates remarkable therapeutic efficacy in the nonobese diabetic/severe combined immunodeficiency AML models.  These findings indicate that GSL is an ample source for chem. agents against AML stem or progenitor cells and that GSL is potentially highly useful to explore anti-CSC approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps_V3OAFoCjrVg90H21EOLACvtfcHk0liJZcr7zkE7ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktbzN&md5=064c942ed395fc35e71155c45206a5bf</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm301064b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301064b%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DZhai%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DGuaianolide%2520sesquiterpene%2520lactones%252C%2520a%2520source%2520to%2520discover%2520agents%2520that%2520selectively%2520inhibit%2520acute%2520myelogenous%2520leukemia%2520stem%2520and%2520progenitor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8757%26epage%3D8769%26doi%3D10.1021%2Fjm301064b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Wedel-Parlow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wölte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galla, H. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2009.06305.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1111%2Fj.1471-4159.2009.06305.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19656257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ertLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2009&pages=111-118&author=M.+von%0AWedel-Parlowauthor=P.+W%C3%B6lteauthor=H.+J.+Galla&title=Regulation+of+major+efflux+transporters+under+inflammatory+conditions+at+the+blood-brain+barrier+in+vitro&doi=10.1111%2Fj.1471-4159.2009.06305.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro</span></div><div class="casAuthors">von Wedel-Parlow, Magdalena; Woelte, Philipp; Galla, Hans-Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">ATP-driven efflux transport proteins at the blood-brain barrier protect the healthy brain but impede pharmacotherapy of the disordered CNS.  To investigate the question how ATP-binding cassette (ABC)-transporters are regulated during inflammation or infection we analyzed the effects of the cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) on the expression of brain multi-drug resistance proteins in primary cultures of porcine brain capillary endothelial cells.  We found that TNF-α and IL-1β rapidly decrease Abcg2 (BMDP/BCRP) mRNA expression within 6 h.  After 24 and 48 h the mRNA level came back to control values.  The mRNA redn. at 6 h was counter-regulated by the anti-inflammatory glucocorticoid hydrocortisone.  Abcg2 protein levels were suppressed at prolonged stimulations but not after 6 h of stimulation which correlates with Abcg2 specific substrate uptake measurements.  Abcb1 (p-glycoprotein) protein expression was transiently increased after TNF-α addn. within 6 h of incubation followed by a redn. after 24 and 48 h whereas the Abcb1 mRNA levels were not changed.  IL-1β caused a continuous decrease in protein expression of both ABC-transporters.  Long-term treatment with an assumed TNF-α-downstream agent, the vasocon-strictor endothelin-1, induced Abcg2 protein expression but suppressed Abcb1.  Other efflux pumps like multi-drug resistance-assocd. proteins/Abcc were rarely affected.  The present results imply a complex regulation of the two most abundant ABC-transporters at the blood-brain barrier during early inflammation stages suggesting that Abcb1 (p-glycoprotein) is an early target of TNF-α-signaling counter-balanced by Abcg2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnAWI6G1Wpv7Vg90H21EOLACvtfcHk0lirfWALQyAEcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ertLnJ&md5=68f955b8c59d15a53dc8444d8d6fb889</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2009.06305.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2009.06305.x%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BWedel-Parlow%26aufirst%3DM.%26aulast%3DW%25C3%25B6lte%26aufirst%3DP.%26aulast%3DGalla%26aufirst%3DH.%2BJ.%26atitle%3DRegulation%2520of%2520major%2520efflux%2520transporters%2520under%2520inflammatory%2520conditions%2520at%2520the%2520blood-brain%2520barrier%2520in%2520vitro%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D111%26spage%3D111%26epage%3D118%26doi%3D10.1111%2Fj.1471-4159.2009.06305.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasiou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulogiannis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auld, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">1278</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1126/science.1211485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1126%2Fscience.1211485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=22052977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCms7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2011&pages=1278-1283&author=D.+Anastasiouauthor=G.+Poulogiannisauthor=J.+M.+Asaraauthor=M.+B.+Boxerauthor=J.+K.+Jiangauthor=M.+Shenauthor=G.+Bellingerauthor=A.+T.+Sasakiauthor=J.+W.+Locasaleauthor=D.+S.+Auldauthor=C.+J.+Thomasauthor=M.+G.+Vander+Heidenauthor=L.+C.+Cantley&title=Inhibition+of+pyruvate+kinase+M2+by+reactive+oxygen+species+contributes+to+cellular+antioxidant+responses&doi=10.1126%2Fscience.1211485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses</span></div><div class="casAuthors">Anastasiou, Dimitrios; Poulogiannis, George; Asara, John M.; Boxer, Matthew B.; Jiang, Jian-kang; Shen, Min; Bellinger, Gary; Sasaki, Atsuo T.; Locasale, Jason W.; Auld, Douglas S.; Thomas, Craig J.; Vander Heiden, Matthew G.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">6060</span>),
    <span class="NLM_cas:pages">1278-1283</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Control of intracellular reactive oxygen species (ROS) concns. is crit. for cancer cell survival.  We show that, in human lung cancer cells, acute increases in intracellular concns. of ROS caused inhibition of the glycolytic enzyme pyruvate kinase M2 (PKM2) through oxidn. of Cys358.  This inhibition of PKM2 is required to divert glucose flux into the pentose phosphate pathway and thereby generate sufficient reducing potential for detoxification of ROS.  Lung cancer cells in which endogenous PKM2 was replaced with the Cys358 to Ser358 oxidn.-resistant mutant exhibited increased sensitivity to oxidative stress and impaired tumor formation in a xenograft model.  Besides promoting metabolic changes required for proliferation, the regulatory properties of PKM2 may confer an addnl. advantage to cancer cells by allowing them to withstand oxidative stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9SgiOQxnKObVg90H21EOLACvtfcHk0lirfWALQyAEcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCms7jK&md5=9c6ac78508f3c25cbad20d1f8a21b4dc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.1211485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1211485%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasiou%26aufirst%3DD.%26aulast%3DPoulogiannis%26aufirst%3DG.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DBoxer%26aufirst%3DM.%2BB.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DBellinger%26aufirst%3DG.%26aulast%3DSasaki%26aufirst%3DA.%2BT.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26aulast%3DAuld%26aufirst%3DD.%2BS.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DInhibition%2520of%2520pyruvate%2520kinase%2520M2%2520by%2520reactive%2520oxygen%2520species%2520contributes%2520to%2520cellular%2520antioxidant%2520responses%26jtitle%3DScience%26date%3D2011%26volume%3D334%26spage%3D1278%26epage%3D1283%26doi%3D10.1126%2Fscience.1211485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blouin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakikhani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algire, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, M.</span></span> <span> </span><span class="NLM_article-title">Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2009.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.canlet.2009.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=19744772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1Wlu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2010&pages=246-253&author=M.+J.+Blouinauthor=Y.+Zhaoauthor=M.+Zakikhaniauthor=C.+Algireauthor=E.+Piuraauthor=M.+Pollak&title=Loss+of+function+of+PTEN+alters+the+relationship+between+glucose+concentration+and+cell+proliferation%2C+increases+glycolysis%2C+and+sensitizes+cells+to+2-deoxyglucose&doi=10.1016%2Fj.canlet.2009.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose</span></div><div class="casAuthors">Blouin, Marie-Jose; Zhao, Yunhua; Zakikhani, Mahvash; Algire, Carolyn; Piura, Esther; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-253</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">PTEN loss of function enhances proliferation, but effects on cellular energy metab. are less well characterized.  We used an inducible PTEN expression vector in a PTEN-null glioma cell line to examine this issue.  While proliferation of PTEN-pos. cells was insensitive to increases in glucose concn. beyond 2.5 mM, PTEN-null cells significantly increased proliferation with increasing glucose concn. across the normal physiol. range to ∼10 mM, coinciding with a shift to glycolysis and "glucose addiction".  This demonstrates that the impact of loss of function of PTEN is modified by glucose concn., and may be relevant to epidemiol. results linking hyperglycemia to cancer risk and cancer mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOn5gk3F6FTbVg90H21EOLACvtfcHk0lirfWALQyAEcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1Wlu70%253D&md5=49be114e6c700aaffbbcc03a5e2ebc8a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DBlouin%26aufirst%3DM.%2BJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DAlgire%26aufirst%3DC.%26aulast%3DPiura%26aufirst%3DE.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DLoss%2520of%2520function%2520of%2520PTEN%2520alters%2520the%2520relationship%2520between%2520glucose%2520concentration%2520and%2520cell%2520proliferation%252C%2520increases%2520glycolysis%252C%2520and%2520sensitizes%2520cells%2520to%25202-deoxyglucose%26jtitle%3DCancer%2520Lett.%26date%3D2010%26volume%3D289%26spage%3D246%26epage%3D253%26doi%3D10.1016%2Fj.canlet.2009.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Cros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmerlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounarides, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span> <span> </span><span class="NLM_article-title">M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1073/pnas.1212780110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1073%2Fpnas.1212780110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=23267074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=489-494&author=M.+Cortes-Crosauthor=C.+Hemmerlinauthor=S.+Ferrettiauthor=J.+Zhangauthor=J.+S.+Gounaridesauthor=H.+Yinauthor=A.+Mullerauthor=A.+Haberkornauthor=P.+Cheneauthor=W.+R.+Sellersauthor=F.+Hofmann&title=M2+isoform+of+pyruvate+kinase+is+dispensable+for+tumor+maintenance+and+growth&doi=10.1073%2Fpnas.1212780110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth</span></div><div class="casAuthors">Cortes-Cros, Marta; Hemmerlin, Christelle; Ferretti, Stephane; Zhang, Juan; Gounarides, John S.; Yin, Hong; Muller, Alban; Haberkorn, Anne; Chene, Patrick; Sellers, William R.; Hofmann, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">489-494, S489/1-S489/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Many cancer cells have increased rates of aerobic glycolysis, a phenomenon termed the Warburg effect.  In addn., in tumors there is a predominance of expression of the M2 isoform of pyruvate kinase (PKM2).  PKM2 expression was previously shown to be necessary for aerobic glycolysis and to provide a growth advantage to tumors.  Here, the authors report that knockdown of PKM2 in tumor cells led to a decrease in the levels of pyruvate kinase activity and an increase in the pyruvate kinase substrate, phosphoenolpyruvate.  However, lactate prodn. from glucose, although reduced, was not fully inhibited.  Furthermore, the authors are unique in reporting increased serine and glycine biosynthesis from both glucose and glutamine following PKM2 knockdown.  Although PKM2 knockdown resulted in modest impairment of proliferation in vitro, the in vivo growth of established xenograft tumors was unaffected by PKM2 absence.  Thus, these findings indicate that PKM2 is dispensable for tumor maintenance and growth in vivo, suggesting that other metabolic pathways bypass its function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXJi5-fdQ7jLVg90H21EOLACvtfcHk0lhJWGZgpiBsgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOhtLs%253D&md5=5284f54fbaa4dad9b067ee1b0394a7e1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1212780110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1212780110%26sid%3Dliteratum%253Aachs%26aulast%3DCortes-Cros%26aufirst%3DM.%26aulast%3DHemmerlin%26aufirst%3DC.%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGounarides%26aufirst%3DJ.%2BS.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DMuller%26aufirst%3DA.%26aulast%3DHaberkorn%26aufirst%3DA.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DHofmann%26aufirst%3DF.%26atitle%3DM2%2520isoform%2520of%2520pyruvate%2520kinase%2520is%2520dispensable%2520for%2520tumor%2520maintenance%2520and%2520growth%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D489%26epage%3D494%26doi%3D10.1073%2Fpnas.1212780110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Israelsen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayton, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosios, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burga, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kibbey, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Vizio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span> <span> </span><span class="NLM_article-title">PKM2 isoform-specifific deletion reveals a difffferential requirement for pyruvate kinase in tumor cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2013.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1016%2Fj.cell.2013.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=24120138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sktr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2013&pages=397-409&author=W.+J.+Israelsenauthor=T.+L.+Daytonauthor=S.+M.+Davidsonauthor=B.+P.+Fiskeauthor=A.+M.+Hosiosauthor=G.+Bellingerauthor=J.+Liauthor=Y.+Yuauthor=M.+Sasakiauthor=J.+W.+Hornerauthor=L.+N.+Burgaauthor=J.+Xieauthor=M.+J.+Jurczakauthor=R.+A.+DePinhoauthor=C.+B.+Clishauthor=T.+Jacksauthor=R.+G.+Kibbeyauthor=G.+M.+Wulfauthor=D.+Di+Vizioauthor=G.+B.+Millsauthor=L.+C.+Cantleyauthor=M.+G.+Vander+Heiden&title=PKM2+isoform-specifific+deletion+reveals+a+difffferential+requirement+for+pyruvate+kinase+in+tumor+cells&doi=10.1016%2Fj.cell.2013.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells</span></div><div class="casAuthors">Israelsen, William J.; Dayton, Talya L.; Davidson, Shawn M.; Fiske, Brian P.; Hosios, Aaron M.; Bellinger, Gary; Li, Jie; Yu, Yimin; Sasaki, Mika; Horner, James W.; Burga, Laura N.; Xie, Jianxin; Jurczak, Michael J.; DePinho, Ronald A.; Clish, Clary B.; Jacks, Tyler; Kibbey, Richard G.; Wulf, Gerburg M.; Di Vizio, Dolores; Mills, Gordon B.; Cantley, Lewis C.; Vander Heiden, Matthew G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The pyruvate kinase M2 isoform (PKM2) is expressed in cancer and plays a role in regulating anabolic metab.  To det. whether PKM2 is required for tumor formation or growth, we generated mice with a conditional allele that abolishes PKM2 expression without disrupting PKM1 expression.  PKM2 deletion accelerated mammary tumor formation in a Brca1-loss-driven model of breast cancer.  PKM2 null tumors displayed heterogeneous PKM1 expression, with PKM1 found in nonproliferating tumor cells and no detectable pyruvate kinase expression in proliferating cells.  This suggests that PKM2 is not necessary for tumor cell proliferation and implies that the inactive state of PKM2 is assocd. with the proliferating cell population within tumors, whereas nonproliferating tumor cells require active pyruvate kinase.  Consistent with these findings, variable PKM2 expression and heterozygous PKM2 mutations are found in human tumors.  These data suggest that regulation of PKM2 activity supports the different metabolic requirements of proliferating and nonproliferating tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8md57TLpos7Vg90H21EOLACvtfcHk0lhJWGZgpiBsgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sktr%252FI&md5=b2647ac4c5fa6a1fa03664adb60288ee</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2013.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2013.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DIsraelsen%26aufirst%3DW.%2BJ.%26aulast%3DDayton%26aufirst%3DT.%2BL.%26aulast%3DDavidson%26aufirst%3DS.%2BM.%26aulast%3DFiske%26aufirst%3DB.%2BP.%26aulast%3DHosios%26aufirst%3DA.%2BM.%26aulast%3DBellinger%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DM.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DBurga%26aufirst%3DL.%2BN.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DJurczak%26aufirst%3DM.%2BJ.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DKibbey%26aufirst%3DR.%2BG.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26aulast%3DDi%2BVizio%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26atitle%3DPKM2%2520isoform-specifific%2520deletion%2520reveals%2520a%2520difffferential%2520requirement%2520for%2520pyruvate%2520kinase%2520in%2520tumor%2520cells%26jtitle%3DCell%26date%3D2013%26volume%3D155%26spage%3D397%26epage%3D409%26doi%3D10.1016%2Fj.cell.2013.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendez-Lucas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschaharganeh, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvisi, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuneva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Glucose catabolism in liver tumors induced by c-MYC can be sustained by various PKM1/PKM2 ratios and pyruvate kinase activities</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4355</span>– <span class="NLM_lpage">4364</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-0498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=10.1158%2F0008-5472.CAN-17-0498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=28630053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;key=1%3ACAS%3A280%3ADC%252BC1cnpvVajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4355-4364&author=A.+Mendez-Lucasauthor=X.+Liauthor=J.+Huauthor=L.+Cheauthor=X.+Songauthor=J.+Jiaauthor=J.+Wangauthor=C.+Xieauthor=P.+C.+Driscollauthor=D.+F.+Tschaharganehauthor=D.+F.+Calvisiauthor=M.+Yunevaauthor=X.+Chen&title=Glucose+catabolism+in+liver+tumors+induced+by+c-MYC+can+be+sustained+by+various+PKM1%2FPKM2+ratios+and+pyruvate+kinase+activities&doi=10.1158%2F0008-5472.CAN-17-0498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities</span></div><div class="casAuthors">Mendez-Lucas Andres; Driscoll Paul C; Yuneva Mariia; Li Xiaolei; Hu Junjie; Che Li; Song Xinhua; Jia Jiaoyuan; Wang Jingxiao; Xie Chencheng; Chen Xin; Li Xiaolei; Hu Junjie; Chen Xin; Jia Jiaoyuan; Xie Chencheng; Tschaharganeh Darjus F; Tschaharganeh Darjus F; Calvisi Diego F</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4355-4364</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Different pyruvate kinase isoforms are expressed in a tissue-specific manner, with pyruvate kinase M2 (PKM2) suggested to be the predominant isoform in proliferating cells and cancer cells.  Because of differential regulation of enzymatic activities, PKM2, but not PKM1, has been thought to favor cell proliferation.  However, the role of PKM2 in tumorigenesis has been recently challenged.  Here we report that increased glucose catabolism through glycolysis and increased pyruvate kinase activity in c-MYC-driven liver tumors are associated with increased expression of both PKM1 and PKM2 isoforms and decreased expression of the liver-specific isoform of pyruvate kinase, PKL.  Depletion of PKM2 at the time of c-MYC overexpression in murine livers did not affect c-MYC-induced tumorigenesis and resulted in liver tumor formation with decreased pyruvate kinase activity and decreased catabolism of glucose into alanine and the Krebs cycle.  An increased PKM1/PKM2 ratio by ectopic PKM1 expression further decreased glucose flux into serine biosynthesis and increased flux into lactate and the Krebs cycle, resulting in reduced total levels of serine.  However, these changes also did not affect c-MYC-induced liver tumor development.  These results suggest that increased expression of PKM2 is not required to support c-MYC-induced tumorigenesis in the liver and that various PKM1/PKM2 ratios and pyruvate kinase activities can sustain glucose catabolism required for this process.  Cancer Res; 77(16); 4355-64. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRX9xb9_t-_-LFU0A1HOshhfW6udTcc2eaYBCnpQXn4F7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnpvVajtg%253D%253D&md5=f2e79aca961381e431827d62ad50c676</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0498%26sid%3Dliteratum%253Aachs%26aulast%3DMendez-Lucas%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DDriscoll%26aufirst%3DP.%2BC.%26aulast%3DTschaharganeh%26aufirst%3DD.%2BF.%26aulast%3DCalvisi%26aufirst%3DD.%2BF.%26aulast%3DYuneva%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DGlucose%2520catabolism%2520in%2520liver%2520tumors%2520induced%2520by%2520c-MYC%2520can%2520be%2520sustained%2520by%2520various%2520PKM1%252FPKM2%2520ratios%2520and%2520pyruvate%2520kinase%2520activities%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4355%26epage%3D4364%26doi%3D10.1158%2F0008-5472.CAN-17-0498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T5A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T5A','PDB','1T5A'); return false;">PDB: 1T5A</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i47"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01328">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48822"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01328?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01328</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Figures S1–S3, HPLC assessment of purity for compounds <b>5</b> and <b>16</b>, NMR spectra (<sup>1</sup>H NMR, <sup>13</sup>C NMR) of compounds <b>5</b>–<b>16</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01328/suppl_file/jm9b01328_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01328/suppl_file/jm9b01328_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01328/suppl_file/jm9b01328_si_001.pdf">jm9b01328_si_001.pdf (1.49 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01328/suppl_file/jm9b01328_si_002.csv">jm9b01328_si_002.csv (2.39 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01328&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01328" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01328" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                15MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a55e0ccb024bf","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
